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Abstract 
 Persons who inject drugs (PWIDs) are at high-risk of hepatitis C virus (HCV) 
infection due to blood-to-blood contact when sharing injection equipment (World Health 
Organization, 2014). To investigate this health concern, the current thesis research obtained 
the 2008 and 2012 Prince George I-Track survey datasets from the Public Health Agency of 
Canada (2012). Multivariate logistic regression analyses were conducted to determine risk 
behaviours and characteristics associated with HCV infection among PWIDs living in Prince 
George, British Columbia (BC). 
 Two independent variables were significantly associated with HCV infection among 
Prince George PWIDs: injecting for more than two years, Adjusted Odds Ratio (AOR) 7.87, 
p < .001, 95% CI [3.60, 17.18], and injecting alone (versus with others), AOR 2.49, p = .004, 
95% CI [1.35, 4.59]. The study results provide health practitioners with a highly sensitive 
(94.1%) predictive tool to identify PWIDs in Prince George, BC who are most likely to be 
infected with HCV.  
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Glossary 
Back-loading – drawing up a drug into one syringe and then dividing the drug equally  
between two separate syringes (Harm Reduction Coalition [HRC], 2011) 
Cooker – container used for mixing and heating a drug (HRC, 2011). 
Filter – small cotton ball (preferably sterile) that is placed in dissolved drug to remove  
particles prior to injection (HRC, 2011). 
Speedballs – a combination of cocaine and opiate that is injected simultaneously (Centre for 
Addiction and Mental Health [CAMH], 2012). 
Shooting gallery – a place used for drug injection (HRC, 2011).  
Swabs – 70% isopropyl alcohol wipes used to clean skin prior to injection (HRC, 2011). 
Tourniquets -  a strip of elastic tied around the arm to raise veins for injection (HRC, 2011). 
Water – sterile or unsterile liquid required to dissolve drugs prior to injection (HRC, 2011). 
Washes – large amounts of residue from prescription opioids that remain on injection 
equipment and are rinsed with water and re-injected (Roy et al., 2012).   
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CHAPTER 1: Introduction 
Persons who inject drugs (PWIDs) are at high-risk of hepatitis C virus (HCV) 
infection due to blood-to-blood contact when sharing injection equipment (World Health 
Organization [WHO], 2014). The worldwide prevalence of HCV among PWID populations 
is estimated at 67%, or approximately 10 million persons (WHO, 2014). In 2013, the global 
burden of disease from HCV infections attributable to injection drug use (IDU) was 
estimated to be 7.5 million disability adjusted life-years (DALYs): a four-fold increase since 
1990 (Degenhardt et al., 2016). Although regions in Asia jointly account for an estimated 
50% of the IDU-attributable global burden of HCV disease, it is estimated that high-income 
North America (Canada and the United States) accounts for the second largest proportion 
(11%) of IDU-attributable HCV disease burden (Degenhardt et al., 2016). 
In Canada, approximately 225,000 Canadians are chronically infected with HCV, and 
it is estimated that 60-89% of these cases are current or former PWIDs (Degenhardt et al., 
2016; Myers, Shah, Burak, Cooper, & Feld, 2015). Despite the high burden of HCV disease 
among PWIDs living in Canada, extremely low rates of HCV treatment have occurred 
(Degenhardt et al., 2016). Recent advancements in orally-administered direct-acting anti-
viral agents (DAAs) are yielding HCV infection cure rates of more than 90% within 8-24 
weeks of treatment (Pawlotsky, Feld, Zeuzem, & Hoofnagle, 2015). Therefore, enhanced 
screening and timely provision of DAAs to PWIDs infected with HCV has the potential to 
greatly reduce the financial, social, and personal costs of chronic infection.  
Using the 2008 and 2012 Prince George I-Track survey data, the current thesis 
research investigates the risk behaviours and characteristics associated with HCV infection 
among PWIDs living in Prince George, BC. Identifying significantly associated risk 
behaviours and characteristics will assist health practitioners to identify HCV positive 
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PWIDs for screening, monitoring and treatment of chronic HCV (CHC) infections; and to 
identify HCV negative PWIDs for ongoing harm reduction interventions. 
Context of the Current Study 
The I-Track research project is a behavioural and biological surveillance system 
monitoring the prevalence of human immunodeficiency virus (HIV), HCV, and associated 
risk behaviours among PWIDs in Canada (Public Health Agency of Canada [PHAC], 2014). 
The system was developed as part of the Federal Initiative to Address HIV/AIDS and 
funding was provided by the PHAC, regional health authorities, and local community 
agencies (PHAC, 2014). A detailed description of the I-Track research methodology and I-
Track survey is presented in Supplement One. 
Several research studies preceded the selection of Prince George as an I-Track 
sentinel site. The Vancouver Injection Drug Users Study (VIDUS) (Miller et al., 2002; 
Patrick et al., 2001), the At-Risk Youth Survey (ARYS) (Miller et al., 2009; Wood et al., 
2006), the Cedar Project (Craib et al., 2009; Jongbloed et al., 2015; Mehrabadi et al., 2008, 
Miller et al., 2009), as well as research conducted by Callaghan et al. (2003; 2007; 2008) 
identified high HCV prevalence and multiple risk behaviours among PWIDs in Vancouver 
and/or Prince George, BC. Rachlis et al. (2008) also evaluated the risks of HCV transmission 
due to increased mobility of PWIDs between Vancouver and outlying communities such as 
Prince George, BC. A review of these studies will establish the context for the selection of 
Prince George as an I-Track sentinel site, as well as the current thesis research. 
Vancouver Injection Drug Users Survey 
In response to an alarming HIV outbreak in Vancouver, BC, the VIDUS open 
prospective cohort study was initiated in 1996 (Patrick et al., 2001). Eligible PWIDs resided 
in Vancouver, reported injecting drugs in the month prior to enrollment, and were older than 
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13 years (Miller et al., 2002). Baseline and semi-annual questionnaires were administered by 
trained interviewers, and venous blood samples were collected and tested for HIV and HCV 
antibodies (Miller et al., 2002). Among the 1,345 eligible participants, HCV prevalence at 
enrollment was 81.6%, 95% Confidence Interval (CI) [79.6%, 83.6%], and the overall HCV 
incidence density between 1996 and 1999 was 29.1 per 100 person-years, 95% CI [22.3, 
37.3] (Patrick et al., 2001). Of particular interest was the association between age, number of 
years injecting, and HCV serostatus (positive or negative blood test result). HCV positive 
participants were older (median age 35 vs. 25 years) and had been injecting longer (median 
14 vs. 3 years) than HCV negative participants (Patrick et al. 2001). The VIDUS research 
clearly indicated “extreme pressure toward HCV transmission among seronegative [PWIDs]” 
and highlighted significant differences in characteristics and risk behaviours of HCV positive 
and HCV negative PWIDs (Patrick et al., 2001, p. 894).      
 Subsequently, Miller et al. (2002) utilized the VIDUS cohort data to explore risk 
behaviours, HCV prevalence, and HCV incidence among younger PWIDs. Of the 232 
participants aged 13 to 24 years, 46% (n = 107) were HCV positive at initial enrollment 
(Miller et al., 2002). Additionally, 49% of the youth participants who were HCV negative at 
enrollment seroconverted during the initial five-year study period for an estimated incidence 
rate of 37.3 per 100 person-years (Miller et al., 2002). Significant risk behaviours associated 
with HCV seroconversion included daily cocaine use, Risk Ratio (RR) 3.04, 95% CI [1.20, 
7.70]; having a partner who uses injection drugs, RR 2.48, 95% CI [1.08, 5.66]; and requiring 
help injecting, RR 2.48, 95% CI [1.08, 5.66] (Miller et al., 2002). The VIDUS research 
highlighted a narrow window of opportunity for HCV prevention among young PWIDs and 
warranted further investigation of the risk behaviours and characteristics associated with 
HCV infection.    
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At-Risk Youth Survey (ARYS) 
 Evolving from the VIDUS research, the At-Risk Youth Survey (ARYS) was 
implemented to examine risk behaviours and characteristics associated with injection 
initiation among street-involved youth living in Vancouver (Wood et al., 2006). Using an 
open prospective cohort design, enrollment began in October 2005 with baseline interviewer-
administered questionnaires and venous blood samples collected and tested for HIV and 
HCV antibodies (Wood et al., 2006). Eligibility requirements were 1) ages 14 to 26 years, 
and 2) use of drugs other than marijuana in past 30 days (Wood et al., 2006). Follow-up 
questionnaires and venous blood tests were conducted semi-annually to monitor HCV 
incidence, transition to IDU, and associated risk behaviours (Wood et al., 2006).  
 Miller et al. (2009) found ARYS participants who were HCV positive (13%) were 
older in age (p = .035), engaged in sex trade (p = .027), reported childhood sexual abuse (p = 
.040), and reported ever injecting drugs (p < .001). Similar to the VIDUS findings, among 
ARYS participants who reported IDU, the number of years injecting was significantly 
associated with HCV infection, Adjusted Odds Ratio (AOR) 1.23 per year increase, 95% CI 
[1.11, 1.37] (Miller et al., 2009). Additionally, injecting crystal meth at least once per day, 
AOR 3.10, 95% CI [1.25, 7.70], and injecting heroin at least once per day, AOR 8.56, 95% 
CI [3.64, 20.13] were significantly associated with HCV infection (Miller et al., 2009). The 
ARYS results indicated IDU among young PWIDs was high-risk for HCV seroconversion. 
The Cedar Project 
 Concurrent with the ARYS research, the Cedar Project prospective cohort study 
began recruiting self-identified Aboriginal youth aged 14 to 30 years living in Vancouver, 
BC or Prince George, BC (Mehrabadi et al., 2008). Eligible participants reported smoking 
illegal drugs in previous week or injecting illegal drugs within the previous month 
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(Mehrabadi et al., 2008). Similar to the VIDUS and ARYS studies, participants completed 
interviewer-administered questionnaires and provided venous blood samples to be tested for 
HCV and HIV antibodies (Mehrabadi et al., 2008). The purpose of the Cedar Project was to 
compare socio-demographics, drug use patterns, injection practices, sexual experiences, 
lifetime and historical trauma, and HIV and HCV prevalence between young Aboriginals 
living in two urban centres in BC (Mehrabadi et al., 2008). As a resource-based town located 
in northern BC and with approximately 10% of the population self-identified as Aboriginal, 
Prince George was considered ideal to recruit a target population of 300 young Aboriginal 
participants (Mehrabadi et al., 2008). 
HCV prevalence among Cedar Project PWIDs was 62.4% and 57.1% in the Prince 
George and Vancouver cohorts respectively (Craib et al., 2009). The incidence of HCV 
exposure during the first two years of study was 12.9 per 100 person-years in Prince George 
vs. 7.5 in Vancouver (Craib et al., 2009). Despite higher HCV prevalence and incidence in 
the Prince George cohort, the differences were not statistically significant (p =.370) (Craib et 
al., 2009). However, Aboriginal female PWIDs were significantly more likely to be HCV 
positive, AOR 1.9, p = .012, 95% CI [1.1, 3.4]; as were those reporting opiate injection, AOR 
2.7, p = .033, 95% CI [1.0, 7.4]; reusing syringes, AOR 2.4, p < .001, 95% CI [1.3, 4.4]; at 
least one parent attended residential school, AOR 1.9, p = .038, 95% CI [1.1, 3.4]; and 
duration of IDU, AOR 1.4 per year, p < .001, 95% CI [1.3, 1.5] (Craib et al., 2009). The 
Cedar Project results expanded on previous evidence from the VIDUS and ARYS studies, 
and identified multiple risk behaviours and characteristics specific to HCV among young 
Aboriginal PWIDs. 
The Cedar Project findings also demonstrated that 1) HCV had spread to areas outside 
of the downtown east side (DTES) of Vancouver, 2) associated risk behaviours and 
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characteristics were changing, and 3) Aboriginal PWIDs living in rural areas were especially 
vulnerable to HCV infection (Craib et al., 2009). As a result, the Northern BC Aboriginal 
HIV/AIDS Task Force (now named the Northern BC First Nations HIV/AIDs Coalition) was 
established. Sixty Chiefs from Aboriginal communities across northern BC mandated the 
task force to develop a comprehensive strategy to strengthen Aboriginal individuals and 
communities to combat HIV/AIDs and HCV (Carrier Sekani Family Services, 2016). 
Consequently, the task force became a primary stakeholder in the 2008 and 2012 Prince 
George I-Track surveys.   
Prince George Inpatient Detox Research 
Several retrospective medical chart reviews of inpatients admitted to the Prince 
George detoxification centre also occurred concurrently with the VIDUS and ARYS and 
Cedar Project research. A three-year medical chart review conducted by Callaghan and 
Cunningham (2002) compared intravenous and non-intravenous cocaine drug users admitted 
to the Prince George detox centre between 1999 and 2002. The review identified higher rates 
of residential instability, unemployment, Aboriginal ethnicity, problematic opiate use, HCV 
and HIV infections, and cirrhotic liver disease among intravenous cocaine users as compared 
to non-intravenous users (Callaghan & Cunningham, 2002). In particular, Aboriginal PWIDs 
self-reported daily cocaine use, residential instability, and high prevalence of HCV infection 
(Callaghan & Cunningham, 2002). The combination of these risk behaviours revealed the 
potential for HCV transmission to outlying Aboriginal communities throughout northern BC. 
Subsequently, Callaghan, Tavares, and Taylor (2007) investigated the residential 
instability of Aboriginal PWID detox inpatients between on-reserve and off-reserve 
locations. Aboriginal PWIDs who had been admitted at least twice to the detox centre from 
1999 to 2005 were examined for place-of-residency transitions (Callaghan et al., 2007). Of 
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the Aboriginal PWIDs with two admissions, 26%, 95% CI [21%, 31%], who had been living 
off-reserve at first admission had moved to on-reserve by second admission (Callaghan et al., 
2007). Conversely, of those living on-reserve at first admission, 96%, 95% CI [88%, 100%], 
had moved off-reserve by the second admission (Callaghan et al., 2007). Additionally, 46% 
of the Aboriginal PWIDS included in the study had self-reported being HCV positive 
(Callaghan et al., 2007). The results demonstrated significant mobility between on-reserve 
and off-reserve locations, and reiterated the potential for HCV transmission to PWIDs in 
outlying communities.  
Prevalence of HCV in Northern BC 
Between 1998 and 2007, the reportable disease statistics from the BC Centre for 
Disease Control (BCCDC) reported an overall provincial decrease in annual HCV incidence 
(BCCDC, 2008). However, declining provincial HCV incidence rates did not reflect the 
persistently high HCV incidence rates within the Northern Health (NH) region of northern 
BC. With an estimated population of 300,000, the NH region encompasses almost two-thirds 
of BC (600,000 square kilometers) and includes all populations living north of Quesnel and 
west of Valemount (NH, 2016). As shown in Figure 1, the NH region has had persistently 
high HCV incidence rates as compared to national rates since 2003 (BCCDC, 2015).   
High HCV incidence rates within the NH region may have reflected increased HCV 
testing due to an overall increased awareness of HCV prevalence (BCCDC, 2008). Moreover, 
the specific mode of transmission for HCV incident cases was not captured by the BCCDC 
epidemiological data and the incident cases may not have represented incident cases among 
PWIDs (BCCDC, 2008). However, the BCCDC estimated that 54% -70% of all incident 
HCV cases were related to IDU (BCCDC, 2013). Combined with the primary research 
findings, the HCV incidence rates reported within the NH region provided further evidence 
8 
 
that PWIDs in northern BC were particularly vulnerable to HCV infections.  
  
 
Figure 1. A comparison of the NH region and Canadian annual HCV incidence rates per 
100,000 population, 2003-2014 (BCCDC, 2015). 
Summary of the Study Context 
As outlined above, multiple studies establish the context for the selection of Prince 
George as an I-Track sentinel site, as well as the current thesis research. The VIDUS and 
ARYS studies identified multiple risk behaviours associated with HCV infections among 
PWIDs living in Vancouver, BC. The Cedar Project focused on risk behaviours and 
characteristics associated with HCV infections among Aboriginal youth in both Vancouver 
and Prince George. Additionally, the Prince George inpatient detox research identified 
multiple HCV risk behaviours and characteristics within PWIDs in Prince George and 
highlighted the residential mobility of Aboriginal PWIDs to smaller communities within 
northern BC. High annual HCV incidence rates within the NH region warranted the selection 
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of Prince George as an I-Track sentinel site, as well as further research of HCV prevalence 
among high-risk PWID populations living in northern BC.     
Study Purpose 
The purpose of the current thesis research is to investigate the risk behaviours and 
characteristics associated with HCV infection among PWIDs who participated in the Prince 
George I-Track surveys. The research findings will provide evidence-based information to 
guide public health interventions focused on HCV, and will promote improved health and 
wellness for high-risk PWIDs living in northern BC. 
Research Question 
What are the risk behaviours and characteristics associated with HCV infection 
among the PWIDs who participated in the Prince George I-Track surveys? 
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CHAPTER 2: Literature Review 
  A review of the literature was conducted to identify risk behaviours and 
characteristics associated with HCV among PWIDs that had been investigated by previous 
research. Chapter Two will outline the literature search strategy, describe the selection 
criteria for relevant research articles, and present a critical narrative review of the research 
evidence. The results of the review will guide the selection of risk behaviours and 
characteristics to be included in the statistical analyses of the current thesis research. 
Literature Search Strategy 
Using the EBSCO search engine, a search for relevant research was conducted within 
four on-line databases: CINAHL complete, Academic Search Complete, MedLINE, and 
PsycINFO. Grey literature was also located using search engines on the WHO 
(www.who.int), the PHAC (http://www.phac-aspc.gc.ca), and the BCCDC (www.bccdc.ca) 
websites. All searches included subject headings and keywords of [“HCV” OR “hepatitis c” 
OR “hep c” OR “hepatitis c virus”] AND [“IV drug use*” OR “IDU*” OR “intravenous drug 
use*” OR “IVDU*” OR “persons who inject drug*” OR “PWID*”] AND [“risk factor*” OR 
“risk behavio*”]. 
Selection of Relevant Research Articles 
The large number of search results were then limited to 1) English language and 2) 
the publication period of 2010 to 2016. The publication period was selected based on 
significant advancements in HCV virology that occurred in 2010. During that year, the ability 
to replicate HCV in a laboratory setting rapidly expanded the knowledge of HCV infectivity 
and transmission, and has greatly influenced all HCV research conducted since 2010 
(Paintsil, He, Peters, Lindenbach, & Heimer, 2010; Ray, Bailey, & Thomas, 2013). The 
search results with these filters applied rendered 1,192 hits. 
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Research articles that were not peer-reviewed and all duplicates were also removed 
resulting in 419 articles. Manual browsing of abstracts was conducted and all research studies 
conducted in developing countries were removed. It was felt that research conducted in 
developed countries would share similar socio-economic, political, and health care 
infrastructures with the study sample of the current thesis research, thus minimizing 
confounding factors unique to PWID populations in developing countries. 
Manual browsing also identified and removed research articles predominantly 
focused on HIV. The tendency for HCV infections to be lumped in with HIV research is 
problematic because the pathogenicity, modes of transmission, and natural history of the two 
viruses are quite different. A detailed description of the natural history of HCV is provided in 
Supplement Two. Differences in virology result in differences in associated risks: an 
important distinction often overlooked in HIV-focused research. Multiple studies mentioned 
HCV in the title or abstract, but focused the analyses on HIV. These studies were excluded 
from the review due to the lack of attention to HCV-specific risk behaviours and 
characteristics that differ from HIV. 
Additionally, HCV research studies that primarily focused on sub-groups of PWIDs 
were removed from the search results. Such studies had selection criteria that differed from 
the current thesis research. For instance, several studies focused exclusively on incarcerated 
PWIDs; or male PWIDs who have sex with men; or PWIDs who had become re-infected 
with HCV; or PWIDs co-infected with HIV. Arguably, these sub-groups of PWIDs may have 
different risk behaviours (e.g., tattooing, sexual transmission, immune-suppression) from the 
community-based sample of PWIDs who participated in the Prince George I-Track surveys. 
Therefore, research studies that focused on specific sub-groups of PWIDs were excluded. 
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The manual browsing and filtering process resulted in thirty-eight relevant research 
articles. The reference list of each research article was then scanned for articles that appeared 
relevant to the current thesis research or were repeatedly referenced. The scanning process 
resulted in a further twenty-nine research articles which were then filtered using the same 
aforementioned process. Ten research articles were deemed relevant, resulting in forty-eight 
relevant articles to be included in the literature review. Studies that contributed to the context 
of the current thesis research (Chapter One) were also included in the literature review. 
Risk Behaviours and Characteristics 
Several risk behaviours associated with HCV infection among PWIDs were 
repeatedly investigated in the relevant research. Sharing injection equipment; number of 
injection years; drug of choice; injection partners and sexual partners; female gender; 
Aboriginal status, and unstable housing were commonly included in multivariate analyses 
throughout the literature. Each of these risk behaviours and characteristics were also 
suspected to be relevant within the current thesis research. Two further risk behaviours 
considered to be relevant that were not as prevalent in the literature were involvement in sex 
trade and residential mobility. The following narrative critically reviews the related research 
of risk behaviours and characteristics associated with HCV infection among PWIDs. 
Sharing Injection Equipment 
 PWIDs are especially vulnerable to HCV transmission via blood-to-blood contact 
with HCV-infected blood. The prolonged environmental viability of HCV (Paintsil et al., 
2010; 2014), the potential for HCV reservoirs on multiple pieces of injection equipment 
(Doerrbecker et al., 2011; 2013; Hagan et al., 2011; Thibault, Bara, Nefau, & Duplessy-
Garson, 2011), and ubiquitous sharing behaviours among PWIDs (Kim, Jim, McFarland, & 
Raymond, 2015; Palmanteer et al., 2010; 2013; Pouget, Hagan, & Des Jarlais, 2011; Strike et 
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al., 2010) all contribute to high rates of HCV transmission. A review of the related research 
strongly suggests sharing injection equipment is the premier risk factor associated with HCV 
infection among PWIDs.    
Contaminated injection equipment. Multiple laboratory studies have indicated the 
prolonged viability of HCV within needles and syringes. Cardinal research conducted by 
Paintsil et al. (2010) claimed HCV viability in syringes was dependent on syringe type, time, 
and temperature. They found that HCV remained viable in high-void syringes (residual 
volume = 32 µL) at various temperatures for up to nine weeks. Low-void syringes (residual 
volume = 2µL) maintained viable HCV for up to seven days at various temperatures (Paintsil 
et al., 2010). Although laboratory results may not be generalizable to the natural injection 
environment, the Paintsil et al. (2010) findings suggested prolonged HCV viability and 
increased risk for transmission among PWIDs when sharing syringes.  
Further research conducted by Doerrbecker et al. (2011) investigated the stability of 
HCV on cookers commonly shared between PWIDs. After applying a constant heat source to 
an HCV-contaminated cooker for 85-90 seconds, they found HCV infectivity was 
compromised at ~50º C and was undetectable by 65-70º C. Concurrently, observational 
research conducted by Hagan et al. (2011) in multiple shooting galleries found only 12% of 
PWIDs heated cookers for >45 seconds, while almost 50% of those observed heated cookers 
for <15 seconds. The laboratory setting of the Doerrbecker et al. (2011) study may not 
simulate the natural injection environment, while the Hagan et al. (2011) study was strictly 
observational with much potential for confounding factors. However, the combined findings 
strongly suggest the risk for HCV transmission among PWIDs when sharing cookers 
contaminated with infected blood. 
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 Doerrbecker et al. (2013) investigated the survival of HCV in water containers and 
injection filters. In a laboratory setting, room temperature water with high concentrations of 
HCV (500 µL) maintained infectivity for more than twenty-one days, and low concentrations 
(8 - 40 µL) remained infective for four days (Doerrbecker et al., 2013). Additionally, they 
found injection filters consistently harboured infectious HCV (10% of the initial viral load) 
when stored in foil wrappers for 24-48hrs; a common practice among PWIDs. The 
Doerrbecker et al. (2013) findings strongly suggest prolonged viability of HCV and potential 
risk of HCV transmission among PWIDs when sharing contaminated water and filters. 
Thibault, Bara, Nefau, and Duplessy-Garson (2011) found high rates of infective 
HCV detection in pools of used alcohol swabs. By analyzing used injection equipment 
collected from HCV-positive PWIDs, they found blood macroscopically visible on most 
swabs, and levels of HCV RNA were 10-fold higher than in used syringes. Subsequent 
laboratory research found swabs needed at least 50% alcohol concentration and one minute 
of exposure time to render HCV undetectable (Doerrbecker et al., 2013). Paintsil et al. (2014) 
also found that decreasing alcohol concentrations (70% to 7%) became progressively 
ineffective as an antiseptic when applied to HCV contaminated surfaces. The research 
indicates inadequate antiseptic exposure time and/or inadequate antiseptic concentrations 
increase the risk for HCV transmission when sharing swabs.  
A review of the related research strongly suggests that the sharing of any injection 
equipment, not just needles and syringes, among PWIDs potentially increases risk for HCV 
transmission due to prolonged environmental viability. Arguably, the studies were conducted 
in laboratory settings, and may not reflect the natural injection environment. However, the 
prolonged environmental viability of HCV demonstrates the potential for all injection drug 
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equipment to be effective vectors for HCV transmission when contaminated and shared 
among PWIDs.       
Prevalence of sharing injection equipment. Sharing needles/syringes has been 
repeatedly identified as the premier risk behaviour associated with HCV infections among 
PWIDs. Meta-analyses conducted by Palmanteer et al. (2013) reviewed sixteen cross-
sectional and four longitudinal studies to estimate pooled association between needle/syringe 
sharing and HCV prevalence/incidence. Results of their meta-analyses estimated sharing 
needles/syringes was significantly associated with HCV infection, Odds Ratio (OR) 3.34, p < 
.001, 95% CI [2.42, 4.62]. Differences between classification of sharing behaviours, study 
designs, and sample populations create limitations within meta-analyses studies (Palmanteer 
et al., 2013). However, the Palmanteer et al. (2013) meta-analyses strongly suggest prevalent 
sharing behaviours within PWID populations are significantly associated with HCV 
infections.  
Interestingly, the Palmanteer et al. (2013) meta-analyses also highlighted HCV 
prevalence of 82% among PWIDs who reported they had never shared needles/syringes. The 
researchers surmised that the HCV infections were most likely due to ubiquitous sharing of 
injection drug equipment, such as cookers, water, and filters. Such suggestions are supported 
by meta-analyses conducted by Pouget, Hagan, and Des Jarlais (2011). Using twenty-one 
eligible studies, they estimated the population-attributable risk percentages of sharing 
behaviours associated with HCV infection. Among those exposed to HCV through syringe 
sharing, Pouget et al. (2011) estimated that 25% of HCV seroconversions could be prevented 
by eliminating syringe sharing behaviours. Moreover, they estimated 43% of PWIDs sharing 
cookers, 42% of those sharing filters, and 37% of those sharing water could avoid HCV 
seroconversion by eliminating their sharing practices. Similar to the Palmanteer et al. (2013) 
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research, the Pouget et al. (2011) meta-analyses results are limited due to differences between 
study methodologies. However, their study highlights the potential risk for HCV transmission 
among PWIDs who share any injection equipment.   
Of the articles identified in the literature search, two primary research studies focused 
specifically on the prevalence of sharing behaviours within sample PWID populations. 
Cross-sectional research conducted by Strike et al. (2010) found 36% of PWID participants 
living in London, Ontario reported they shared needles, 45% shared cookers, 39% shared 
water, and 29% shared filters in the previous 6 months. Those who self-reported as HCV 
positive (53.1%) also reported distributing used cookers (56.1%), water (54.3%), and filters 
(59.5%) for re-use by other PWIDs (Strike et al., 2010). Although generalizability is limited, 
and selection, recall, and social desirability biases may have influenced the results, self-
reported sharing of injection drug equipment within the sample PWID population was 
prevalent. 
More recently, Kim, Jin, McFarland, and Raymond (2015) found significant 
decreases in reported needle sharing during their longitudinal cohort study of PWIDs living 
in San Francisco, California. Participants reported decreased receptive needle sharing from 
25.5%, 95% CI [19.7, 32.0] to 14%, p < .001, 95% CI [8.6, 20.4]; decreased receptive cooker 
sharing from 46.5%, 95% CI [39.1, 54.1] to 37.9%, p = .003, 95% CI [31.8, 44.1]; and 
decreased receptive water sharing from 38.3%, 95% CI [31.0, 46.0] to 25.5%, p < .001, 95% 
CI [20.3, 31.3] (Kim et al., 2015). Reports of distributive sharing decreased, but such reports 
may be limited by social desirability bias (Kim et al., 2015). Although the longitudinal cohort 
study identifies decreasing trends of self-reported sharing behaviours, the overall receptive 
sharing of injection equipment among PWIDs remains prevalent.   
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Summary of sharing injection equipment. A review of the research supports the 
claim that sharing of injection equipment is the premier risk behaviour associated with HCV 
infections among PWIDs. The prolonged environmental viability of HCV greatly contributes 
to the risk of transmission when sharing any injection equipment among PWIDs. The high 
prevalence of HCV within PWID populations, as well as ubiquitous sharing behaviours 
contribute to the high-risk for HCV transmission. The research evidence demonstrates that 
sharing injection equipment is a premier risk factor for HCV infection among PWIDs and 
will be included in the bivariate and multivariate analyses of the current thesis research.   
Number of Injection Years 
Multiple studies in the relevant literature have investigated the number of injection 
years as a risk factor for HCV infections among PWIDs. Longitudinal studies have identified 
increasing HCV incidence rates for PWIDs as duration of drug injection increases (Roy, 
Boudreau & Boivin, 2009; Spittal et al., 2012). Additionally, cross-sectional studies have 
found significant associations between number of injection years and HCV infections (Craib 
et al., 2009; Garfein et al., 2012; Havens et al., 2013; Miller et al., 2009; PHAC, 2010). A 
review of the related research strongly suggests the number of injection years is an important 
risk behaviour significantly associated with HCV infections among PWIDs.      
Number of years to seroconversion. Longitudinal cohort studies provide temporal 
data to estimate incidence of HCV infection among PWIDs. Roy, Boudreau, and Boivin 
(2009) used prospective cohort data from young street-involved PWIDs in Montreal to 
estimate that 55% of HCV negative participants seroconverted within four years of injection 
initiation. They also found the median length of time to HCV infection was 3.3 years, and 
estimates of HCV incidence dropped significantly after the first four years of injection (p = 
.002). Arguably, the study participants were aged 14 to 23 years and maturational bias may 
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limit the generalizability of the results. For instance, an older cohort of injection initiates may 
engage in different risk behaviours resulting in different rates of HCV incidence from first 
injection. However, the Roy et al. (2009) findings indicate the first four years of injection are 
high-risk for HCV infection among young PWIDs.  
The Cedar Project estimated hazard ratios between the number of years injecting and 
HCV infection (Spittal et al., 2012). Using prospective cohort data of young Aboriginal 
participants who were HCV negative, they estimated that those who had been injecting for 
less than two years experienced HCV seroconversion at more than four times the rate of 
those who had injected more than five years, Adjusted Hazard Ratio (AHR) 4.14, p < .001, 
95% CI [1.91, 8.94]. Additionally, the HCV incidence density of those reporting injecting 
drugs for two years or less was 26.3 per 100 person-years (Spittal et al., 2012). Survivorship 
bias may have caused under-estimations by excluding the highest risk participants who were 
(already) HCV positive at baseline, and attrition bias may have skewed results due to missing 
data from non-returners. However, the Spittal et al. (2012) research suggests high incidence 
of HCV infection among young Aboriginal PWIDs during the initial two years of IDU.      
Multiple cross-sectional studies suggest the number of injection years is significantly 
associated with HCV infections among PWIDs. The national I-Track, Phase 1 survey 
reported young street-involved PWIDs aged 20 to 24 years were five times more likely to be 
HCV positive than those aged 15 to 19 years, OR 5.2, p < .001, 95% CI [2.7, 9.9] (PHAC, 
2010). Similarly, the national Enhanced Street-Involved Youth Survey [E-SYS] found street-
involved PWIDs aged 20 to 24 years were four times more likely to be HCV positive than 
younger PWIDs, OR 4.0, p < .001, 95% CI [2.9, 5.5] (PHAC, 2010). In both studies, young 
PWIDs in the older age group were significantly more likely to be HCV positive.  
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Similarly, cross-sectional data from the ARYS and Cedar Project studies indicate the 
number of injection years is significantly associated with HCV infection among young 
PWIDs. At baseline, young PWIDs in the ARYS study were 1.23 times more likely to be 
HCV positive per year of IDU, AOR 1.23, 95% CI [1.11, 1.37] (Miller, Kerr, Fischer, Zhang, 
& Wood, 2009). The Cedar Project also found young Aboriginal PWIDs were 1.4 times more 
likely to be HCV positive per year of IDU, AOR 1.4, 95% CI [1.3, 1.5] (Craib et al., 2009). 
Both observational studies suggest the number of injection years is a significant risk factor 
associated with HCV among young PWIDs. 
Among adult PWIDs, significant associations between number of years injecting and 
HCV infection have also been identified. Cross-sectional research conducted by Garfein et al. 
(2012) found the risk of HCV among adult PWIDs increased by almost three times per year 
of injecting, AOR 2.82, p < .001, 95% CI [2.06, 3.84]. Similar observational research by 
Havens et al. (2013) found rural Appalachian PWIDs injecting who had been injecting for 
more than five years were three times more likely to be HCV positive, AOR 3.08, p < .001, 
95% CI [1.67, 5.66]. The cross-sectional studies strongly suggest the number of injection 
years is significantly associated with HCV infection among several PWID samples.  
Summary of number of injection years. A review of both longitudinal and cross-
sectional research indicates the number of injection years is a significant risk behaviour 
associated with HCV infection among PWIDs. Unfortunately, differences in study methods 
and categorization of injection years (e.g., range of ages vs. per year of injection) make it 
difficult to further synthesize the evidence. Thus, the current thesis research estimates the 
greatest risk for HCV seroconversion occurs within the first two years of injection, and the 
independent variable IV_INJECTION_YEARS will be categorized accordingly.           
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Drug of Choice 
 Drug of choice refers to the type of drug that each individual PWID prefers to inject. 
Cocaine, amphetamine, heroin, and prescription opioids (POs) are the most common drugs 
reported to be injected by PWIDs. The amphetamine category in the current thesis research 
includes crystal meth and methamphetamine. Heroin and POs such as morphine, 
hydromorphone, fentanyl, methadone, oxycodone, and codeine are all classified as opiates. 
Each of these injection drugs of choice have been found to be significantly associated with 
HCV infections among PWIDs in the related research.  
Confounding considerations. Although the related research has investigated the 
drug of choice as the risk factor associated with HCV, the injection behaviours that coincide 
with each drug may be underlying confounders. For example, cocaine injection is typically 
associated with a bingeing pattern of drug use with multiple injections occurring over 
relatively short periods of time (hours/days) (De, Jolly, Cox, & Boivin, 2006). It is not the 
cocaine use per se, but the increased frequency of injections that greatly increase the chance 
of exposure to blood-borne pathogens such as HCV. Therefore, frequency of injection would 
be the true associated risk behaviour. 
Conversely, opiate injections typically occur two to three times daily over longer 
periods of time (weeks/months/years). The longer duration of injection may increase the 
chance of being exposed to HCV infection. However, opiate injection behaviours often 
involve multiple “washes” to get the entire amount of drug injected (Roy et al., 2012, p. 249). 
Therefore, sharing “washes” may be the true risk behaviour associated with HCV infections 
rather than drug of choice. Although drug of choice may be confounded by underlying 
injection behaviours, the related research investigates drug of choice and the current thesis 
research will do so also.      
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Cocaine injection. Two longitudinal cohort studies in the literature review have 
investigated cocaine injection as a risk factor for HCV seroconversion among PWIDs. Using 
prospective cohort data of HCV negative PWIDs living in Montreal, Bruneau et al. (2012) 
found cocaine injectors were three times more likely to become HCV infected than those not 
injecting cocaine, AHR 3.00, p < .05, 95% CI [1.44, 6.24]. As previously noted, longitudinal 
cohort analyses are susceptible to underestimations due to survivorship bias when PWIDs at 
highest risk are excluded because they are already infected with HCV at baseline. Attrition 
bias may also lead to underestimations and systematic errors when participants enrolled in 
the study are lost to follow-up at subsequent meetings. Bruneau et al. (2012) acknowledge 
such limitations in their study design. Despite underestimations, their findings strongly 
identify cocaine injection as a significantly associated risk behaviour for HCV infection 
among PWIDs.    
Similarly, Grebely et al. (2014) used VIDUS longitudinal data from 1996 to 2012 to 
estimate hazard ratios of cocaine injection associated with HCV seroconversion. Within the 
large sample population of PWIDs who were HCV negative at baseline, cocaine injection 
was significantly associated with HCV seroconversion, AHR 1.77, p < .05, 95% CI [1.20, 
2.61] (Grebely et al., 2014). Once again, the results may be underestimated due to attrition or 
survivorship bias. However, the research results indicate cocaine injection is a significant risk 
behaviour associated with HCV seroconversion even among the lowest risk PWIDs.  
Cocaine injection has also been associated with HCV infections among PWIDs in 
cross-sectional research. Roux, Fugon, Jones, and Comer (2013) found cocaine injectors in 
their study to be more than eight times more likely to be HCV positive than non-injection 
cocaine users, AOR 8.52, p < .001, 95% CI [2.58, 28.21]. However, they did not compare 
cocaine injection with other injection drugs, and their small sample population limited 
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generalizability. Concurrently, Havens et al. (2013) found rural Appalachian cocaine 
injectors were more than twice as likely to be HCV positive than other PWIDs, AOR 2.13, p 
< .001, 95% CI [1.31, 3.45]. They also identified cocaine injectors reported significantly 
more years of injecting drugs than PO injectors, AOR 4.85, p < .001, 95% CI [2.70, 8.71]. 
With biases and limitations in mind, the cross-sectional study findings suggest cocaine 
injection is significantly associated with HCV infection among PWIDs. 
Methamphetamine injection. Research by Miller, Kerr, Fischer, Zhang, and Wood 
(2009) used baseline data from the ARYS cohort study to investigate methamphetamine as a 
risk behaviour associated with HCV infection among young PWIDs. Those who reported 
methamphetamine injection at least once per day were more than three times more likely to 
be HCV positive, AOR 3.10, 95% CI [1.25, 7.70] (Miller et al., 2009). Particularly 
concerning, almost half of the young PWIDs in the Miller et al. (2009) study reported 
injecting methamphetamine on a daily basis, thus increasing their risk for HCV infection. 
Moreover, research conducted by Werb et al. (2013) identified methamphetamine use was 
independently associated with the initiation of IDU among street-involved youth, AHR 1.93, 
95% CI [1.31, 2.85].  
Grebely et al. (2014) also identified increased reports of methamphetamine injection 
in their study using VIDUS cohort data from 1996-2012. Prior to 2006, methamphetamine 
injection was not reported by HCV negative participants, whereas 35% of HCV negative 
participants reported injecting methamphetamine between 2006 and 2012 (Grebely et al., 
2014). Those that reported methamphetamine injection during this time had 2.5-fold greater 
risk of HCV seroconversion, AHR 2.53, p < .05, 95% CI [1.11, 5.73]. However, associations 
between methamphetamine injection and HCV infection may be specific to PWIDs living in 
the DTES of Vancouver.  
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Opiate injection. Several studies in the related research have found heroin injection 
to be significantly associated with HCV infection. The Roux et al. (2013) study identified 
PWIDs who injected heroin were more than three times more likely to be HCV infected than 
non-injection heroin users, AOR 3.49, p = .040, 95% CI [1.09, 11.18]. Miller et al. (2009) 
found ARYS participants who reported injecting heroin more than once per day were greater 
than eight times more likely to be HCV positive, AOR 8.56, 95% CI [3.64, 20.13]. 
Additionally, PWIDs in the VIDUS study who were HCV negative at baseline and reported 
injecting heroin were found to have 1.5-fold greater risk of HCV seroconversion, AHR 1.57, 
p < .05, 95% CI [1.05, 2.35] (Grebely et al., 2014). Although the odds/hazards are greatly 
varied between studies, the related research repeatedly indicates PWIDs who inject heroin are 
at increased risk for HCV infection. 
Differences between heroin injection versus PO injection, and associated risks for 
HCV infection are also identified in the related research. Havens et al. (2013) found PWIDs 
injecting POs were more than twice as likely to be HCV infected than those who were 
injecting just heroin, AOR 2.22, p < .05, 95% CI [1.13, 4.35]. Zibbell, Hart-Malloy, Barry, 
Fan, and Flannigan (2014) found similar risk associations between PO use and HCV 
infection. Notably, PWIDs reporting PO injection were more than five times more likely to 
be HCV positive than PWIDs who did not inject POs, AOR 5.53, p < .05, 95% CI [1.92, 
15.91] (Zibbell et al., 2014). Similarly, Bruneau et al. (2012) investigated HCV infections 
among PWIDs who reported injecting both heroin and POs, as well as those who reported 
using POs exclusively. For those reporting only injecting POs in the previous 6 months, the 
risk of HCV seroconversion was almost three times greater than those who had injected both 
heroin and POs, AHR 2.88, p < .05, 95% CI [1.52, 5.45] (Bruneau et al., 2012). Although 
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both heroin and POs are opiates, the research suggests that each drug type has different 
injection practices resulting in different risk behaviours associated with HCV infection.  
Research conducted by Roy et al. (2011) in downtown Montreal has identified 
multiple risk behaviours associated specifically with the injection of POs among PWIDs. 
Although POs are readily available, dose-reliable, and easy to divide, the small doses and 
methods of manufacturing (e.g., time-release beads) require more frequent injections (Roy et 
al., 2011). Furthermore, Roy et al. (2012) describe how PO injection preparation leaves large 
quantities of residue in the syringe, requiring multiple “washes” to get the full effect of the 
drug (p. 249). They further explain that injecting POs also requires a lot of water to dissolve, 
thus requiring multiple injections, as well as multiple uses of cotton filters and cookers. 
Surprisingly, Roy et al. (2012) report that most PWIDs in their study did not realize “doing a 
wash” with someone else’s used equipment was high-risk sharing behaviour (p. 249).    
Other related research further explains important characteristics of PO injection that 
may contribute to the increased risk for HCV infection. Havens et al. (2013) found PO 
injectors were almost seven times more likely to share syringes, OR 6.87, p < .01, 95% CI 
[1.61, 29.4]; and almost eight times more likely to share other injection equipment, OR 7.66, 
p < .01, 95% CI [2.34, 25.1]. Additionally, Zibbell (2015) explains that PO injectors may be 
at significantly higher risk for HCV due to “abuse-deterrent formulations” that cause POs to 
not dissolve, but clump when prepared for injection (Zibbell, 2015, p. 7). According to 
Zibbell (2015), this process may actually contribute to the risk for HCV infection because 
“people attempt to circumvent the diversion formulations, resulting in more opportunities for 
HCV contamination on drug preparation equipment” (p. 7). Therefore, the frequency of 
injection, multiple pieces of shared equipment, and the lack of awareness of potential risks of 
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sharing all contribute to PO injection being significantly associated with HCV infections 
among PWIDs.       
Summary of drug of choice. The research suggests cocaine, amphetamine, and 
opiate injection are all significant risk behaviours associated with HCV infection among 
PWIDs. Additionally, there is mounting evidence that injecting POs is particularly high-risk 
for sharing used injection equipment and HCV transmission. Drug of choice may be a proxy 
for underlying injection behaviours such as frequency of injection and sharing of injection 
equipment. However, to remain congruent with the related research, drug of choice will be 
investigated in the multivariate analyses of the current thesis research.   
Injection Drug Partners 
 Research focussed on long-term injection drug partnerships, as well as sexual 
injection partnerships have found both to be associated with HCV infection among PWIDs. 
Research has also identified PWIDs who are involved in sex trade relationships are 
particularly vulnerable to HCV infections. A review of the related research indicates injection 
drug partnerships are a significant risk factor associated with HCV infection among PWIDs. 
Non-sexual injection partners. High-risk sharing behaviours between opiate 
injection partners have been evidenced in the related research. Hahn, Evans, Davidson, Lum, 
and Page (2010) claim receptive sharing of injection equipment is almost twice as likely to 
occur among long-term opiate injection partners than among non-opiate injection partners. 
Their research identified the longer opiate injection partners have been acquainted, the 
greater the risk for sharing injection equipment, OR 1.77, p < .05, 95% CI [2.40, 5.64]. 
Moreover, opiate injection partners who resided together shared a significantly higher risk of 
sharing injection equipment, OR 3.29, p < .05, 95% CI [1.68, 6.41] (Hahn et al., 2010). 
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Therefore, research suggests the risk for sharing equipment greatly increases as injection 
drug partnerships mature, leading to increased risk for HCV infection. 
Obviously, the length of an injection partner relationship and associated risk for HCV 
infection is particularly concerning among sero-discordant PWIDs. A longitudinal study 
conducted by Morris et al. (2014) found an HCV incidence rate of 23.8 per 100 person-years 
among sero-discordant injection partners. Sero-discordant injection partners who had co-
habited for ≥ 28 days were almost five times more likely to share syringes, Adjusted Risk 
Ratio (ARR) 4.90, p < .05, 95% CI [1.01, 24.30]; and greater than eight times more likely to 
share other injection equipment, ARR 8.62, p < .05, 95% CI [2.40, 31.30] (Morris et al., 
2014). Despite the small sample size and broad CIs, the research indicates PWIDs who are in 
sero-discordant injection partnerships are at increased risk for HCV sero-conversion the 
longer they are involved with an HCV-infected partner.  
Sexual injection partners. When considering HCV transmission within sexual 
partnerships, it is important to remember that “sexual partners of people infected with HCV 
may become infected, although the risk is very low in heterosexual couples” (WHO, 2014, p. 
16). Christian, Hopenhayn, Christian, McIntosh, and Koch (2010) describe HCV infections 
as “inefficiently transmitted” via sexual behaviours, and conclude that transmission between 
sexual partners must then occur as a result of high-risk injection behaviours (p. 125). A 
systematic review conducted by Tohme and Holmberg (2010) concluded “the real risk for 
sexual transmission [of HCV] …is unprotected sex between HIV-infected partners, 
particularly HIV positive MSM [men who have sex with men]” (p. 1502). Notably, the sub-
population of male PWIDs who are HIV positive and are sexually involved with other men 
are high-risk for HCV transmission via sexual contact. However, among all other PWIDs the 
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premier risk behaviour for HCV transmission within sexual injection partnerships continues 
to be sharing injection equipment, not sexual transmission. 
PWIDs who are both injection partners and sexual partners have been repeatedly 
found to be at increased risk for HCV infection compared with non-intimate injection 
partners. According to Morris et al. (2014), injection partners who are co-habiting and are 
sexually involved are at significant risk for receptive syringe sharing, ARR 5.45, p < .05, 
95% CI [1.72, 17.18]; and receptive cooker use, ARR 7.40, p < .05, 95% CI [1.95, 28.04]. 
Similarly, research conducted by Evans, Morris, Yu, Page, and Hahn (2014) found PWIDs 
involved in HCV sero-discordant sexual relationships reported receptive syringe sharing 
(15%), receptive cooker sharing (28%) and receptive syringe backloading (56%).  
Receptive sharing between sexual injection partners highlights unique vulnerabilities 
within the context of intimate relationships. As evidenced by Wagner, Bloom, Hathazi, 
Sanders, and Lankenau (2013), female PWIDs are especially vulnerable in intimate injection 
drug relationships. After multiple interviews, they found female PWIDs reported a lack of 
control over drug preparation and injection processes; most often to their male sexual 
partners. Further research indicates gender and age differences contribute to early injection 
initiation when young high-risk females become sexually involved with older, male PWIDs 
(Roy, Boivin, & Leclerc, 2011). As postulated by Hahn et al. (2010), partnership age 
differences and partnership gender may contribute to inequities within sexual injection 
partnerships, leaving young female PWIDs particularly vulnerable to receptive sharing and 
HCV infection. 
Involvement in sex work. Defined as exchanging sex for money, drugs, shelter or 
other commodities, PWIDs involved with sex trade work are particularly vulnerable to HCV 
infections (Shannon et al., 2010). The ARYS longitudinal cohort research identified both 
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male and female youth who transitioned to survival sex work were at significantly higher risk 
for HCV infection than those not involved in survival sex work, AHR 2.30, p < .05, 95% CI 
[1.27, 4.15] (Chettiar, Shannon, Wood, Zhang, & Kerr, 2010). Similarly, female Aboriginal 
participants in the Cedar Project who reported sex trade involvement were almost twice as 
likely to be HCV positive than those not involved in sex work, OR 1.76, p = .031, 95% CI 
[1.05, 2.95] (Mehrabadi et al., 2008). In both of these studies, it remains unclear if survival 
sex work preceded the high-risk injection practices and HCV infection, or whether the high-
risk injection practices and HCV infection preceded sex work involvement.    
Research conducted by Shannon et al. (2010) suggests receptive syringe sharing is a 
significant risk behaviour among sex trade workers, AOR 1.8, p < .05, 95% CI [1.00, 3.24]. 
Similarly, Mehrabadi et al. (2008) found Aboriginal female sex workers reported much 
higher risk of lending, OR 3.02, p = .01, 95% CI [1.33, 6.89], and borrowing used needles, 
OR 2.06, p = .029, 95% CI [1.07, 3.94], than those not involved in sex work. Multiple sexual 
injection partners, as well as multiple socio-economic inequities result in extreme 
vulnerability for sharing injection equipment and HCV infection among PWIDs involved in 
sex work. 
Summary of injection partners. A review of the related research suggests injection 
partners are significantly associated with HCV infection because of high-risk sharing 
behaviours, not sexual transmission. The risk for sharing injection equipment with injection 
partners is associated with the length of injection relationship, sexual injection partnerships, 
and involvement in sex work. As such, the current research thesis will investigate injection 
partners as a risk behaviour associated with HCV infection.  
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Female Gender 
 Throughout the related research, female gender has repeatedly been investigated as a 
characteristic associated with HCV infection among PWIDs. Multiple studies indicate female 
PWIDs are significantly more likely to be HCV positive than their male PWID counterparts 
(Craib et al., 2009; Cullen et al., 2015; Iversen et al., 2010; Mehrabadi et al., 2008; PHAC, 
2010; Roy et al., 2012). To explain the gender-based difference in HCV infections among 
PWIDs, the literature suggests female PWIDs experience injection initiation at a younger 
age, are more susceptible to receptive sharing within injection relationships, and are more 
often involved with survival sex work. Although female PWIDs report fewer years of IDU, 
gender-based vulnerabilities may increase their risk for HCV infection.  
Gender and injection initiation. Initiation into IDU greatly increases the risk for 
HCV transmission among PWIDs due to the increased risk of blood-to-blood contact. 
Prospective cohort data collected from street-youth in Montreal found young females and 
males were initiated into IDU at similar rates: 7.0 per 100 person-years, 95% CI [5.2, 9.4], 
vs. 5.9 per 100 person-years, 95% CI [4.7, 7.2], respectively (Roy et al., 2011). Multivariate 
analyses revealed young females were at significantly higher risk to initiate injection when 
they were homeless in the previous six months, AHR 2.49, 95% CI [1.21, 5.15], and were 
socializing with others who inject drugs, AHR 4.46, 95% CI [2.39, 8.33] (Roy et al., 2011). 
Conversely, significant risk factors for male injection initiation included; homelessness prior 
to age 16, AHR 1.68, 95% CI [1.04, 2.71], and incest or rape prior to age 14, AHR 1.98, 95% 
CI [1.18, 3.3]. The Roy et al. (2011) findings indicate gender-based differences in risk factors 
for injection initiation, and suggest young homeless females experience injection initiation 
within networks of experienced PWIDs, potentially increasing exposure to HCV infections. 
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Hadland et al. (2012) further investigated the phenomenon of injection initiation 
among young PWIDs. Using prospective cohort data, they found youth aged 14 to 26 years 
who had experienced childhood sexual abuse were almost three times more likely to initiate 
IDU than those who had not been abused, AHR 2.71, p = .003, 95% CI [1.42, 5.30]. 
Additionally, female gender was not significantly associated with injection initiation, but a 
significantly larger proportion of females reported childhood sexual abuse than males (58% 
vs. 42%, p < .001) (Hadland et al., 2012). Although the results imply there may be multiple 
factors influencing injection initiation, the Hadland et al. (2012) study suggests childhood 
sexual abuse is significantly associated with IDU and more research is needed to identify 
possible gender-based differences.  
 Gender-based power imbalances. Power imbalances within social networks may 
explain why female PWIDs are more vulnerable to HCV infection. Roy et al. (2011) 
questioned why female PWIDs most often reported being initiated into IDU by romantic 
partners. They theorized that injection initiation reflects socially embedded gender inequities 
resulting in a lack of power and control for females within sexual partnerships. After 
injection initiation, the lack of power and control over drug supply and injection practices 
results in female PWIDs being vulnerable to receptive sharing, or being “second on the 
needle” (Craib et al., 2009, p. e225).  
Iversen et al. (2010) claim that within the context of intimate relationships, receptive 
sharing can imply trust, commitment, and intimacy, thus leading to increased risk for HCV. 
They further surmise that refusing to share equipment might be perceived as a lack of trust, 
and lead to abusive consequences for female PWIDs. Thus, power imbalances within sexual 
injection partnerships may strongly influence injection behaviours where female PWIDs are 
at increased risk for receptive sharing and HCV infection.  
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Power imbalances were also explored by Scheidell et al. (2015) when they 
investigated female PWIDs’ ability to plan for safe injection. Their research findings reported 
female PWIDs had adequate planning abilities for safe injection, were well-prepared with 
sterile injection equipment, and demonstrated safe injection knowledge. However, the 
Scheidell et al. (2015) study identified female PWIDs remained at high-risk for receptive 
needle sharing and HCV infection. They postulate that “gendered power dynamics may limit 
women’s ability to negotiate harm reduction strategies if male partners control the drug 
supply and injection equipment” (p. 35). Therefore, the research infers high-risk sharing 
behaviours and increased risk for HCV infection among female PWIDs are embedded within 
complex power imbalances within injection relationships. 
Receptive sharing of injection equipment. The related research consistently 
demonstrates that female PWIDs may be particularly vulnerable to receptive sharing 
practices due to age, gender, and socioeconomic inequities. For example, female PWIDs 
participating in the Edmonton I-Track survey were younger (p = .002), more likely to inject 
with their sex partners (p = .002), more likely to share needles (p < .001), and more likely to 
be paid for sex (p < .001) than their male counterparts (Plitt et al., 2010). Similarly, Hahn et 
al. (2010) found female PWIDs injecting with male sexual partners were almost twice as 
likely to report receptive needle sharing, OR 1.73, p < .05, 95% CI [1.03, 2.90].  
Research conducted by Iversen et al. (2010) found females who had been injecting for 
four years or less were particularly vulnerable to receptive needle sharing (p < .001), 
receptive equipment sharing (p = .004), and being injected by someone else (p < .001). In 
their large cross-sectional study, reports of receptive sharing decreased for female PWIDs as 
the duration of injection years increased, suggesting a change in sharing behaviours with age. 
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However, other confounding factors, as well as social desirability bias and recall bias may 
have influenced the results.  
Involvement in the sex trade. Both female and male PWIDs involved in sex-trade 
work are at very high-risk for injection initiation and HCV infections. For instance, Miller et 
al. (2011) found that young Aboriginals involved in sex trade work were almost four times 
more likely to transition to IDU that those not involved, AHR 3.94, p < .001, 95% CI [1.45, 
10.71]. Moreover, the related research repeatedly indicates female PWIDs are particularly 
vulnerable to involvement in sex work. For instance, Aboriginal female participants in the 
Prince George cohort of the Cedar Project research were almost twenty-five times more 
likely than males to have ever been paid for sex, OR 24.3, p < .05, 95% CI [11.6, 50.8] 
(Mehrabadi et al., 2008). Chettiar et al. (2010) also found female street involved youth were 
three times more likely to be involved in survival sex work than males, AOR 3.02, p < .05, 
95% CI [1.66, 5.46]. The over-representation of female PWIDs in sex work supports the 
proposed theory that age, gender, and socioeconomic inequities greatly influence female 
PWIDs’ abilities to maintain control over their bodies and their injection practices, resulting 
in high-risk sharing behaviours and HCV infection.  
Summary of female gender. The related research strongly suggests that gender-
based differences in injection initiation, sexual injection partnerships, and sex trade 
involvement are complex vulnerabilities facing female PWIDs. Each of these risk behaviours 
has been associated with HCV infection among female PWIDs in various studies, and 
highlights the prevalence of gender-based receptive sharing practices. As a result, the current 
thesis research will investigate gender as a risk factor associated with HCV infection among 
the Prince George I-Track PWIDs.  
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Aboriginal Status 
HCV infection among Aboriginals has been deemed a “broken spirit” disease due to 
multiple associated risk behaviours embedded in historical and personal trauma (Rempel & 
Uhanova, 2012, p. 3912). A meta-analyses of HCV prevalence and incidence within 
racial/ethnic groups from different national territories was conducted by Lelutui-Weinberger 
et al. (2009). They found Aboriginals in Australia and Canada were twice as likely as their 
“white” counterparts to be HCV positive, OR 2.04, p < .05, 95% CI [1.48, 2.82]. In Canada, a 
national surveillance report also found HCV incidence among Aboriginals was almost five 
times the rate of non-Aboriginals, 203 per 100,000 population vs. 36 per 100,000 population 
respectively (PHAC, 2010). A review of the related research strongly suggests Aboriginal 
PWIDs are particularly vulnerable to risk behaviours associated with HCV infection.    
Aboriginal PWIDs. According to national HCV surveillance research, Aboriginals 
are clearly overrepresented within the PWID population (PHAC, 2010). Among incident 
cases of HCV infections, the prevalence of IDU is significantly higher among Aboriginals 
than in the non-Aboriginal population, 67.3% vs. 53.6%, p < .001 (PHAC, 2010). Street-
involved Aboriginal youth are also over-represented within PWID populations, contributing 
to high prevalence of HCV infection among Aboriginal youth (7.4%) as compared with other 
ethnicities (2.8%), p < .05 (PHAC, 2010). The obvious over-representation of Aboriginal 
ethnicity within PWID populations suggests multiple, complex socio-economic factors.   
Researchers postulate that IDU and subsequent HCV infection among Aboriginals 
directly stem from intergenerational effects of residential school (Craib et al., 2009; Spittal et 
al., 2012). Inarguably, the residential school legacy has resulted in devastating historical and 
personal trauma, and widespread socio-economic inequities for Aboriginals across Canada 
(Craib et al., 2009). As stated by Craib et al. (2009), “drug use is just one way that people 
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deal with the complex effects of poverty, despair, discrimination, loss of language and 
traditional territories, erosion of culture” (p. e225). Socio-cultural inequities greatly 
contribute to the over-representation of Aboriginals involved in high-risk behaviour such as 
IDU, and result in particular vulnerability to blood-borne infections such as HCV.  
Aboriginal injection initiation. Unfortunately, Aboriginal youth and Aboriginal 
females appear to be most vulnerable to the intergenerational effects of historical and 
collective trauma. For example, national surveillance research found Aboriginal PWIDs are 
initiated into IDU at an earlier age than non-Aboriginal PWIDs, and more than one fifth of 
young Aboriginal PWIDs (21.9%) reported initiating injection before age 16 years (PHAC, 
2010). Compared with other ethnicities, early injection initiation was significantly more 
prevalent (p = .004) among young Aboriginals (PHAC, 2010). As discussed previously in 
this chapter, early injection initiation is a risk factor for HCV infection and may be due to 
power and control imbalances that exist between injection partners, leaving the younger, 
female partner more vulnerable to receptive sharing.   
The Cedar Project research has specifically looked at HCV infections among drug-
using Aboriginal youth in Prince George and Vancouver, BC (Craib et al., 2009; Mehrabadi 
et al., 2008; Miller et al., 2011; Spittal et al., 2012). Using prospective cohort data, incidence 
of HCV seroconversions among young Aboriginal PWIDs was estimated to be 26.3 incident 
cases per 100 person-years within the first two years of injection initiation (Spittal et al., 
2012). According to Miller et al. (2011), injection initiation was significantly associated with 
sex work, AHR 3.94, p < .001, 95% CI [1.45, 10.71]. Further analyses of the cross-sectional 
baseline data indicated female gender, AOR 2.44, p < .001, 95% CI [1.48, 4.01]; and history 
of incarceration, AOR 2.95, p < .001, 95% CI [1.92, 4.54], were also significantly associated 
with injection initiation (Miller et al., 2011). The Cedar Project research highlights the risk 
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behaviours associated with injection initiation and subsequent HCV infections among 
vulnerable young Aboriginal PWIDs.  
Aboriginal PWIDs and sharing behaviours. Aboriginal PWIDs have also been 
found to be at higher risk for sharing injection equipment than non-Aboriginal PWIDs 
(PHAC, 2010). National surveillance research found Aboriginal PWIDs who were HCV 
positive were more likely to borrow needles than those who were HCV negative, OR 1.6, p = 
.047, 95% CI [1.0, 2.7] (PHAC, 2010). However, young Aboriginal PWIDs were two times 
more likely to borrow used injection equipment than non-Aboriginal PWIDs, OR 2.1, p = 
.030, 95% CI [1.1, 4.1] (PHAC, 2010). Participants in the Cedar Project were more than 
twice as likely to be HCV positive when reporting equipment sharing, AOR 2.56, p < .001, 
95% CI [1.47, 4.49] (Spittal et al., 2012). The related research indicates Aboriginal PWIDs 
report prevalent sharing behaviours resulting in increased risk for HCV transmission. 
The related research proposes reasons for why high-risk sharing behaviours are 
prevalent among Aboriginal PWIDs. Miller et al. (2009) surmise that historical and sexual 
traumas lead young Aboriginal people “to experiment with injection drugs to numb feelings 
of shame and isolation” (p. 1152). Moreover, early intervention and harm reduction strategies 
are not tailored to the needs of high-risk Aboriginal youth who have been subjected to 
“racialized care”, and harbour “generations of mistrust of both provincial and federal 
authorities” (Spittal et al., 2012, p. 8). Lelutui-Weinberger et al. (2009) also suggest health 
disparities such as “unequal access to resources…. result in uneven disease distribution” (p. 
3). They theorize that Aboriginals are predisposed to risky behaviours due to “individual, 
community, or social conditions of disadvantage”, which manifest as “reduced access to 
healthcare, services, and prevention” (p. 3). The related research suggests there are multiple, 
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complex historical and persistent inequities facing Aboriginal PWIDs that result in increased 
risk-taking behaviours and HCV infections.   
Aboriginal female PWIDs. As noted previously, female PWIDs are particularly 
vulnerable to multiple risk behaviours associated with HCV infection. However, the related 
research indicates Aboriginal females are even more vulnerable. A large cross-sectional 
study of PWIDs conducted in Australia found Aboriginal female PWIDs who had been 
injecting for four or less years were almost twice as likely to be HCV positive than non-
Aboriginal female PWIDs, AOR 1.71, p = .005, 95% CI [1.18, 2.48] (Iversen et al., 2010). 
Young Aboriginal female PWIDs participating in the Cedar Project were also almost twice as 
likely to be HCV positive than their Aboriginal male counterparts, AOR 1.9, p = .012, 95% 
CI [1.1, 3.4] (Craib et al., 2009). The research indicates Aboriginal female PWIDs are at 
greater risk for HCV than both non-Aboriginal female PWIDs, and Aboriginal male PWIDs.  
As stated by Spittal et al. (2012), “impoverished Aboriginal women involved in sex 
work and concomitant illicit drug use continue to be exposed to alarming levels of drug 
related harm, infectious disease, and violent predation” (p. 8). They found Aboriginal female 
PWIDs involved in sex trade work were significantly more likely to be HCV positive than 
those not involved, AHR 1.59, p = .030, 95% CI [1.05, 2.42]. Moreover, a higher proportion 
of Aboriginal female PWIDs living in Prince George reported sex-trade involvement than 
Aboriginal female PWIDs living in Vancouver (56%) suggesting greater inequities facing 
young Aboriginal females in northern BC (Mehrabadi et al., 2008).  
Summary of Aboriginal status. Research strongly suggests Aboriginal PWIDs are 
particularly vulnerable to high-risk behaviours for HCV infections. Associated risk 
behaviours of early injection initiation and sharing injection equipment are significantly more 
prevalent among young Aboriginal PWIDs than non-Aboriginals. The related research also 
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indicates female Aboriginal PWIDs are particularly vulnerable to IDU, early injection 
initiation, sex trade work, and HCV infections. As stated by Rempel and Uhanova (2012), 
“the face of the indigenous HCV infected individual is becoming increasingly female and 
younger compared with non-indigenous counterparts” (p. 3912). The current thesis research 
will explore both Aboriginal status and Aboriginal females as characteristics associated with 
HCV among the Prince George I-Track participants. 
Unstable Housing 
The related research investigates unstable housing as a potential risk factor associated 
with HCV infections among PWIDs. Unstable housing includes living in multiple residences, 
living in shelters, and/or living on the street. Only one study in the literature review found 
unstable housing to be associated with HCV infection, AHR 1.61, p < .05, 95% CI [1.10, 
2.36] (Grebely et al., 2014). However, unstable housing has been associated with a history of 
abuse, Aboriginal status, and an increased risk for sharing injection equipment when 
injecting in public places. Thus, the research suggests unstable housing is an important 
consideration for risks associated with HCV infections among PWIDs.  
History of abuse and unstable housing. The related research indicates young 
PWIDs who lack stable housing are more vulnerable to abuse and violence. For instance, 
Rachlis et al. (2009) found homeless youth were more likely to report a history of physical 
abuse, OR 1.49, p = .035, 95% CI [1.03, 2.16]; or to have been a victim of violence, AOR 
1.57, p = .020, 95% CI [1.07, 2.30]. The Cedar Project also found the most transient young 
Aboriginal PWIDs (lived in more than six places in previous six months) were significantly 
more likely to report having been sexually assaulted, AOR 2.48, p = .008, 95% CI [1.26, 
4.86] (Jongbloed et al., 2015). The cross-sectional results are unable to determine if history 
of abuse leads to unstable housing, or unstable housing leads to increased abuse. However, a 
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history of abuse has been associated with unstable housing, as well as early injection 
initiation and survival sex work; all of which are also risk behaviours associated with HCV 
infection among PWIDs.   
Aboriginals and unstable housing. In the Cedar Project research, young Aboriginal 
drug users reported experiencing unstable housing more often in Prince George than in 
Vancouver (Jongbloed et al., 2015). In fact, the researchers found 90% of the Prince George 
participants reported living in two or more places, while almost 20% reported having lived in 
more than six different places in the previous six months. Jongbloed et al. (2015) propose 
that unstable housing is a result of a lack of affordable housing, as well as frequent visits to 
outlying communities and reserves. Furthermore, they claim housing instability among 
Aboriginals is directly associated with the “historic dispossession of traditional territories and 
forced displacement from community structures” (p. 125). The research suggests young 
Aboriginals are particularly vulnerable to unstable housing, and such instability leads to high-
risk injection behaviours of sharing injection equipment, injection initiation, and survival sex 
work. Consequently, Aboriginal PWIDs are particularly vulnerable to HCV infection. 
Injection in public places. Two studies in the related research found injecting in 
public places as a risk behaviour associated with unstable housing. Rachlis et al. (2009) 
found PWIDs who had unstable housing were more than twice as likely to inject drugs in 
public places, AOR 2.32, p < .001, 95% CI [1.43, 3.78]. Jongbloed et al. (2015) also found 
unstable housing was significantly associated with public injection, AOR 2.87, p < .001, 95% 
CI [1.65, 5.00]. The researchers claim that public injection increases the risk for sharing 
injection equipment due to rushed injection practices and fear of interruption (e.g., police 
presence) (Rachlis et al., 2009). Therefore, the research suggests unstable housing increases 
risk for HCV infection among PWIDs due to increased risk for sharing injection equipment. 
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Other risk behaviours and unstable housing. Two other risk behaviours 
significantly associated with HCV infections have also been found to be associated with 
unstable housing. For instance, the Cedar Project found survival sex work was significantly 
associated with unstable housing among young Aboriginal females, AOR 3.52, p < .001, 
95% CI [2.06, 6.05] (Jongbloed et al., 2015). Additionally, Feng et al. (2013) found injection 
initiation to be significantly associated with unstable housing, AHR 1.80, p = .014, 95% CI 
[1.13, 2.87]. Although unstable housing may not be directly associated with HCV infections 
among PWIDs, these studies suggest it is an important risk behaviour to consider due to 
significant associations with sex work and injection initiation.    
Summary of unstable housing. A review of related research indicates unstable 
housing is significantly associated with history of abuse, Aboriginal status, and injecting in 
public places. Although only one study has identified unstable housing as a risk behaviour 
significantly associated with HCV infections among PWIDs, several studies have identified 
multiple common risk behaviours associated with both HCV infections and unstable housing. 
As a result, unstable housing will be investigated in the current thesis research.   
Residential Mobility 
Residential mobility has been considered in the related research as a potential risk 
behaviour associated with HCV infections among PWIDs. Residential mobility may 
contribute to HCV transmission due to limited harm reduction services in outlying, under-
sourced areas, and subsequent increased risk of sharing injection equipment among transient 
PWIDs. Although the related research does not indicate residential mobility as a risk factor 
directly associated with HCV infection among PWIDs, the potential for HCV transmission to 
outlying, under-sourced areas due to sharing injection equipment must be considered. 
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Travel to outlying areas. As described by Rachlis et al. (2008), when IDU and 
residential mobility overlap, highly mobile individuals can potentially spread HCV from 
areas of high prevalence to areas of low prevalence. Their study investigated risk behaviours 
of VIDUS participants when they travelled from the DTES to outlying areas. Interestingly, 
the study found alcohol use was the only significant risk behaviour reported, AOR 1.25, p = 
.011, 95% CI [1.05, 1.48]; and migration out of the DTES appeared to have protective effects 
on high-risk injection behaviours (Rachlis et al., 2008). In fact, the Rachlis et al. (2008) study 
suggests that PWIDs migrate to outlying communities to escape heavy drug use and high-risk 
behaviours. However, such results must be viewed with caution because attrition bias may 
have excluded the most transient and highest-risk PWIDs from the study conclusions. 
Montgomery et al. (2012) also investigated risk behaviours of highly-mobile young 
PWIDs in their cross-sectional study. Their findings indicated PWIDs reported high-risk 
sharing behaviours when injecting drugs in urban centres with populations greater than 
500,000, AOR 7.05, p < .01, 95% CI [2.25, 22.06]. An increased number of travelling 
partners, AOR 2.77, p < .01, 95% CI [1.46, 5.27], and alcohol use, AOR 3.03, p < .01, 95% 
CI [1.32, 6.97], were also significantly associated with the risk of sharing equipment among 
travelling PWIDs (Montgomery et al., 2012). Capturing data from transient PWIDs is very 
difficult due to selection bias, but the Montgomery et al. (2012) study indicates riskier 
injection behaviours occur in larger urban centres, and suggests the risk of HCV transmission 
into smaller, outlying areas may be unfounded. However, such findings must be viewed with 
caution due to attrition and selection bias, and further research is warranted. 
Travel to Aboriginal communities. Callaghan et al. (2007) identified significant 
mobility between on-reserve and off-reserve settings reported by Aboriginal PWIDs admitted 
to the Prince George detox unit. Their review of medical charts found 26% of inpatient 
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Aboriginal PWIDs reported moving to on-reserve settings between admissions, whereas 96% 
of Aboriginal PWIDs had transitioned to living off-reserve. The demonstrated transience is 
concerning because 46% of the participants self-reported as HCV positive, indicating 
potential risk for transmission among PWIDs moving between urban and rural communities 
(Callaghan et al., 2007).  
Similarly, Jongbloed et al. (2015) found young Aboriginal participants in the Prince 
George cohort of the Cedar Project who were highly transient were significantly more likely 
to report visiting a reserve in the previous six months (p < .001), and significantly more 
likely to be HCV positive (p = .015). Although the Prince George cohort reported transient 
behaviours, the researchers propose that frequent visits to reserves may actually serve as a 
protective factor due to stronger ties with family and home community (Jongbloed et al., 
2015). However, reported transience of Aboriginal PWIDs between on-reserve and off-
reserve locations still suggests potential risk for HCV transmission to outlying communities. 
Summary of residential mobility. Residential mobility has been considered as a 
potential risk factor for HCV transmission among PWIDs to outlying areas. Two research 
studies found high-risk injection behaviours were reported to occur less often when PWIDs 
travelled to smaller communities, and two other studies reported high residential mobility 
among Aboriginal PWIDs. Although the latter studies did not specifically investigate risk 
behaviours associated with transience, they highlight the potential transmission of HCV 
among Aboriginal PWIDs travelling to smaller, rural communities. Due to the high 
prevalence of HCV infection within the Prince George I-Track sample, the large proportion 
of Aboriginal participants, and frequent reports of travel to/from locations outside of Prince 
George, residential mobility will be considered as a risk factor associated with HCV infection 
among PWIDs in the current thesis research.   
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History of Incarceration 
 During the literature search, multiple research studies were excluded from the final 
literature review because they focused exclusively on sub-populations of incarcerated 
PWIDs. However, several studies included in the literature review did investigate 
incarceration as a risk factor associated with HCV within general PWID populations. Indeed, 
the research findings strongly suggest a history of incarceration is significantly associated 
with HCV infection among PWIDs (Bruneau et al., 2012; Cullen et al., 2015; Hahn et al., 
2012; Iversen et al., 2010; Palmanteer et al., 2013). Despite repeated indications that 
incarceration is a significant risk factor associated with HCV infections among PWIDs, 
limitations within the Prince George I-Track survey dataset do not allow for it to be included 
in the analyses of the current thesis research.   
Summary of the Literature Review 
A review of the related research has highlighted multiple risk behaviours and 
characteristics associated with HCV infections within PWID populations. As presented in 
Figure 2, the premier risk behaviour associated with HCV infection among PWIDs is sharing 
injection equipment. Multiple risk behaviours and characteristics have been found to be 
associated with sharing injection equipment; namely, injection years, drug of choice, 
injection partners, female gender, Aboriginal ethnicity, unstable housing, and residential 
mobility. With the exception of history of incarceration, all of these risk behaviours and 
characteristics will be investigated in the current thesis research. 
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Figure 2. Diagram of risk behaviours and characteristics associated with HCV infection. 
Limitations in the Related Research 
The literature review process highlights several limitations in the related research. 
First of all, the literature search found an overwhelming number of primary research studies, 
but very few meta-analyses and systematic reviews of risk behaviours and characteristics 
associated with HCV among PWIDs. This is somewhat surprising considering the vast 
amount of research that has been conducted within PWID populations. Unfortunately, the 
multitude of small-scale studies with differing selection criteria and differing research 
methods does not allow risk behaviours and characteristics associated with HCV among 
PWIDs to be easily synthesized. 
Secondly, the studies included in the literature review, as well as the current thesis 
research all rely on serum HCV antibody test results to determine prevalence of HCV 
infection. However, serum HCV antibody tests only identify PWIDs who have been exposed 
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to HCV, not those who actually have acute or chronic infections (WHO, 2014). Due to 
spontaneous clearance, 15% to 45% of incident cases are able to overcome the HCV 
infection with an effective host immune response, but will still test positive for HCV 
antibodies (BCCDC, 2013; WHO, 2014). Therefore, analyses involving HCV prevalence 
based on serum antibody tests are prone to over-estimations, and results must be considered 
with caution. A detailed explanation of HCV virology is provided in Supplement Two.     
Finally, engaging PWIDs in research studies is very challenging due to social stigma 
and marginalization of the study population. As a result, the most appropriate quantitative 
research methods are observational cross-sectional and/or longitudinal cohort studies. 
Limitations in cross-sectional studies include the inability to determine causation or temporal 
change (Lavrakas, 2008). Longitudinal studies are also unable to determine causation, and 
they are particularly reliant on participants’ return for follow-up interviews (Lavrakas, 2008). 
However, implementing experimental methods would be impossible without ethical 
ramifications. Therefore, limitations of cross-sectional and longitudinal study methods of the 
related research must be accepted and considered when reviewing results.   
Multiple limitations inherent to observational research may have influenced the 
validity of the research findings. For instance, each of the primary studies relied on 
convenience sampling at locations where PWIDs would be easily recruited (e.g., NEPs) 
resulting in a non-probability sample population (Lavrakas, 2008). Moreover, each study 
implemented some form of interviewer-administered survey tool reliant on self-reporting of 
behaviours and are subject to recall bias and social desirability bias (Lavrakas, 2008). 
Interviewer-administered questionnaires may also create bias whereby participants’ 
responses are affected by facial expressions, tone of voice, and body language of the 
45 
 
interviewer (Lavrakas, 2008). The potential for such biases must be considered as a limitation 
of the study designs and results in the related research.  
Specific to longitudinal studies, when participants do not return for follow-up 
interviews the research results are subject to attrition bias (Lavrakas, 2008). Moreover, if 
follow-up interviews are conducted a long time after baseline interviews, maturational bias 
may be confounding the observed changes (Lavrakas, 2008). Survivorship bias also 
influences longitudinal studies by disregarding the highest-risk individuals who presented 
with the outcome of interest at baseline, thus excluding them from incidence calculations. 
(Lavrakas, 2008). Despite these limitation, observational cross-sectional and longitudinal 
research remain the most effective, efficient, economically feasible, and ethical study designs 
for engaging vulnerable PWID populations.    
Gaps in the Related Research 
The majority of studies in the related research have been focused on PWID 
populations living in large metropolitan centres. Exceptions include the Prince George cohort 
of the Cedar Project research (Craib et al., 2009; Mehrabadi et al., 2008; Miller et al., 2009; 
Spittal et al., 2012); northern sentinel sites in the I-Track survey including Saskatoon, 
Thunder Bay, Sudbury, and Prince George (PHAC, 2014); and studies conducted in the rural 
Appalachian region of Kentucky (Christian et al., 2010; Havens et al., 2013). In an attempt to 
address the paucity of HCV research outside of large metropolitan centres, the current thesis 
research will explore risk behaviours and characteristics associated with HCV among PWIDs 
living in the northern, non-metropolitan location of Prince George, BC.   
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CHAPTER 3: Research Methods 
 The purpose of this chapter is to describe the research methods used to investigate the 
risk behaviours and characteristics associated with HCV among the Prince George I-Track 
participants. After outlining the harm reduction theoretical framework, a detailed description 
of the categorical variables to be included in the statistical analyses is presented, followed by 
a description of the analytic plan. By the end of Chapter Three, the reader will understand the 
methods used to investigate the research question: What are the risk behaviours and 
characteristics associated with HCV infection among the PWIDs who participated in the 
Prince George I-Track surveys?    
Harm Reduction Framework 
The current thesis research is grounded in a harm reduction conceptual framework. 
Harm reduction is defined as “any policy or program designed to reduce drug-related harm 
without requiring the cessation of drug-use” (Erickson et al., 2002, p. 1). Harm reduction 
policies and programs accept the fact that mind-altering substances will inevitably be used in 
society, and advocate for drug users’ dignity and individual rights regardless of his/her 
choice to use substances (Riley & O’Hare, 2000). Moreover, harm reduction interventions 
focus primarily on the harms resulting from drug use, not the extent of the drug user’s 
addiction (Riley & O’Hare, 2000). However, harm reduction interventions also consider the 
effect of drug-related problems and associated harms beyond the needs of individual users to 
include the interests of the community and society (Riley & O’Hare, 2000).  
A harm reduction framework can be difficult to translate into effective health care 
practices, especially with prevalent societal judgments and stigma placed on persons with 
addictions. Unfortunately, it is often falsely criticized as enabling drug use. But evidence 
shows it actually engages individuals in the first step toward cessation (Riley & O’Hare, 
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2002). Harm reduction is compatible with the pursuit of abstinence, but requires intervention 
programs and health care workers to remain neutral when an individual is not ready to 
abstain (Riley & O’Hare, 2002). Furthermore, harm reduction interventions require ongoing 
advocacy against discriminatory drug and policing policies, and awareness of entrenched 
social inequities such as unstable housing and poverty that can severely interfere with an 
individual’s ability to escape the cycle of addiction (Riley & O’Hare, 2002). The current 
thesis research is grounded in a harm reduction framework, and the results of the 
investigation will contribute to the development of harm reduction services for PWID 
populations in northern BC.  
Research Ethics Approval 
The national I-Track research project was approved by the National Research Ethics 
Board of Health Canada, the Northern Health Research Review Committee, and the Research 
Ethics Board at the Centre for Addiction and Mental Health in Toronto (PHAC, 2013). The 
current thesis research proposal to utilize the Prince George I-Track survey data was 
approved by the University of Northern British Columbia Research Ethics Board in April 
2014 (Appendix A). All ethics approvals followed the Tri-Council Policy Statement for 
Ethical Conduct for Research Involving Humans (CIHR, 2010). 
Obtaining the Data 
As part of the initial data-sharing agreement among the local partners, written consent 
to use the Prince George I-Track survey data for the current thesis research was obtained 
from Carrier Sekani Family Services, Northern Health, and the Northern BC First Nations 
HIV/AIDS Coalition (Appendix B). The local stakeholders agreed that access to study data 
would be granted if all parties gave their consent. They also agreed that future disclosure of 
study results would require approval from all stakeholders. In January 2014, permission to 
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use the Prince George I-Track data was confirmed (E. Palmantier, personal communication, 
January 23, 2014).  
Data Preparation 
 The raw data of the Prince George I-Track surveys was provided by PHAC in a 
digital spreadsheet format. The digital spreadsheet was compatible with IBM SPSS Statistics 
23.0 software and this software was used for all data preparation and analyses. Using SPSS 
Statistics 23.0 software, cleaning the data, filtering incomplete and duplicate cases, and 
merging and re-coding of variables was conducted. The data preparation process for all 
variables investigated in the current thesis research will be described in this section. 
I-Track All-phases Dataset 
The Prince George I-Track all-phases dataset contains 307 subjects and 700 variables 
representing all possible responses to each question asked in the 2008 and 2012 I-Track 
surveys. Responses to several questions in the Phase 2 and Phase 3 questionnaires were 
entered in the all-phases dataset as separate variables due to differences in wording or 
response codes. In order to conduct further analyses, these variables were re-coded and 
merged together to integrate the all-phases data into uniform categorical variables. 
Integrating the data from both I-Track survey phases maximizes the sample size and 
improves the statistical power of data analyses. 
The All-phases Codebook 
The All-phases Codebook is a reference guide for the coding sequences of responses 
to each I-Track survey question and is specific to each sentinel site (PHAC, 2014). The 
Prince George All-phases Codebook numerically lists the I-Track core questions, site specific 
questions, and all responses in a user-friendly manner. When working with the Prince George 
I-Track dataset, the variable names and numeric codes listed in the spreadsheet are easily 
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cross-referenced in the All-phases Codebook to the original survey question and answer key. 
As such, the All-phases Codebook was an invaluable resource throughout the data 
preparation process. 
Cleaning the Data 
Cleaning the data involved 1) becoming familiar with the All-phases Codebook, 2) 
reviewing the numbers entered into variable data columns, and 3) scanning for missing 
values and outliers within each variable. Cleaning the data is a very important process 
because simple problems in the primary data can introduce significant bias and error into the 
advanced data analyses (Field, 2013). Therefore, the first step in data preparation was to use 
the All-phases Codebook to identify and address missing values and outliers. 
 Missing values. Missing values were not found in the dataset because the interviews 
had been conducted using computerized questionnaires whereby the interviewer could not 
advance to the next question unless a numeric response was entered by the interviewer 
(PHAC, 2012). Therefore, there were no literal instances of missing data, but occasional 
responses of “not stated", don't know" and "refused" were recorded. In order to avoid small 
cell sizes, these responses were considered uncertain and were filtered out of the advanced 
analyses. It is strongly recommended that all cell sizes in bivariate analyses have at least five 
cases because test statistics used in advanced analyses are greatly affected by errors if cell 
sizes are too small or empty (Field, 2013; Hilbe, 2009, Hosmer & Lemeshow, 2000; 
Tabachnick & Fidell, 2013).  
Outliers. Creating frequency tables of variables in SPSS allowed for outliers in the 
data to be identified. Outliers are values that are very different or unusual compared to the 
rest of the values in the variable data. Outliers introduce bias into data results and are 
described as “any data point > 3*IQR (Interquartile range)” within a variable (Field, 2013). 
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Therefore, in order for the concept of “outlier” to have any meaning a distance between 
values must be defined. In the current thesis research, all variables were formatted into 
binary, ordinal, or nominal categories and distances between values were not possible. Thus, 
there were no outliers in the categorical variables which may have introduced significant bias 
into the advanced analyses. 
Filtering Incomplete and Duplicate Cases 
 The next step in data preparation was to identify incomplete survey data and duplicate 
cases. Participants included in the sample needed to meet certain eligibility requirements to 
be included in the current thesis research; namely, a valid DBS sample tested for HCV, and a 
complete set of responses to the survey questions. To avoid deleting data from the original 
dataset, a filter variable (FV) was created to allow for the selection of participants from the 
Prince George I-Track sample who were eligible for further analyses in the current thesis 
research. The FV was applied prior to any statistical analyses. 
Incomplete surveys and invalid DBS samples. There were two participants who 
refused to answer any of the survey questions beyond a few initial questions. Although these 
participants provided valid DBS samples for HCV testing, they were excluded from the 
current thesis sample due to missing data for all independent variables. Similarly, eleven 
participants answered the interview questions, but did not provide valid DBS samples. These 
cases were also excluded from the current thesis sample because they had missing values for 
the dependent variable (DV_HCV). Therefore, a total of thirteen participants were excluded 
from the sample and the statistical analyses of the current thesis research.  
Duplicate participants. At the beginning of the I-Track interview, each participant 
provided three initials and a date of birth. Using a computer-generated encryption software, 
these letters and numbers were converted into an encrypted label named encrypt_id to protect 
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the identity of the participant (PHAC, 2012). The encryption process ensured that all personal 
information remained anonymous and confidential throughout the research project (PHAC, 
2012). The encrypt_id variable also allowed for participant characteristics and risk 
behaviours to be linked with their HCV test results (PHAC, 2012).  
 Using the encrypt_id variable, twenty-three duplicate participants (same initials and 
same date of birth) were identified between surveys. Including duplicate participants would 
violate assumptions of independence and introduce significant error into advanced analyses 
(Field, 2013). Therefore, a new variable ENCRYPT_ID was created in which the duplicates 
from the Phase 2 dataset were removed. The removal of duplicates from Phase 2 ensured the 
most recent information from returning participants was included in the analyses. The 
removal of duplicates also explains the difference in number of eligible participants between 
surveys (Phase 2: n = 129, Phase 3: n = 143).  
As described previously, there were thirteen invalid DBS samples and/or incomplete 
questionnaires that were excluded from the sample population. A further twenty-three 
duplicate participants were removed from the Phase 2 dataset, for a total of thirty-six invalid 
participants. However, one of the participants was a duplicate and had also produced an 
invalid DBS in Phase 3. Therefore, a total of thirty-five participants with invalid DBS 
samples or questionnaires, and/or duplicate data needed to be excluded from the original 
sample population prior to further analyses. The final sample included 272 participants. 
Creating a filter variable. A FV was required to select only the participants eligible 
for further analyses in the current thesis research. First of all, a new HCV_VALID variable 
was created by re-coding all invalid DBS samples and/or incomplete questionnaires with a 
value of "0", and all valid DBS samples and complete questionnaires with value of "1". 
Secondly, a new variable ENCRYPT _ID_VALID was also re-coded from the original 
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ENCRYPT_ID variable with all duplicates being coded as “0” and all non-duplicates coded as 
“1”. Finally, a variable ELIGIBLE_PARTICIPANTS was computed by combining all cases 
with “1” values in the ENCRYPT_ID_VALID and HCV_VALID variables. The 
FV_ELIGIBLE_PARTICIPANTS variable was then applied as a filter prior to any further data 
analyses. All further description, analyses, and discussion of the current thesis research is 
based on the filtered sample population of 272 eligible participants.  
Re-coding and Merging of Variables 
 The final step in data preparation was to merge and re-code the dependent and 
independent variables to be used in the analyses. I-Track survey questions that had different 
response codes between phases were re-coded and merged into new variables that shared the 
same answer key. All new variables that were created for the current thesis research were 
displayed in capital letters in the all-phases data file in order to easily distinguish between the 
original raw variables and the new created variables. Once re-coded and merged, the new 
variables contained the integrated all-phases data suitable for further analyses. A detailed 
description of the re-coding and merging process, as well as confirming variable frequencies 
ensures replicability and reliability of the results of the current thesis research. 
Dependent variable (DV) – HCV status. The dependent variable DV_HCV_VALID 
represents each DBS test result and has a binary outcome of 0 = HCV negative, or 1 = HCV 
positive. The proportion of HCV negative participants was 30.1% (n = 82), and HCV positive 
participants was 69.9% (n = 190). The dependent variable DV_HCV_VALID will be used in 
all statistical analyses in the current thesis research.    
Independent variable (IV) – Sharing injection equipment. As noted in the 
literature review, receptive sharing behaviours have been repeatedly associated with HCV 
infection among PWIDs (Kim et al., 2015; Palmanteer et al., 2013; Pouget et al., 2011; Strike 
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et al., 2010). Two questions in both phases of the I-Track survey ask participants about 
receptive sharing behaviours: “In the past 6 months, when you injected drugs, did you use 
NEEDLES and/or SYRINGES that had already been used by someone else including your 
sex partner?” and “In the past 6 months, when you injected drugs, did you use water, filters, 
cookers/spoons, tourniquets\ties, swabs, and/or acidifiers that had already been used by 
someone else?” (PHAC, 2012). The associated variables borrow_needles and 
any_borrow_equip were merged to create the IV_RECEPTIVE_SHARING variable. Of the 
participants who answered the questions, 69.5% (n = 187) denied receptive sharing, and 
30.5% (n = 82) reported receptive sharing in the 6 months prior to the survey. Three 
participants provided uncertain responses and were not included in further analyses.  
IV – Injection years. The literature review repeatedly indicated injection years were 
significantly associated with HCV infection among PWIDs (Craib et al., 2009; Garfein et al., 
2012; Havens et al., 2013; Miller et al., 2009; PHAC, 2010; Roy et al., 2009; Spittal et al., 
2012). Consistent between both phases, the questions “How old are you now?” and “How old 
were you the first time you injected for non-medicinal purposes?” were asked. The responses 
were coded as two continuous variables: age and age_injt (PHAC, 2012). A new continuous 
variable INJECTION_CAREER was computed by subtracting the age_injt from the age 
variable. The new variable had a normal distribution with no identified outliers.  
The INJECTION_CAREER continuous variable was then re-coded into a categorical 
variable named IV_INJECTION_YEARS. The new variable contained two categories: less 
than or equal to 2 years of injecting, and more than 2 years of injecting. These two categories 
were generalized from the related research that had the first two years of IDU as particularly 
high-risk for HCV infections among PWIDs (Havens et al., 2013; Roy et al., 2009; Spittal et 
al., 2012). The IV_INJECTION_YEARS categorical variable identified 14.9% (n = 40) of 
54 
 
participants had been injecting for less than or equal to two years, 85.1% (n = 228) had been 
injecting for more than two years. Four participants had provided uncertain responses and 
were excluded from further analyses.   
IV - Drug of choice. The related research investigated cocaine, amphetamine, 
opiates, and POs injection as risk behaviours associated with HCV infections among PWIDs 
(Bruneau et al., 2012; Grebely et al., 2014; Havens et al., 2013; Miller et al., 2009; Roux et 
al., 2013; Zibbell et al., 2014). Accordingly, the variable IV_DRUG_OF_CHOICE3 was 
created from the variable most_drug, which was associated with the question “In the past 6 
months, which [drug] did you inject most often?” (PHAC, 2012). Drug types were re-coded 
into categories of 1) cocaine/crack; 2) opiates (heroin, prescribed methadone, non-prescribed 
methadone, prescribed morphine, non-prescribed morphine, Diluadid, 
Oxycontin/Oxycodone, Fentanyl, Hydromorph-Contin, Demerol, and Suboxone); 3) 
amphetamine; and 4) other (three reported speedballs and one reported Benzodiazepines).  
Of all I-Track participants, 58.1% (n = 155) reported injecting cocaine most often, 
37.8% (n = 101) reported injecting opiates, 4.1% (n = 11) reported injecting amphetamine, 
and 1.4% (n = 4) reported injecting other substances in the six months prior to the survey. 
Due to small cell size, the fourth category was excluded from further analyses. Three 
participants also provided uncertain responses and were excluded from further analyses.  
The small cell size (n = 11) of the amphetamine category required careful assessment 
during further analyses because small cell sizes can result in unstable multivariate LR models 
and unreliable results (Field, 2013; Hilbe, 2009). In anticipation of this category being 
statistically problematic, an IV_DRUG_OF_CHOICE2 variable was created by combining 
the cocaine/crack and amphetamine categories into a new category labeled stimulants. The 
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two-category variable resulted in 62.6% (n = 166) of participants reporting stimulant use, and 
37.4% (n = 99) reporting opiate use most often in the six months prior to the I-Track survey.  
IV - Injection partners. Injection partners were identified as a risk factor associated 
with HCV among PWIDs in the related literature (Christian et al., 2010; Evans et al., 2014; 
Hahn et al., 2010; Morris et al., 2013; Roy et al., 2011; Wagner et al., 2013). The I-Track 
survey question pertaining to injection partners was “In the past 6 months, with whom did 
you inject most often?” and coincided with the variable most_drug_partner (PHAC, 2012). 
However, the original variable had several categories with less than five responses and 
needed to be re-coded into IV_INJECTION_PARTNERS. The new variable contained two 
categories: 1) inject with others, and 2) inject alone. Of all I-Track participants, 57.4% (n = 
155) reported injecting with others, while 42.6% (n = 115) reported injecting alone. Two 
participants gave uncertain responses and were not included in further analyses. 
IV - Sex trade. Involvement in the sex trade has been identified in the related 
research as a risk factor associated with HCV among PWIDs (Chettiar et al., 2010; 
Mehrabadi et al., 2008; Miller et al., 2011; Roy et al., 2011; Shannon et al., 2010). Both 
phases of the I-Track survey asked the questions: “In the past 6 months, did you have 
vaginal, oral, or anal sex with a CLIENT female sex partner?” and “In the past 6 months, did 
you have vaginal, oral, or anal sex with a CLIENT male sex partner?” (PHAC, 2012). The 
associated variables in the original dataset were f_client_sextype and m_client_sextype, and 
these were merged into a new variable named IV_SEX_TRADE. Of the participants who 
provided responses, 74.1% (n = 197) reported no involvement in the sex trade, and 25.9% (n 
= 69) reported they were involved in the sex trade within the previous six months. Six 
participants provided uncertain responses and were not included in further analyses. 
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IV – Gender. Female gender has been repeatedly identified in the related research as 
significantly associated with HCV among PWIDs (Craib et al., 2009; Cullen et al., 2015; 
Hadland et al., 2012; Hahn et al., 2010; Iversen et al., 2010; Mehrabadi et al, 2008; PHAC, 
2010; Plitt et al., 2010; Roy et al., 2011; Scheidell et al., 2015). The IV_SEX_GENDER 
variable was created by re-coding and combining the data from the Phase 2 sex_birth 
variable and the Phase 3 gender variable. The Phase 2 questionnaire asked "What was your 
sex at birth?" and offered only the answers of "Female" or “Male". The Phase 3 questionnaire 
asked the same question, but with a third option of "Other". The question "Which gender do 
you most identify with?" was also asked in the Phase 3 survey. Three participants responded 
that they were born "Other", but self-identified with female gender. It was decided that 
leaving these three participants in their own category would jeopardize anonymity and 
confidentiality. However, the question of whether to exclude the three transgendered 
participants from the IV_SEX_GENDER variable remained. 
 Gender identity is defined as "one's sense of oneself as male, female or transgender" 
and "is a process of self-identity as chosen by the individual" (American Psychological 
Association, 2011, p. 4). Clinical guidelines developed by the American Psychological 
Association (2011) strongly advocate that transgendered individuals are extremely 
marginalized and misunderstood, and must be treated carefully when involved in research. 
Furthermore, human rights policy enforces "integration and full participation" of 
transgendered persons because "segregation or exclusion is less dignified and unacceptable" 
(Ontario Human Rights Commission, 2014, p. 25). Clearly, including or excluding these 
participants from further analyses was a challenging dilemma.  
 Including the three transgendered participants as female could introduce behaviours 
and characteristics that are significantly different from other female PWID participants, thus 
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influencing the statistical associations of the IV_SEX_GENDER variable. However, exclusion 
of these participants would be unethical and discriminatory. As a result, the three participants 
were re-coded as female and included in the IV_SEX_GENDER variable because 1) this was 
their self-identified gender, 2) they identify with behaviours similar to other females, and 3) 
excluding them would reinforce deeply entrenched social discrimination. The decision 
resulted in the IV_SEX_GENDER variable with two categories: 50.7% (n = 138) female 
participants, and 49.3% (n = 134) male participants. 
IV - Aboriginal status. Several studies in the related research identified Aboriginal 
status as a risk factor associated with HCV infection within the PWID population (Craib et 
al., 2009; Iversen et al., 2010; Lelutui-Weinberger et al., 2009; Mehrabadi et al., 2008; Miller 
et al., 2011; PHAC, 2010; Spittal et al., 2012). The question, “Are you an Aboriginal 
person?" was asked in both phases of the Prince George I-Track survey. The variable 
maintained its original label of aboriginal, and no further re-coding was required prior to 
analyses. Aboriginal status was clearly defined in the interview as Métis, First Nations, 
Aboriginal, Inuit, and non-status Indians and participants self-identified as one of two 
options: "Aboriginal", or “non_Aboriginal" (PHAC, 2012). Of the eligible participants, 
65.3% (n = 177) self-identified as Aboriginal, and 34.7% (n = 94) as non-Aboriginal. One 
participant’s response was uncertain and was excluded from further analyses. 
IV - Housing. Several studies in the related research considered unstable housing as a 
potential risk factor for HCV infection among PWIDs (Feng et al., 2013; Grebely et al., 
2015; Jongbloed et al., 2015; Rachlis et al., 2009). All participants in the I-Track surveys 
were asked the question “In the past 6 months, what types of places have you lived in?” 
(PHAC, 2012). The participant provided “Yes” or “No” answers to a list of fourteen housing 
types read by the interviewer. These included: own apartment, friend’s place, hospital, 
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hotel/motel room, jail or prison, parent’s house, other relative’s house, psychiatric institute, 
recovery house or detox, rooming or boarding house, shelter/hostel, transition house/halfway 
house, and public place (street, park, squats, washroom, stairwell) (PHAC, 2012). To create 
the variable IV_HOUSING, the number of places lived was computed by totalling the number 
of “Yes” answers for all housing variables.  
The Cedar Project research attempted to define unstable housing as “low transience = 
living in one place”, “moderate transience = living in two to five places”, and “high 
transience = living in more than six places” in previous 6 months (Jongbloed et al., 2015, p. 
127). However, such categorization with the Prince George I-Track data resulted in small cell 
sizes and compromised the validity of further analyses. Therefore, the total responses were 
re-coded into the categories 1) one place in past 6 months, and 2) two or more places in past 
6 months. Both categories have adequate cell size for further analyses with 37.5% (n = 102) 
of participants living in one place, and 62.5% (n = 170) living in two or more places within 
Prince George in the six months prior to the I-Track survey.  
IV - Residential mobility. Residential mobility has also been investigated as a risk 
factor associated with HCV among PWIDs in the related research (Callaghan et al., 2007; 
Jongbloed et al., 2015; Montgomery et al., 2012; Rachlis et al., 2008). The I-Track survey 
participants were asked “Have you lived in more than one city or community in the past 6 
months?” and the corresponding variable in the dataset was residence_6months (PHAC, 
2012) There were two possible responses to this question: “No” or “Yes - at least one other 
city or community”. All participants responded to this question, and 69.5% (n = 189) 
reported they had not lived anywhere else, whereas 30.5% (n = 83) reported they had lived in 
at least one other city or community in the previous six months. 
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 IV – Travel to DTES. Another I-Track survey question that captures the residential 
mobility of the Prince George I-Track participants is “In the past 6 months, have you 
travelled to or lived in the Downtown Eastside of Vancouver (DTES)?” (PHAC, 2012). As 
identified in the literature review, travel to and from the DTES to outlying areas such as 
Prince George was suspected to be associated with transmission of HCV infection into rural 
PWID populations (Jongbloed et al., 2015; Mehrabadi et al., 2008; Rachlis et al., 2008). The 
variable for this question in Phase 2 was pg_travel_eastvanc, and Phase 3 was pg_eastside. 
The Phase 2 and Phase 3 variables were merged into a new variable IV_TRAVEL_EASTVAN. 
All participants responded to the question with 88.6% (n = 241) reporting no travel to the 
DTES, and 11.4% (n = 31) reporting travel to the DTES in the previous six months. 
Summary of Data Preparation 
The previous section has described the process of preparing the I-Track data for 
further statistical analyses in the current thesis research. Cleaning the data ensured missing 
values were identified and addressed within the dataset. Creating an FV ensured duplicate 
participants, and those with incomplete questionnaires or invalid DBS samples were 
excluded from further analyses. The final sample population of 272 participants was 
confirmed during the diligent data preparation process. 
The selection of IVs was guided by the related research. Variables were merged and 
re-coded to establish categories that would be meaningful within the current thesis research 
and consistent with the larger body of literature. Frequencies of each variable were assessed 
for adequate cell sizes (greater than five cases), and uncertain responses were filtered out of 
further analyses. The data preparation process confirmed one DV (DV_HCV_VALID), and 
ten IVs to be including in analyses (IV_RECEPTIVE_SHARING; IV_aboriginal; 
IV_INJECTION_YEARS; IV_DRUG_OF_CHOICE (2 and 3); IV_INJECTION_PARTNERS; 
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IV_SEX_TRADE; IV_SEX_GENDER; IV_HOUSING; IV_residence_6months; and 
IV_TRAVEL_EASTVAN). 
Analytic Plan 
 The analytic plan outlines how the data were analyzed to answer the current thesis 
research question: What are the risk behaviours and characteristics associated with HCV 
among PWIDs in Prince George, BC? The statistical method of multivariate logistic 
regression (LR) was selected to generate ORs of associations between the DV and ten IVs, 
and to predict probabilities of group membership of HCV status (yes/no). Building the LR 
model required several steps that are described in the remainder of Chapter Three.  
First of all, bivariate analyses, its assumptions, and the appropriate test statistics will 
be explained. Secondly, the use of multivariate LR, its assumptions, and appropriate test 
statistics will be discussed and the model building process outlined. Selection of IVs to be 
included in the model will be based on the related research findings, as well as clinical 
expertise. Thirdly, assessing the fit of the best LR model will be described. Finally, methods 
for interpreting the results of the multivariate LR will be presented. The results of each step 
outlined in the analytic plan are presented in Chapter Four.   
Bivariate Analyses 
 The study of the statistical relationship between two variables is referred to as 
bivariate analyses (Tabachnick & Fidell, 2013). When analyzing relationships between two 
discrete categorical variables, 2 x 2 contingency tables are created and the chi-square (χ2) test 
of independence is used to evaluate the bivariate relationship (Tabachnick & Fidell, 2013). 
As outlined in the data preparation process, all variables investigated in the current thesis 
research are discrete and categorical. Therefore, χ2 analyses were conducted to assess the 
statistical relationship between the DV and each IV of interest in the study.      
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The χ2 statistical test. The χ2 statistical test is based on differences between expected 
frequencies that are generated by the null hypothesis, and observed frequencies within the 
data (Tabachnick & Fidell, 2013). If the observed frequencies are similar to the expected 
frequencies, the χ2 test result is small, the null hypothesis is retained, and the variables are 
deemed independent (Tabachnick & Fidell, 2013). However, if observed and expected 
frequencies are sufficiently different, the χ2 test result is large, the null hypothesis is rejected, 
and the variables are considered to be related (Tabachnick & Fidell, 2013). The χ2 test 
statistic was used to determine the statistical relationship between the DV and each IV in the 
current thesis research.  
For the purposes of the current research, if the calculated significance for the χ2 test 
statistic was p < .10, the null hypothesis of no relationship between variables was rejected. In 
other words, the relationship between the DV and IV was accepted as statistically significant 
and was selected for multivariate analyses. According to Hilbe (2009), the use p < .250 is 
acceptable unless other standards are expected within a body of research. Conservative p-
values result in fewer variables and is preferable for small sample sizes (Hilbe, 2009). The 
related research used p < .10 in bivariate analyses, and this standard was maintained in the 
current research also. 
Assumptions of χ2 analyses. There are two important assumptions pertaining to χ2 
analyses of categorical data: independence and expected frequencies (Field, 2013). First of 
all, the use of χ2 analyses requires that the assumption of independence is maintained (Field, 
2013; Tabachnick & Fidell, 2013). This means that each case (person, item, or entity) can be 
counted in only one cell of the χ2 table. If the same entity is present in more than one cell, the 
assumption of independence is violated and the χ2 analyses is not valid (Field, 2013). 
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Applying the FV to the Prince George I-Track data resulted in the removal of duplicate cases, 
and maintained the assumption of independence.  
Secondly, χ2 analyses of two categorical variables with two categories each (2 x 2 
contingency tables) requires the expected frequency of cases in all cells to be greater than 
five (Field, 2013; Hilbe, 2009; Hosmer & Lemeshow, 2000; Tabachnick & Fidell, 2013). 
Similarly, in χ2 analyses of two categorical variables with more than two categories, all 
expected frequencies in each cell must be greater than one, and no more than 20% of all cells 
can have less than five cases (Field, 2013; Tabachnick & Fidell, 2013). If the cell sizes are 
too small, the assumption of expected frequencies is violated and the test power is drastically 
reduced (Field, 2013; Tabachnick & Fidell, 2013). During the data preparation process, the 
frequency of cases within each category of each variable was greater than five. However, 
some cell sizes decreased substantially during χ2 analyses and were collapsed into broader 
categories or were removed from further multivariate analyses. 
Summary of bivariate analyses. Upon completion of the χ2 analyses, significant 
relationships (p < .10) between the DV and each of the IVs were identified. If cells did not 
have five cases, the categories of the IV were re-considered, collapsed into broader 
categories, or removed from the multivariate analyses. The final selection of variables for 
multivariate analyses was not limited to statistical significance, but remained grounded in 
clinical knowledge of risk behaviours and characteristics associated with HCV among 
PWIDs (Field, 2013; Hilbe, 2009). 
Multivariate Analyses 
 The relationships between a DV and multiple IVs can be statistically analyzed using 
multivariate LR analyses (Tabachnick & Fidell, 2013). Multivariate LR is very popular in 
health science research because it allows the prediction of binary disease outcomes such as 
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“disease” or “no disease”, and emphasizes the probability of each outcome for each case 
(Tabachnick & Fidell, 2013). Moreover, multivariate LR provides flexibility in analyses 
because it does not require IVs to be normally distributed, nor to be linearly related to the 
DV, nor of equal variance within each group (Tabachnick & Fidell, 2013). The current thesis 
research used multivariate LR to investigate the relationship between the DV and 
multivariate IVs, to estimate ORs, and to predict probabilities of HCV infections among 
PWIDs who participated in the Prince George I-Track surveys.   
Multivariate LR. Multivariate LR involves a discrete DV that is either binary or 
dichotomous, as well as multiple IVs that are discrete, dichotomous, continuous, or a mixture 
of all three (Tabachnick & Fidell, 2013). While linear regression estimates the value of Y 
from known values of one IV (X1) or several IVs (Xs), multivariate LR estimates the 
probability of Y occurring based on known values of IVs (Xs) (Field, 2013). Using 
logarithmic transformations, the non-linear relationships in categorical data can be expressed 
in a linear manner (Field, 2013).  
Known as the logit, the natural (loge) of the odds (ln[odds]) is the link function that 
linearizes the relationship of the categorical DV to multiple IVs (Hilbe, 2009). Using the 
logit, the goal of multivariate LR is “to find the best linear combination of [IVs] that 
maximizes the likelihood of obtaining the observed [DV] frequencies” (Tabachnick & Fidell, 
2013, p. 440). Multivariate LR was used in the current thesis research to compare various 
predictor models estimated from the observed Prince George I-Track data, to select the 
model with the best fit, and to interpret the results of the final LR model. 
Assumptions and issues of multivariate LR. There are several important 
assumptions and issues that must be considered when using multivariate LR. Similar to χ2 
bivariate analyses, the assumption of independence must be maintained, namely; every case 
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(person, item, entity) in each cell must be different and unrelated (Field, 2013; Tabachnick & 
Fidell, 2013). If the same case is present in more than one cell, the independence assumption 
is violated and causes over-dispersion (Field, 2013). Over-dispersion results in very small 
standard errors (SEs), overly large test statistic results, and narrow confidence intervals (CIs) 
which appear very significant, but are actually incorrect (Field, 2013). The dispersion 
parameter (ϕ) is calculated using the χ2 goodness-of-fit statistic, and is concerning if the ratio 
is near or greater than two (Field, 2013). In the current thesis research, over-dispersion was 
not a concern because the FV removed all duplicate cases from the study sample. 
 Secondly, incomplete information causes significant errors in the statistical results of 
multivariate LR (Field, 2013). Within the categories of IVs, if too many cells are empty, or if 
more than 20% of cells have less than five cases, extremely large parameter estimates and 
SEs will result (Field, 2013; Hilbe, 2009; Tabachnick & Fidell, 2013). During the χ2 analyses, 
cells that were empty or had very few cases were identified. As recommended by Tabachnick 
and Fidell (2013), categories with few cases within an IV were collapsed, or the IV was 
excluded from further multivariate LR analyses.  
Another multivariate LR concern is “over-fitting” and occurs when the DV is 
perfectly predicted by one of the IVs in the model (Hosmer & Lemeshow, 2000, p. 92). 
When this occurs, largely over-estimated β coefficients and SEs will be observed, and 
predicted probabilities will be only zero or 1.0 (Hosmer & Lemeshow, 2000). The most 
likely cause of over-fitting is when there are too many IVs and too few cases resulting in 
small cell sizes and instability in the multivariate LR model. One solution to over-fitting 
proposed by Tabachnick and Fidell (2013) is to collect more data, while another solution 
would be to reduce the number of IVs in the multivariate LR model. 
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Hosmer and Lemeshow (2000) suggest using the “rule of ten” to avoid problems of 
over-fitting within multivariate LR models. The “rule of ten” refers to the maximum number 
of events per parameter (variable) in the LR model, and is calculated with the equation “p + 1 
≤ min (n1, n0)/10 parameters” (Hosmer & Lemeshow, 2000, p. 347). According to Hosmer 
and Lemeshow (2000), the rule of ten is considered “a simple solution to a complex problem 
...and should only be used as a guideline for parameter selection in an LR model” (p. 347). 
When applying the events per parameter equation to the current thesis research, the result is 
approximately nine parameters [(272 + 1) (.35) / 10 = 9.55]. Therefore, when building the 
multivariate LR model, nine parameters (variables) were used as a guideline. 
Three other issues common in multivariate LR models include; linearity of the logit, 
outliers in the solution, and multicollinearity (Tabachnick & Fidell, 2013). Linearity of the 
logit is an assumption that there is a linear relationship between all continuous IVs and the 
logit of the DV within the multivariate LR model (Field, 2013). Although important, the 
current thesis research had no continuous IVs, so further explanation of this assumption is 
irrelevant.  
Outliers in the solution refer to “outlier” cases that are very poorly predicted by the 
LR model and show a high probability for belonging to another category (Tabachnick & 
Fidell, 2013). Outliers are found when examining the residuals of the IVs, and the model is 
considered to be a poor fit if there are too many (Tabachnick & Fidell, 2013). The current 
thesis research generated a summary of residual statistics using the SPSS statistics software, 
and the residuals were inspected for unusual cases (Field, 2013). 
Multicollinearity refers to the biasing effect of collinearity of two or more IVs (Field, 
2013). Tabachnick and Fidell (2013) recommend using multiway frequency analyses to 
detect multicollinearity issues, whereas Hosmer and Lemeshow (2000) and Field (2013) 
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recommend using linear regression methods for collinearity analyses. These methods were 
not investigated in the current thesis research because there were no indications of 
multicollinearity; such as “aberrantly large estimated standard errors” or “evidence of 
degradation in the fit” of the model (Hosmer & Lemeshow, 2000, p. 141). 
Selection of IVs for LR model. Regardless of the statistical significance of 
relationships found between the DV and IVs in χ2 bivariate analyses, the selection of IVs for 
multivariate LR modeling was grounded in the theoretical and clinical knowledge of the 
disease of study (Tabachnick & Fidell, 2013). Therefore, variables that lacked statistical 
significance (p > .10) in the bivariate analyses were still included in the multivariate 
analyses. Despite the “rule of ten” recommending the number be limited to nine, ten IVs 
were included in the multivariate LR model because there were no obvious reasons for 
exclusion. Reasons for exclusion of IVs were small cell sizes in categories that could not be 
collapsed, evidence of over-fitting, and/or evidence of multicollinearity. All ten IVs were 
supported as clinically relevant in the related research. 
Interaction terms. Sometimes an interaction between two IVs is significantly 
associated with the DV and can be assessed in an LR model as an interaction term (Field, 
2013). The literature review in the current thesis research repeatedly highlighted Aboriginal 
female PWIDs as being particularly high-risk for HCV infection. Therefore, an appropriate 
interaction term to include in the multivariate LR model would be: IV_aboriginal x 
IV_SEX_GENDER. The interaction term would identify if the combined effect of Aboriginal 
and female characteristics was significantly associated with HCV infection among PWIDs. 
In order to be valid, the inclusion of an interaction term requires that the original IVs also be 
maintained in the multivariate LR model regardless of overall effect (Field, 2013). Therefore, 
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in addition to the ten original IVs, the interaction term IV_aboriginal x IV_SEX_GENDER 
was included in the model.   
Multivariate LR Model Building  
Once the ten IVs had been assessed using χ2 bivariate analyses, all variables 
(regardless of statistical significance) and one interaction variable were included in the 
multivariate LR model using sequential forced entry methods (Field, 2013; Tabachnick & 
Fidell, 2013). In this approach, all IVs and the DV were initially introduced into the full 
model. A new model was then constructed with only the IVs that had statistically significant 
Wald tests (p < .05) and Exp (β) with 95% CIs that did not cross 1.0 (Field, 2013).  
The full model was then compared with the new model using the Omnibus Test of 
Model Coefficient. Using the deviance calculation (-2LL) of each model, this test statistic 
identifies if the full model shows improvement of fit over the new model (Field, 2013). The 
difference between the deviance of each model is treated as a χ2 value and is assigned a p-
value based on the χ2 distribution table. If the fit of the full model shows no significant 
improvement (p > .05), the new model is accepted as the best model (Field, 2013).  
Assessing the fit of the best model. Once selected, the overall fit of the best model 
was confirmed using the Hosmer and Lemeshow (2000) goodness of fit (GOF) test. 
Standardized residuals were analysed using Cooks distance, DF Betas, and leverage values. 
SEs of the coefficient, and the 95% CIs of the Exp (β) were also reviewed. A re-sampling 
procedure called bootstrapping was used to test the reliability of the 95% CIs of the best 
model. Each of these assessment methods confirmed a well-fitted model. 
Hosmer and Lemeshow goodness of fit (GOF) test. The GOF test uses decile tables 
of probability values to compare actual observed counts in the data with fitted or expected 
counts in the model, and theoretically these counts should be close (Hilbe, 2009). Based on a 
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χ2 distribution, a well-fitted model has a low GOF statistic with a p-value greater than .05 
(Hilbe, 2009). However, Hosmer and Lemeshow (2000) strongly recommend that residual 
outliers be analyzed before accepting a model as well-fitted based on the GOF statistic. 
Residual outliers. Examining standardized residuals isolates points where the model 
fits poorly, as well as points that greatly influence the model (Field, 2013). Standardized 
residuals are calculated by SPSS when the LR model is constructed. No more that 5% of 
residuals should be greater than +/- 1.96 and no more than 1% should be greater than +/- 2.58 
(Field, 2013). Cases above 3.0 are also concerning, and must be inspected (Field, 2013). 
Any residuals with a Cooks distance and/or DF Beta value greater than 1.0 greatly 
influence the fit of the model (Field, 2013). Leverage values must be between zero and 1.0, 
and should lie close to the expected leverage value (Field, 2013). Expected leverage is 
calculated by (k + 1)/N where k is the number of predictors and N is the sample size (Filed, 
2013). Values greater than two to three times larger than the expected leverage are overly 
influential on model fit (Field, 2013). The residuals of the best model were carefully 
examined to ensure a well-fitted model.  
Standard errors and 95% CIs of Exp (β). As stated previously, large SEs indicate a 
violation of the assumptions of multivariate LR, such as over-fitting, missing data, and 
multicollinearity (Field, 2013). Therefore, large SEs require careful inspection, adjustment, 
and possible removal of problematic IVs from the model. Additionally, if the 95% CIs of Exp 
(β) included the value of 1.0, the variable was removed from the model because it indicated 
an ambiguous relationship between the IV and DV (Field, 2013). 
Bootstrapping. Bootstrapping is a statistical process whereby multivariate small 
samples (at least 1,000) are randomly taken from the data, and a parameter of interest is 
estimated from each sample (Field, 2013). Each bootstrap sample is returned to the original 
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sample before the next random sample is selected (Field, 2013). Standard deviations are 
estimated and 95% CIs for the β coefficients are estimated (Field, 2013). Large discrepancies 
between the SEs of the original model and the bootstrapped model, as well as CIs that cross 
zero indicate a poorly fit model. Due to the small dataset, a bootstrap of 1,000 samples was 
implemented and assessed in the multivariate analyses. 
Interpreting the results of the best model. Multivariate LR models are used to 
predict the category of the DV (e.g., HCV positive and HCV negative) to which an individual 
case belongs (Tabachnick & Fidell, 2013). Once the best model is established and an 
acceptable fit confirmed, the results of the best model can be interpreted in several ways. The 
current thesis research interpreted the ORs for HCV exposure, and estimated predictive 
probabilities from the multivariate LR model. 
Odds ratios (ORs). ORs are an important method of interpreting multivariate LR 
modeling. The OR is defined as “the change in odds of being in one of the categories of 
outcome when the value of the predictor increases by one unit” (Tabachnick & Fidell, 2013, 
p. 463). An OR greater than 1.0 indicates an increase in the odds of having the outcome of 
study (HCV positive). Conversely, an OR less than 1.0 indicates reduced odds of having the 
outcome. The equation for calculating ORs is: OR = (a/b) / (c/d) = a*d / b*c (Tabachnick & 
Fidell, 2013, p. 464). The ORs were displayed in output tables as Exp (β) values along with 
95% CIs for each independent variable entered into the LR model.  
Classification of predicted outcomes. The classification table, classification matrix, 
and a receiver operating characteristic (ROC) curve will be used to interpret predicted 
probability (Ŷi) values. To understand classification and ROC curves, the concepts of 
sensitivity and specificity must be defined (Hilbe, 2009). The sensitivity of a test refers to the 
probability of testing positive and actually having the disease, whereas the specificity of a 
70 
 
test refers to the probability of testing negative and actually not having the disease (Hilbe, 
2009). The point where sensitivity and specificity are the closest in a classification table is 
the optimal cut-off for the percentage of correct classifications (Hilbe, 2009).  
ROC curves utilize predictive probabilities to determine the “model’s ability to 
discriminate between those subjects who experience the outcome of interest versus those who 
do not” (Hosmer & Lemeshow, 2000, p. 160). A multivariate LR model with no predictive 
value (very poor fit) has a slope of 1.0, and an ROC of 0.5 (Hilbe, 2009). As the multivariate 
LR model improves in fit and predictive value, the area under the ROC curve increases 
(Hilbe, 2009).  ROC curve values greater than 0.95 are highly unlikely, and most ROC values 
range from 0.6 to 0.9 for well-fitted models (Hilbe, 2009). An ROC curve was created and 
interpreted in the results of the current thesis research. 
Probability prediction equation. Multivariate LR modeling results can be expressed 
in an equation that predicts the probability of each having the disease outcome (DV = 1.0) 
from a particular combination of scores in the IVs (Tabachnick & Fidell, 2013). As presented 
in Tabachnick and Fidell (2013), the probability prediction equation is: 
  Prob (HCV) = Ŷi =  e (b0 + b1X1i + b2X2i)             
              1 + e (b0 + b1X1i + b2X2i)      
(p. 448). The β coefficients calculated by the multivariate LR model were entered into the 
prediction equation, and HCV probabilities were calculated for each IV category.  
Summary of Analytic Plan 
 The analytic plan has described the analyses methods used in the current thesis 
research. Bivariate χ2 methods were used to evaluate relationships between the DV and each 
IV, and to determine if small cell sizes needed attention. Subsequently, multivariate LR 
analyses assessed the statistical relationships between the DV and multiple IVs, and a 
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predictive LR model was created. A classification matrix and ROC curve visually displayed 
the sensitivity and specificity of the model predictions. Finally, the multivariate LR model 
provided ORs for each IV, and a prediction equation calculated the probability of new cases 
being in one of the DV categories. Results of bivariate and multivariate analyses are 
presented in Chapter Four. 
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CHAPTER 4: Results 
 The results of the analytic plan outlined in Chapter Three will be presented in this 
chapter. First of all, descriptive statistics of the sample population will be presented. 
Secondly, bivariate analyses of the relationship between the DV and each of the selected IVs 
will be conducted. Thirdly, the multivariate LR model will be constructed and goodness-of-
fit test statistics, an examination of residuals, and bootstrapping will assess the fit. Finally, 
the ORs, classification table, classification matrix, ROC curve and prediction equations will 
be interpreted. Discussion of the results are presented in Chapter Five.  
Descriptive Statistics 
 The sample consisted of 272 eligible participants. Within the sample, 50.7% (n = 138) 
were females and 49.3% (n = 134) were males. The age of eligible participants ranged from 
17 years to 65 years. Overall, the population had an average age of 40 years. HCV prevalence 
among eligible participants was 69.9% (n = 190). Table 1 displays percentages of males and 
females in each category of the variables to be included in the bivariate analyses. 
Table 1 
Percentages of male and female participants across categories of study variables 
 
Variable Label 
(Variable Name)  
 
Male 
% (n) 
 
Female 
% (n) 
 
Total 
% (n) 
 
Missing 
% (n) 
 
HCV status (Positive) 
(DV_HCV_VALID) 
 
32.7 (89) 
 
37.1 (101) 
 
69.9 (190) 
 
0.0 (0) 
 
Aboriginal (Yes) 
(IV_aboriginal) 
 
24.0 (65) 
 
41.3 (112) 
 
65.3 (177) 
 
0.4 (1) 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
Two years or less 
More than two years 
 
 
 
9.0 (24) 
41.0 (110) 
 
 
 
6.0 (16) 
44.0 (118) 
 
 
 
14.7 (40) 
83.8 (228) 
 
 
 
1.5 (4) 
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Table 1 (Continued) 
 
Injection partners 
(IV_INJECTION_PARTNERS) 
Injecting alone 
Injecting with others 
 
 
 
20.0 (54) 
29.3 (79) 
 
 
 
22.6 (61) 
28.1 (76) 
 
 
 
42.6 (115) 
57.4 (155) 
 
 
 
0.7 (2) 
 
Unstable housing (Two or more places) 
(IV_HOUSING) 
 
30.9 (84) 
 
31.6 (86) 
 
62.5 (170) 
 
0.0 (0) 
 
Residential mobility (Yes) 
(IV_residence6months) 
 
14.3 (39) 
 
16.2 (44) 
 
30.5 (83) 
 
0.0 (0) 
 
Receptive sharing (Yes) 
(IV_RECEPTIVE_SHARING) 
 
14.1 (38) 
 
16.4 (44) 
 
30.5 (82) 
 
1.1 (3) 
 
Drug of choice* 
(IV_DRUG_OF_CHOICE2) 
Stimulants 
Opiates 
 
 
 
31.1 (83) 
19.1 (51) 
 
 
 
31.1 (83) 
18.7 (50) 
 
 
 
61.0 (166) 
37.1 (101) 
 
 
 
1.9 (5) 
 
Travel to DTES (Yes) 
(IV_TRAVEL_EASTVAN) 
 
5.1 (14) 
 
 
6.3 (17) 
 
11.4 (31) 
 
0.0 (0) 
 
Involved in sex trade (Yes) 
(IV_SEX_TRADE) 
 
2.3 (6) 
 
23.7 (63) 
 
25.9 (69) 
 
2.2 (6) 
* Drug of choice will be investigated using the IV_DRUG_OF_CHOICE2 variable. Supplement Three presents 
the analyses of IV_DRUG_OF_CHOICE3. 
 
Bivariate Analyses 
Using χ2 bivariate analyses, relationships between the DV and each IV were evaluated 
using 2 x 2 contingency tables. Adequate cell sizes (> 5 cases) were confirmed, and 
relationships were considered statistically significant if the χ2 test statistic had a p-value of ≤ 
.10 (Hilbe, 2009). As shown in Table 2, three of the IVs had statistically significant 
relationships with the DV: number of years injecting (IV_INJECTION_YEARS), injection 
partners (IV_INJECTION_PARTNERS), and unstable housing (IV_HOUSING). Seven IVs 
were not statistically significant in the bivariate analyses. According to best practices for 
multivariate LR model-building, statistically significant as well as clinically relevant IVs 
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should be included in multivariate analyses (Field, 2013; Hilbe, 2009; Hosmer & Lemeshow, 
2000; Tabachnick & Fidell, 2013). Therefore, all ten variables were included in the initial 
multivariate LR model. 
Table 2 
Results of bivariate analyses using 2 x 2 contingency tables 
 
Variable Label 
(Variable Name) 
 
HCV Status 
Positive % (n) Negative % (n) 
 
Pearson χ2 
 
p 
 
Aboriginal status (IV_aboriginal) 
Aboriginal 
Non-Aboriginal 
 
 
45.0 (122) 
24.7 (67) 
 
 
20.3 (55) 
10.0 (27) 
 
 
.16 
 
 
.689 
 
Drug of choice 
(IV_DRUG_OF_CHOICE2) 
Stimulants 
Opiates 
 
 
 
42.7 (114) 
27.3 (73) 
 
 
 
19.5 (52) 
10.5 (28) 
 
 
 
.39 
 
 
 
.533 
 
Gender (IV_SEX_GENDER) 
Male 
Female 
 
 
32.7 (89) 
37.1 (101) 
 
 
16.5 (45) 
13.6 (37) 
 
 
1.48 
 
 
.224 
 
Injection partners 
(IV_INJECTION_PARTNERS) 
Inject alone 
Inject with others 
 
 
 
33.4 (93) 
35.6 (96) 
 
 
 
8.1 (22) 
21.9 (59) 
 
 
 
11.27 
 
 
 
.001 
 
Involved in sex trade 
(IV_SEX_TRADE) 
Yes 
No 
 
 
 
17.7 (47) 
53.0 (141) 
 
 
 
8.3 (22) 
21.1 (56) 
 
 
 
.30 
 
 
 
.587 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
Two years or less 
More than two years 
 
 
 
4.5 (12) 
65.7 (176) 
 
 
 
10.4 (28) 
19.4 (52) 
 
 
 
39.19 
 
 
 
.000 
 
Receptive sharing 
(IV_RECEPTIVE_SHARING) 
Yes 
No 
 
 
 
19.7 (53) 
50.6 (136) 
 
 
 
10.8 (29) 
18.9 (51) 
 
 
 
1.79 
 
 
 
.181 
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Table 2 (Continued) 
 
Residential mobility 
(IV_residence6months) 
Yes 
No 
 
 
19.5 (53) 
50.4 (137) 
 
 
11.0 (30) 
19.1 (52) 
 
 
2.04 
 
 
.153 
 
Travel to DTES 
(IV_TRAVEL_EASTVAN) 
Yes 
No 
 
 
 
8.5 (23) 
61.4 (167) 
 
 
 
2.9 (8) 
27.2 (74) 
 
 
 
.31 
 
 
 
.576 
 
Unstable housing (IV_HOUSING) 
One place 
Two or more places 
 
 
28.7 (78) 
41.2 (112) 
 
 
8.8 (24) 
21.3 (58) 
 
 
3.40 
 
 
.065 
 
Multivariate Logistic Regression 
 To build the logistic regression model, ten IVs were entered into the multivariate LR 
model with the DV. The interaction variable of IV_SEX_GENDER x IV_aboriginal was also 
included in the model and is justified by multiple studies in the related research (Craib et al., 
2009; Cullen et al., 2015; Hadland et al., 2012; Hahn et al., 2010; Iversen et al., 2010; 
Mehrabadi et al., 2008; PHAC, 2010; Plitt et al., 2010; Roy et al., 2011; Scheidell et al., 
2015). Moreover, female Aboriginal participants were significantly overrepresented in the 
study sample of the current thesis research (χ2 = 33.05, p < .001).  
The results of the initial full model are presented in Table 3. Two IVs had significant 
Wald statistics (p < .05): number of years injecting (IV_INJECTION_YEARS), and injection 
partners (IV_INJECTION_PARTNERS).  
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Table 3 
Initial full model including ten IVs and one interaction variable 
 
Variable 
 
β 
 
SE 
 
Wald 
 
p 
 
Exp (β) 
95% CI 
lower, upper 
 
Aboriginal status 
(IV_aboriginal) 
 
.25 
 
1.06 
 
.06 
 
.813 
 
1.28 
 
.16, 10.16 
 
Aboriginal status x Gender  
(IV_aboriginal x 
IV_SEX_GENDER) 
 
-.06 
 
.76 
 
.01 
 
.941 
 
.95 
 
.21, 4.21 
 
Drug of choice 
(IV_DRUG_OF_CHOICE2) 
 
.10 
 
.33 
 
.10 
 
.756 
 
1.11 
 
.58, 2.12 
 
Gender 
IV_SEX_GENDER 
 
.66 
 
1.06 
 
.39 
 
.532 
 
1.94 
 
.24, 15.39 
 
Injection partners 
(IV_INJECTION_PARTNERS) 
 
.87 
 
.34 
 
6.51 
 
.011 
 
2.39 
 
1.22, 4.68 
 
Involved in sex trade 
(IV_SEX_TRADE) 
 
-.46 
 
.43 
 
1.12 
 
.290 
 
.63 
 
.27, 1.48 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
 
2.16 
 
.43 
 
24.74 
 
.000 
 
8.67 
 
3.70, 20.31 
 
Receptive sharing 
(IV_RECEPTIVE_SHARING) 
 
-.09 
 
.35 
 
.06 
 
.803 
 
.92 
 
.46, 1.81 
 
Residential mobility 
(IV_residence6months) 
 
-.53 
 
.36 
 
2.24 
 
.135 
 
.59 
 
.30, 1.18 
 
Travel to DTES 
(IV_TRAVEL_EASTVAN) 
 
.23 
 
.49 
 
.21 
 
.646 
 
1.25 
 
.48, 3.27 
 
Unstable housing 
(IV_HOUSING) 
 
-.33 
 
.35 
 
.85 
 
.356 
 
.72 
 
.36, 1.44 
 
Constant 
 
-4.75 
 
1.91 
 
5.98 
 
.014 
 
.01 
 
 
Table 4 displays the new model that was created including only the two significant 
variables: number of years injecting (IV_INJECTION_YEARS) and injection partners 
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(IV_INJECTION PARTNERS). Using sequential logistic regression methods, the fit of the 
new model was compared with the fit of the full model. As shown in Table 5, the Omnibus 
Test of Model Coefficients shows the difference between the deviance (-2LL) of the full 
model and the deviance of the new model results in an insignificant χ2 (p = .585). Thus, the 
new model containing only two variables is a better fit and is accepted as the best model. 
Table 4  
New model including two significant IVs 
 
Variable 
 
Β 
 
SE 
 
Wald 
 
p 
 
Exp (β) 
95% CI 
lower, upper 
 
Injection partners 
IV_INJECTION_PARTNERS 
 
.87 
 
.33 
 
7.16 
 
.007 
 
2.38 
 
1.26, 4.50 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
 
2.17 
 
.42 
 
27.18 
 
.000 
 
8.78 
 
3.88, 19.86 
 
Constant 
 
-4.26 
 
.91 
 
21.89 
 
.000 
 
.01 
 
 
Table 5 
Test statistics comparing the fit of the new model with the initial full model 
 
Test statistic 
 
New model 
 
Full model 
 
Omnibus Test of Model 
Coefficients (Block) 
 
χ2 = 40.42, df (2), p < .001 
 
χ2 = 7.69, df (9), p = .565 
 
-2 Log Likelihood (-2LL) 
 
261.11 
 
253.42 
 
After selecting the new model over the full model, multivariate LR was conducted 
once more to create a final best model of the two significant IVs number of years injecting 
(IV_INJECTION_YEARS) and injection partners (IV_INJECTION_PARTNERS). The 
results of the final best model are presented in Table 6. Changes in values in the final best 
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model as compared with the previous models are due to an increased number of selected 
cases. The initial full model had twenty cases with missing observations that were removed 
from the analyses resulting in 252 selected cases. The final best model had only six cases 
removed due to missing observations resulting in 266 cases selected for the LR analyses. 
Table 6 
Final best model including two significant IVs 
 
Variable 
 
β 
 
SE 
 
Wald 
 
p 
 
Exp (β) 
95% CI 
lower, upper 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
 
2.06 
 
.40 
 
 
26.75 
 
.000 
 
7.87 
 
3.60, 17.18 
 
Injection Partners 
IV_INJECTION_PARTNERS 
 
.91 
 
.31 
 
8.52 
 
.004 
 
2.49 
 
1.35, 4.59 
 
Constant 
 
-4.17 
 
.87 
 
23.25 
 
.000 
 
.02 
 
 
Assessing the Fit of the Best Model 
 The final best model had an insignificant Hosmer and Lemeshow GOF test result of 
χ2 = .37, p = .832 indicating a well-fit model. The dispersion parameter is calculated as χ2 
(.37) / df (2) = .185. The value was not greater than one and over-dispersion was not a 
concern. Over-dispersion indicates a violation in the assumption of independence where the 
same cases are represented in more than one category and would be indicated by very small 
SEs, overly large test statistic results, and narrow confidence intervals (CIs) which appear 
very significant, but are actually incorrect (Field, 2013). Not surprisingly, over-dispersion is 
not a concern because the filter variable (FV_ELIGIBLE_PARTICIPANTS) removed all 
duplicate cases from the sample population. 
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 Residual outliers. A case-wise listing of standardized z-score residuals showed no 
outliers greater than two standard deviations = +/- 2.58. However, examining the 
standardized z-score residuals indicated fourteen cases (5%) were outside of +/- 1.96. The 
percentage of standardized z-score residuals within this range matches the acceptable limit of 
5% (Field, 2013). Upon closer inspection, all fourteen cases reported injecting alone and 
injecting for more than two years: the two risks behaviours significantly associated with 
HCV infection in the multivariate LR model. However, all fourteen cases were HCV 
negative and represent PWIDs who have managed to remain uninfected despite high-risk 
behaviours. These cases represent points where the model fits poorly (Field, 2013).  
 All Cook’s distance values were less than one, and all DF Betas of the constant and 
the IVs were also less than one. The outer leverage limits were calculated as 3(k + 1) / N = 
0.03. Eleven cases (4%) were found to have leverage values greater than the acceptable outer 
limit. Closer inspection revealed all cases had reported injecting for less than two years and 
were injecting with others, but were HCV positive. These cases represent PWIDs who 
reported low-risk behaviours, but had still been infected with HCV. Once again, these cases 
represent points where the model fits poorly (Field, 2013). 
Bootstrapping. A bootstrap was completed and results are presented in Table 7.      
SEs and 95% CIs are not excessively large and do not differ greatly from the best model. The 
bootstrap results combined with the GOF tests and standardized residuals confirm the best 
model is well-fitted and acceptable for interpretation.   
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Table 7 
Bootstrap of best model (1,000 samples) 
 
Variable 
 
β 
 
SE 
 
P 
 
Exp (β) 
95% CI 
lower, upper 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
 
2.06 
 
.44 
 
.001 
 
7.86 
 
3.68, 20.57 
 
Injection partners 
(IV_INJECTION_PARTNERS) 
 
.91 
 
.33 
 
.001 
 
2.49 
 
1.37, 4.99 
 
Constant 
 
-1.20 
 
.42 
 
.003 
 
0.30 
 
0.12, 0.63 
 
Interpretation of Multivariate LR Results 
Odds Ratios (ORs) 
Two ORs can be interpreted from the multivariate LR best model results. First of all, 
the adjusted odds associated with being HCV positive are almost 7.9 higher for PWIDs who 
have been injecting for more than two years compared to those injecting for two years of less, 
AOR 7.87, p = .001, 95% CI [3.60, 17.18]. Secondly, the adjusted odds associated with being 
HCV positive are almost 2.5 higher for PWIDs who inject alone compared to those who are 
injecting with others, AOR 2.49, p = .004, 95% CI [1.35, 4.59]. 
Notably, the ORs must not be interpreted as risk ratios (RRs) for two reasons. First of 
all, the I-Track dataset is retrospective and was created by merging single observation points. 
RRs can only be calculated from prospective data collected from multiple points of 
observation such as clinical trials or longitudinal cohort studies (Friis & Sellers, 2009). 
Secondly, although ORs and RRs may approximate when the disease of study is rare, ORs 
will substantially overestimate or underestimate RRs when the disease is common (Andrade, 
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2015; Cummings, 2009). Since HCV infection within the PWID study sample was very 
common (~70%), the ORs in the current thesis research can not be used to approximate RRs.  
Classification Table 
As shown in Table 8, the number of observed HCV positive lab tests was 187 and the 
best model correctly predicted 176 cases as HCV positive. Therefore, the sensitivity of HCV 
true positives is 176/187 = 94.1%. Conversely, the number of observed HCV negative lab 
tests was 79 and the best model correctly predicted 27 as HCV negative. Therefore, the 
specificity of HCV true negatives is 27/79 = 34.2%. The overall percentage of correct 
predictions is calculated as predicted positives + predicted negatives / sample size = 176 + 27 
/ 266 = 76.3%. The observed prevalence of HCV positive lab results was 187 / 266 = 70.3%, 
indicating an overall improvement in correct predictions of 6%. 
Table 8 
 
Classification table of best model results 
 
 
Observed 
 
Predicted 
  
HCV status 
 
Percentage  
HCV negative by 
lab test 
HCV positive by 
lab test 
 
Correct 
 
HCV 
status 
HCV negative by 
lab test 
 
27 
 
52 
 
34.2 
HCV positive by 
lab test 
 
11 
 
176 
 
94.1 
 
Overall Percentage 
   
76.3 
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Classification Matrix 
The classification matrix presented in Figure 3 visually displays the predicted 
probability of group membership (HCV yes/no). HCV positive status is represented by the 
number one (1), and HCV negative status is represented with zero (0). Each number in the 
matrix represents ten cases. Cases with a predicted probability of HCV negative status are 
located to the left of the cut-point of .70, and cases with predicted probability of HCV 
positive status are located to the right. However, the matrix displays ten true positive cases to 
the left of the .70 cut-point that have been incorrectly predicted to be HCV negative by the 
LR model. The matrix also shows there are fifty true negative cases that have been 
incorrectly classified as positive to the right of the .70 cut-point. The true cases that have 
been incorrectly predicted represent points where the multivariate LR model fits poorly.    
 
 
Figure 3. Classification matrix of best model. 
 
             Observed Groups and Predicted Probabilities
     160 +                                                                                                    +
         I                                                                                                    I
         I                                                                                                    I
F        I                                                                      1                             I
R    120 +                                                                      1                             +
E        I                                                                      1                             I
Q        I                                                                      1              1              I
U        I                                                                      1              1              I
E     80 +                                                                      1              1              +
N        I                                                                      1              1              I
C        I                                                                      1              1              I
Y        I                                                                      1              1              I
      40 +                                                                      0              1              +
         I                       1                                              0              1              I
         I                       0                                              0              1              I
         I                       0                  0                           0              0              I
Predicted ---------+---------+---------+---------+---------+---------+---------+---------+---------+----------
  Prob:   0       .1        .2        .3        .4        .5        .6        .7        .8        .9         1
  Group:  0000000000000000000000000000000000000000000000000000000000000000000000111111111111111111111111111111
          Predicted Probability is of Membership for HCV positive by lab test
          The Cut Value is .70
          Symbols: 0 - HCV negative by lab test
                   1 - HCV positive by lab test
          Each Symbol Represents 10 Cases.
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Table 9 
Sensitivity and specificity of the ROC curve 
 
HCV positive if greater 
than or equal: 
 
Sensitivity 
 
Specificity 
 
.00 
 
1.00 
 
.00 
 
.33 
 
.96 
 
.25 
 
.57 
 
.94 
 
.34 
 
.78 
 
.47 
 
.82 
 
1.00 
 
.00 
 
1.00 
 
Prediction Equation 
 Predicted probability of having the disease outcome (HCV status = 1) is calculated for 
each category in the IVs using the following equation (Tabachnick & Fidell, 2013, p. 447): 
  Prob (HCV) = Ŷi =  e (b0 + b1X1i + b2X2i)             
           1 + e (b0 + b1X1i + b2X2i)      
As shown in Table 10, the β coefficients calculated in the multivariate LR model are inserted 
into the equation to calculate the predicted probabilities (Tabachnick & Fidell, 2013).  
Table 10 
Predicted probabilities of being HCV positive for each risk behaviour category 
 
Variable 
 
Injects with others 
(IV_INJECTION_ 
PARTNERS = 1) 
 
Injects alone 
(IV_INJECTION_ 
PARTNERS = 2) 
 
Injecting for two years or less 
(IV_INJECTION_YEARS = 1) 
 
Prob (HCV) = 0.23 
 
Prob (HCV) = 0.43 
 
Injecting for more than two years 
(IV_INJECTION_YEARS = 2) 
 
Prob (HCV) = 0.70 
 
Prob (HCV) = 0.86 
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 The calculations indicate if a PWID has been injecting for more than two years and 
reports injecting alone, there is a probability of 0.86 that they will be HCV positive. 
Conversely, if a PWID has been injecting for less than two years and reports injecting with 
others, there in only a probability of 0.23 that they will be HCV positive. Calculations for 
each predicted probability equation are presented in Supplement Three. 
Summary of Results 
 The results of the bivariate and multivariate analyses have been presented in Chapter 
Four. Bivariate analyses were used to identify the associations between the DV and IVs, and 
alert the researcher to small cell sizes. Constructing the multivariate LR model required 
several steps and the fit of the best model was confirmed by several statistical assessments. 
Once the best model was established, ORs, classification table and matrix, ROC curve, and 
predicted probabilities were interpreted. The multivariate LR analyses identified two IVs 
significantly associated with HCV infection: number of years injecting 
(IV_INJECTION_YEARS) and injection partners (IV_INJECTION_PARTNERS). A 
discussion of the public health implications of the results is presented in Chapter Five.  
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CHAPTER 5: Discussion and Conclusion 
The fifth and final chapter of the current research thesis will discuss the results of the 
multivariate LR analyses. First of all, a review of the risk behaviours significantly associated 
with HCV among the Prince George I-Track participants will be presented. Secondly, public 
health implications and limitations of the study are identified, and future recommendations 
proposed. In conclusion, a summation of the study findings and relevance is provided. 
Risk Behaviours Associated with HCV 
The odds of being HCV positive for PWIDs who reported IDU for more than two 
years were almost 7.9, OR 7.87, p < .001, 95% CI [3.60, 17.18]. The predicted probability of 
being HCV positive for PWIDs injecting more than two years and injecting with others vs. 
injecting alone was 0.70 and 0.86, respectively. Thus, the number of years injecting is a very 
important risk behaviour to consider when exploring HCV infections among PWIDs. These 
results are consistent with other studies in the related research that have identified number of 
years injecting to be significantly associated with HCV among PWIDs (Craib et al., 2009; 
Garfein et al., 2012; Havens et al., 2013; Miller et al., 2009; PHAC, 2010; Roy et al., 2009; 
Spittal et al., 2012). 
The odds of being HCV positive for PWIDs who reported injecting alone were almost 
2.5, OR 2.49, p = .004, 95% CI [1.35, 4.59]. The predicted probability of being HCV positive 
for PWIDs injecting alone for more than two years vs. two years or less was 0.43 and 0.23 
respectively. Interestingly, studies in the related research did not investigate PWIDs who 
reported injecting alone, but rather focused on length of injection partnerships and sexual 
partnerships between PWIDs (Christian et al., 2010; Evans et al., 2014; Hahn et al., 2010; 
Morris et al., 2013; Roy et al., 2011; Wagner et al., 2013). It is uncertain why HCV positive 
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PWIDs in the Prince George I-Track survey were significantly more likely to report injecting 
alone when other studies have not identified this phenomenon. 
A possible hypothesis is that PWIDs who are injecting alone are more established in 
their injection behaviours, and/or are more cognizant of the risks of injecting with others. An 
awareness of their own HCV positive serostatus may result in injecting alone to avoid putting 
others at risk. A second hypothesis for the injecting alone phenomenon would be social 
desirability bias affecting participant responses during the survey interview. The lack of 
related research on the phenomenon of injecting alone is puzzling, and further research is 
needed to explore injection behaviours among HCV-positive PWIDs. 
In contrast to those PWIDs who reported injecting alone, those who reported injecting 
with others were much less likely to be HCV positive despite engaging in high-risk 
behaviours. PWIDs may be injecting with others because they are not established in their 
injection behaviours (early initiates or sporadic binge users), are unaware of their own HCV 
serostatus, and/or are unaware of the risks of contracting blood-borne pathogens when 
injecting with others. Such risk-taking behaviours are undoubtedly influenced by multiple 
complex psycho-social factors (e.g., low self-esteem, peer pressure, history of trauma/abuse). 
The results clearly indicate PWIDs who reported injecting with others were significantly 
more likely to be HCV negative, and are at very high-risk for HCV seroconversion. 
Aboriginal Female PWIDs 
 Aboriginal female PWIDs were significantly overrepresented in the study sample (χ2 
= 33.05, p < .001). To explore this overrepresentation, the gender (IV_SEX_GENDER) and 
Aboriginal status (IV_aboriginal) variables were entered into the multivariate LR model. An 
interaction variable (IV_SEX_GENDER x IV_aboriginal) was also included to assess the 
combined effect of gender and Aboriginal status in the model. The multivariate LR analyses 
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did not find any of these variables to be significantly associated with HCV among the PWID 
participants. However, several studies in the related research have clearly identified 
Aboriginal female PWIDs as particularly vulnerable to HCV infections (Craib et al., 2009; 
Iversen et al., 2010; Mehrabadi et al., 2008; Spittal et al., 2012). Although the current thesis 
research did not identify Aboriginal status and female gender as a significantly associated 
characteristics, it is highly suspected that Aboriginal female PWIDS are at very high-risk for 
HCV infection.  
Public Health Implications 
Identifying HCV Positive PWIDs 
Applying the results of the multivariate LR model to clinical practice greatly 
improves the prediction of PWIDs who are HCV positive (sensitivity). Public health 
practitioners can ask PWID patients “How long have you been injecting drugs?” and “Do 
you inject alone or with others?”. If responses are “more than two years” and “injecting 
alone”, they will be able to accurately predict 94.1% of HCV positive PWIDs. As a result, 
PWIDs predicted to be at high-risk for HCV can be targeted for HCV screening, as well as 
ongoing harm reduction interventions to reduce the spread of HCV. 
The ability for health practitioners to identify HCV positive PWIDs is very important 
considering recent advances in DAA treatment for those with chronic hepatitis C (CHC) 
infections. One of the primary recommendations proposed in the Canadian consensus 
guidelines for the management of CHC states: “To reduce the burden of HCV-related 
morbidity and mortality in Canada, strategies for case identification, harm reduction, and 
disease management – including but not limited to antiviral therapy – should be developed 
and implemented” (Myers et al., 2015, p. 2). The current thesis research has found two risk 
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behaviours significantly associated with HCV among PWIDs, and the results greatly improve 
the ability to predict those most likely to be HCV positive.  
Identifying HCV Negative PWIDs 
Ideally, the multivariate LR model would maximize both sensitivity and specificity 
for predicting HCV positive and HCV negative PWIDs respectively. However, the results of 
the multivariate LR model in the current thesis research do not provide a clinically useful 
prediction model for identifying PWIDs who are HCV negative (specificity = 34%). During 
the initial development of the thesis project, identifying HCV negative PWIDs who might be 
at high risk for seroconversion was considered an important goal for harm reduction services 
and HCV prevention within PWID populations. However, further refinement of the 
specificity of the multivariate LR model is now considered clinically irrelevant – especially 
given the transformative changes in HCV treatment at present.  
At this time, public health approaches for HCV management in PWID populations are 
changing dramatically. Ideally, all PWIDs – regardless of likelihood of HCV positive or 
HCV negative status – should be screened and engaged in HCV treatment. Given that 
approximately 70% of PWIDs worldwide are HCV positive (and approximately 70% of the 
Prince George sample were positive) it may be helpful for public health programs to 
implement a seek-and-treat approach for all PWIDs, regardless of risk factors associated with 
HCV status. However, despite the potential success of HCV treatment for infected PWIDs, it 
remains imperative that HCV treatment be combined with ongoing harm reduction services 
such as NEPs to decrease the risk of transmission. The risk factors associated with HCV 
infection among PWIDs identified by the current thesis research provide guidance for such 
public health policies and harm reduction strategies. 
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Limitations 
I-Track Study Design 
 There are several limitations within the I-Track research project that influence the 
results of the current research. First of all, the convenience sampling method introduces a 
selection bias into the data (Lavrakas, 2008). The PWIDs who participated in the I-Track 
survey were familiar with the Prince George NEP, and felt comfortable going to this location 
to complete the survey. However, there may be other PWIDs in Prince George who did not 
complete the survey because 1) they did not know about the survey, 2) did not want to go to 
the NEP to participate due to stigma or triggers, or 3) were not available to participate (e.g., 
out of town, in treatment, incarcerated). As a result, the data may not be truly representative 
of the PWID population, and the generalizability of the current thesis results are limited. 
 Secondly, interviewer bias may have been introduced into the data due to different 
interviewers in each phase of the survey. Despite standardized I-Track training, each 
interviewer would bring their own tone of voice, body language, level of comfort, and 
previous rapport to the interview (Lavrakas, 2008). Moreover, most of the participants were 
familiar with the Phase 3 interviewers because they had all been employees at the NEP. All 
NEP staff are required to teach harm reduction practices to clients whenever possible. For the 
same staff to ask clients about unsafe injection practices and unsafe sexual behaviours may 
have affected what participants were willing to disclose; thus, introducing social desirability 
bias into the results (Lavrakas, 2008). 
Current Thesis Research Methods 
There are also several limitations in the research methods of the current thesis 
research. First of all, the data were obtained from the observational, cross-sectional I-Track 
research survey. As such, the current study is unable to determine causation or temporal 
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change, and associations between the DV and IVs may be greatly influenced by confounding 
factors (Lavrakas, 2008). Secondly, the prevalence estimates obtained from the I-Track 
survey results are only valid for that specific “snapshot” in time. The current thesis research 
relies heavily on those prevalence point estimates, and may not be representative of the true 
HCV prevalence among PWIDs in Prince George. 
Thirdly, merging the datasets from the 2008 and 2012 I-Track surveys almost doubled 
the sample size, but small cell sizes remained a limitation during the multivariate LR 
analyses of the current thesis research. Fourthly, it was assumed that relations between the 
DV and the IVs remained constant across the 2008 and 2012 I-Track survey cycles. 
However, there may have been differences between the two survey cycles that were lost 
when the datasets were merged.  
 Finally, the HCV antibody test used in the I-Track survey only provides prevalence 
estimates of lifetime exposure to HCV, and not necessarily active infection. As outlined in 
Supplement Three, it is broadly estimated that spontaneous clearance of HCV infection 
occurs in 15% to 45% of those infected (BCCDC, 2013; WHO, 2014). Therefore, the HCV 
prevalence estimates used in the current research thesis may be somewhat misleading 
because not all PWIDs who have been exposed to HCV remain infected. Obtaining more 
accurate HCV prevalence estimates would require HCV RNA tests to confirm active 
infections (Myers et al., 2012). Notably, all studies in the related research used HCV 
antibody tests to estimate HCV prevalence and incidence, and such methods may 
substantially over-estimate the true prevalence and incidence of active HCV infections 
among PWIDs.  
Despite limitations in the I-Track study design and the current research thesis 
methods, risk behaviours significantly associated with HCV among PWIDs in Prince George 
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have been identified. Undoubtedly, involving PWIDs in research studies is very challenging 
due to social stigma and marginalization, and the I-Track survey was able to effectively 
engage PWIDs using anonymous, observational, cross-sectional methods. As stated in 
Chapter Two, implementing experimental methods would be impossible without ethical 
ramifications. Therefore, the current thesis research was able to conduct important research 
using the survey data, and the results are very relevant to the health and wellness of the 
Prince George PWID population.   
Recommendations 
Harm Reduction Interventions 
It has been repeatedly evidenced in the related research that sharing of any injection 
equipment is high-risk for HCV seroconversion among PWIDs (Kim et al., 2015; Palmanteer 
et al., 2013; Pouget et al., 2011; Strike et al., 2010). Although the current thesis research did 
not find receptive sharing significantly associated with HCV among the Prince George 
PWIDs, this risk behaviour for HCV seroconversion may be confounded by the number of 
injection years and injecting partners. For example, the longer someone engages in IDU the 
higher the risk for sharing equipment which then leads to HCV infection. Similarly, injecting 
with others increases the risk for sharing equipment and becoming infected with HCV. Thus, 
the underlying risk behaviour for HCV infection remains sharing injection equipment. 
As repeatedly recommended by the BCCDC (2013) and the WHO (2014), harm 
reduction strategies must find methods to provide unlimited availability of sterile injection 
equipment to PWIDs. Additionally, accurate information on the prolonged environmental 
viability of HCV, the risks of injection practices such as "washes", and suggestions of safer 
injection overall must be provided (BCCDC, 2013; WHO, 2014). In accordance with these 
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recommendations, the current thesis research has highlighted the ongoing need for harm 
reduction services for all PWIDs.   
Improvements in HCV Screening 
Throughout the related research and current thesis research, HCV prevalence and 
incidence within PWID populations has been estimated using HCV antibody testing. This 
method of testing is cost-effective and efficient, but it provides only the prevalence of HCV 
exposure, not active infection. However, it is broadly estimated that 15% to 45% of incident 
HCV infections are eliminated by spontaneous clearance of the host’s immune system 
(BCCDC, 2013; WHO, 2014). Therefore, all prevalence estimates based on HCV antibody 
testing must be viewed with caution because they only indicate lifetime exposure to HCV. 
Utilizing HCV RNA tests to confirm active HCV infection would establish accurate 
HCV prevalence estimates and incidence rates, but such tests are very expensive (PHAC, 
2009). A less expensive HCV RNA test that accurately identifies active HCV infection 
(similar to the HIV point-of-care test) would greatly improve the diagnosis of HCV among 
PWIDs (Pawlotsky et al., 2015). In the meantime, HCV prevention, screening, and treatment 
among PWIDs will depend on the timely follow-up of HCV RNA testing after a positive 
HCV antibody test. Such timely follow-up will be dependent on the availability and expertise 
of pubic health practitioners. 
Providing PWIDs with HCV Treatment 
Recent advances in HCV treatment have led to cure rates of more than 90% from 
DAAs (Pawlotsky et al., 2015).  Moreover, DAA treatment are proving accessible and 
sustainable for PWIDs who have previously been excluded due to co-morbidities, risk of 
liver toxicity, and poor adherence (Pawlotsky et al., 2015). Harm reduction-based treatment 
programs designed to establish rapport, maintain adherence, and provide medical monitoring 
94 
 
for PWIDs have proven successful for HIV antiviral programs, and similar initiatives may be 
equally successful with HCV (Pawlotsky et al., 2015). HCV treatment for PWIDS is 
important because decreasing viral loads through effective treatment programs will reduce 
HCV incidence and prevalence among PWIDs. 
Engaging PWIDs in HCV screening and DAA treatment will also greatly reduce the 
financial, social, and personal costs of chronic infection (Myers et al., 2015). The financial 
burden of HCV disease (excluding treatment) in Canada in 2013 was estimated at $52,000 
(non-fibrotic stage) per patient to approximately $328,000 (liver transplant) per patient 
(Myers et al., 2014). Total costs associated with CHC are expected to increase by 60% 
annually to its peak in 2032 (Myers et al., 2014). Current costs of DAAs are estimated at 
$1,000 (USD) per pill for an estimated cost of $56,000 to $84,000 for 8 to 12 weeks of 
uncomplicated treatment (Pawlotsky et al., 2015).  
With an estimated 80% of incident cases occurring among PWIDs, the need for 
prompt HCV screening and treatment interventions is imperative (Degenhardt et al., 2016). 
As stated in the CASL (2015) guidelines, “increased resources are needed to improve HCV 
treatment capacity… including the training of expert treaters and the public funding of 
treatment nurses” (Myers et al., 2015, p. 3). Clearly, the future burden of HCV disease will 
be dependent on current allocations of resources and funding to treat HCV infected PWIDs 
and provide harm reduction services to reduce HCV incidence. The current thesis research 
provides evidence of risk behaviours associated with HCV among PWIDs, and contributes to 
the identification of HCV positive PWIDs in Prince George.  
Rural PWID Populations 
As noted in the summary of Chapter Two, the lack of HCV research focused on 
northern, non-metropolitan populations of PWIDs is a notable gap in the related literature. 
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Prince George is known as “BC’s Northern Capital” because it is an urban hub for the 
northern two-thirds of the province. With a population of approximately 80,000, it is far from 
being a metropolitan centre. However, there are comprehensive health care services available 
in Prince George, and PWIDs living in the city have access to several harm reduction 
programs (e.g., daily NEP and evening Outreach services). As a result of the current health 
care infrastructure in Prince George, developing and implementing an effective HCV 
screening and treatment program would be feasible, and is clearly warranted by the high 
prevalence of HCV among PWIDs identified in the current thesis research.  
The current thesis research found one-third of PWID participants reported living 
outside of Prince George in the six months prior to the surveys. However, residential 
mobility was not found to be a significant risk behaviour associated with HCV in the current 
thesis research, and unfortunately only Phase 3 of the Prince George I-Track survey inquired 
specifically about travel to outlying communities, and was not eligible for advanced analyses. 
Despite these results, it remains strongly suspected that PWIDs living in rural communities 
throughout northern BC are at high risk for HCV infection due to the high prevalence of 
HCV among PWIDs, the reported residential mobility, and limited access to harm reduction 
services in outlying communities. 
Previous research studies have also identified increased residential mobility among 
PWIDs living in outlying communities in northern BC, and have speculated on the high risk 
for HCV transmission (Callaghan et al., 2007; Jongbloed et al., 2015; Mehrabadi et al., 2008; 
Rachlis et al., 2008). Additionally, annual epidemiological data collected by the BCCDC 
indicates the HCV incidence rate in 2015 in the Northwest sub-region was 53.2 per 100,000 
population, and the Northeast sub-region was 54.6 per 100,000 population. Both rates are 
substantially higher than the national incidence rate of 29.4 per 100,000 population (BCCDC, 
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2016). In light of these research findings and the limited availability of harm reduction 
services in outlying communities, an HCV screening campaign for PWIDs living throughout 
northern BC is clearly warranted. 
Aboriginal PWIDs  
According to a study compiled by PHAC (2010), the HCV incidence rate among 
Aboriginals is almost five times higher compared with other Canadians: 4.34 per 100,000 
population vs. 0.90 per 100,000 population respectively. Therefore, not only are Aboriginal 
PWIDs at increased risk for HCV infections, but the general Aboriginal population is also at 
increased risk. In response to the stark difference in HCV incidence between Aboriginals and 
non-Aboriginals, a pilot study similar to the I-Track survey named A-Track was conducted in 
Regina, Saskatchewan in 2011. HCV prevalence of the general Aboriginal population was 
41.6% (n = 434) with significantly more males (46.1%) than females (36.9%) testing positive 
(PHAC, 2014b). With a large Aboriginal population living in northern BC, an A-Track 
survey would establish prevalence estimates and identify risk behaviours among Aboriginals 
vulnerable to HCV infections.  
Specific to Aboriginal PWIDs living in Prince George, a task force similar to the HIV 
AIDS Coalition of the Carrier Sekani Family services (2016) is warranted. Aboriginal leaders 
and health care stakeholders need to establish a task force mandated to address HCV 
infections and engage Aboriginal PWIDs in a culturally appropriate manner. A primary focus 
of the task force would be to engage with Aboriginal female PWIDs and high-risk Aboriginal 
youth, as these sub-populations have been identified in the related research as particularly 
vulnerable. Culturally sensitive HCV screening to estimate prevalence, as well as prompt 
HCV RNA testing and treatment would greatly benefit Aboriginal PWIDs in Prince George.  
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Attitudes toward HCV 
Qualitative research conducted by Rhodes and Treloar (2008) highlighted a common 
belief among PWIDs that HCV is “no big deal”, that “everybody’s got it”, and that they “will 
not live long enough to die from HCV” (Rhodes & Taylor, 2008, p. 1594). Unfortunately, 
dismissive attitudes toward HCV have been inadvertently propagated and perpetuated by 
public health research and initiatives focusing primarily on the HIV epidemic, while ignoring 
the long-term effects of HCV infection (Rhodes & Treloar, 2008). As result, HCV health 
campaigns will need to directly address the entrenched belief systems shared by PWIDs that 
HCV is ubiquitous and trivial compared to HIV. 
In addition to entrenched beliefs normalizing and dismissing HCV, PWIDs have 
displayed much confusion about HCV transmission and testing (Rhodes & Treloar, 2008; 
PHAC, 2012). The risk of sharing any injection equipment (not just needles and syringes) 
must be reiterated, and safer injection practices promoted to decrease the risk of HCV 
infection. Explanations of HCV antibody tests, HCV RNA tests, and the progression of HCV 
to chronic illness must inform PWIDs of long-term health problems related to the illness. 
Careful evaluation of HCV education programs tailored, not only to the PWID population, 
but also to public health practitioners will improve the overall understanding of HCV 
infections, prevent further transmission, and promote treatment for infected PWIDs.  
Conclusion 
For almost two decades, research studies have reported unacceptably high HCV 
prevalence and incidence among PWIDs in Canada. For example, Patrick et al. (2001) 
reported HCV prevalence among PWID participants in the VIDUS study as 81.6%, 95% CI 
[79.6%, 83.6%] long ago in 1999. Unfortunately, the extensive harm reduction and 
prevention efforts tailored to HIV have been ineffective at curbing the spread of HCV within 
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PWID populations. Although some risk factors are similar between HIV and HCV, the latter 
is more complicated due to its prolonged environmental viability, asymptomatic hosts, and 
the ubiquitous sharing of injection equipment (not just needles and syringes) among PWIDs.  
The current thesis research investigated the risk behaviours and characteristics 
associated with HCV infection among PWIDs who participated in the Prince George I-Track 
surveys. Independent variables of interest included receptive sharing, number of years 
injecting, injection partners, drug of choice, unstable housing, residential mobility, female 
gender, travel to DTES, involvement in sex trade, and Aboriginal status. Each of these 
variables were evidenced in the related research as risk behaviours and characteristics 
associated with HCV infection. Using multivariate LR analyses, the current research thesis 
found risk behaviours of injecting for more than two years and injecting alone to be 
significantly associated with HCV among PWIDs in Prince George.  
The results of the current thesis research contribute to knowledge of HCV infections 
among PWIDs living in Prince George, BC. Although not generalizable to other PWID 
populations, the results provide evidence to guide the development of HCV prevention, 
screening and treatment programs tailored to the Prince George PWID populations. It is 
hoped that the current thesis research will increase awareness and understanding of HCV 
infections among PWIDs, promote the ongoing provision of accessible harm reduction 
services to PWIDs, and encourage prompt HCV screening and treatment of infected PWIDs 
to reduce the financial, social, and personal costs of living with chronic HCV infection.   
  
99 
 
References 
Andrade, C. (2015). Understanding relative risk, odds ratios, and related terms. Journal of  
Clinical Psychology, 76 (7), e857-e861. doi: 10.4088/JCP.15f10150 
American Psychological Association. (2011). Definitions Related to Sexual Orientation and  
Gender Diversity in APA Documents. Retrieved on August 18, 2016 from 
https://www.apa.org/pi/lgbt/resources/sexuality-definitions.pdf 
Apsinall, E., Corson, S., Doyle, J., Grebely, J., Hutchinson, S., Dore, G., …Hellard, M.  
(2013). Treatment of hepatitis virus infection among people who are actively 
injecting drugs: A systematic review and meta-analyses. Clinical Infectious Diseases, 
57 (Suppl 2), S80-S89. doi: 10.1093/cid/cit306 
British Columbia Centre for Disease Control [BCCDC]. (2015). Reportable Disease  
Dashboard. Retrieved on April 2, 2017 from http://www.bccdc.ca/health-
info/disease-system-statistics/reportable-disease-dashboard?Disease=Hepatitis+C 
British Columbia Centre for Disease Control [BCCDC]. (2013). Communicable Disease  
Control Manual. Vancouver, British Columbia: BCCDC. 
British Columbia Centre for Disease Control [BCCDC]. (2011). Decreasing HIV infections  
among people who inject drugs by injection in British Columba: Potential 
explanations and recommendations for further action. Vancouver, BC: Office of the 
Provincial Health Officer. 
British Columbia Centre for Disease Control [BCCDC]. (2009). Hepatitis C. British  
Columbia 2009 Annual Summary of Reportable Diseases. Vancouver, BC: Provincial 
Health Services Authority. 
Bruneau, J., Roy, E., Arruda, N., Zang, G., & Jutras-Aswad, D. (2012). The rising prevalence 
100 
 
of prescription opioid injection and its associated with hepatitis C incidence among 
street-drug users. Addiction, 107, 1318-1327. doi:10.1111/j.1360-0443.2012.03803.x 
Callaghan, R., & Cunningham, J. (2002). Intravenous and non-intravenous cocaine abusers 
admitted to inpatient detoxification treatment: a 3-year medical-chart review of 
patient characteristics and predictors of treatment re-admission. Drug and Alcohol 
Dependence, 68, 323-328.  
Callaghan, R., Cull, R., Vettese, L., & Taylor, L. (2006). A gendered analysis of Canadian 
Aboriginal individuals admitted to inpatient substance abuse detoxification: A three-
year medical chart review. The American Journal on Addictions, 15, 380-386. 
doi:10.1080/10550490600860270 
Callaghan, R., Tavares, J., & Taylor, L. (2007). Mobility patterns of Aboriginal injection 
drug users between on- and off-reserve settings in northern British Columbia, Canada. 
International Journal of Circumpolar Health, 66 (3), 241-247. 
Callaghan, R., Strike, C., Kerr, T., Fischer, B., Buxton, J., Stevens, E., …Victor, J. (2008). 
Increasing prevalence of cocaine as the primary detoxification diagnosis among 
admissions presenting with current intravenous drug use. Canadian Journal of Public 
Health, 99 (3), 178-181.  
Callaghan, R.C., Palmantier E, Strike C., Tarasuk, J., Ogunnaike-Cooke, S., Reschny, J.,  
Boire, M., Broomsgrove, S., Moss-Brender, E., Gatley, J.M. (Revision requested). 
Mobility and people who inject drugs: Implications for HIV and hepatitis C 
transmission in Aboriginal and other communities in northern British Columbia, 
Canada. International Journal of Circumpolar Health. 
Carrier Sekani Family Services. (2016). HIV AIDS Coalition. Retrieved on April 2, 2017  
from http://www.csfs.org/services/hiv-aids-coalition 
101 
 
Centre for Addiction and Mental Health (2012). Heroin. Retrieved on April 5, 2017 from  
http://www.camh.ca/en/hospital/health_information/a_z_mental_health_and_addictio
n_information/Heroin/Pages/default.aspx 
Christian, W., Hopenhayn, C., Christian, A., McIntosh, D., & Koch, A. (2010). Viral  
hepatitis and injection drug users in Appalachian Kentucky: A survey of rural health 
department clients. Public Health Reports, 125, 121-128.  
Craib, K., Spittal, P., Patel, S., Christian, W., Moniruzzaman, A., Pearce, M., …Schechter,  
M. (2009). Prevalence and incidence of hepatitis C virus infection among Aboriginal 
young people who use drugs: results from the Cedar Project. Open Medicine, 3(4), 
e220-e227. 
Cullen, K., Hope, V., Croxford, S., Shute, J., Ncube, F., & Parry, J. (2015). Factors 
associated with recently acquired hepatitis C virus infection in people who inject 
drugs in England, Wales and Northern Ireland: new findings from an unlinked 
anonymous monitoring survey. Epidemiology & Infection, 143, 1398-1407. 
doi:10.1017/S0950268814002040 
Cummings, P. (2009). The relative merits of risk ratios and odds ratios. Archives of Pediatric  
and Adolescent Medicine, 163 (5), 438-445. 
Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L., Hickman, M., …Vos,  
T. (2016). Estimating the burden of disease attributable to injecting drug use as a risk 
factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of 
Disease Study 2013. The Lancet Infectious Diseases, 16, 1385-1398. 
doi: http://dx.doi.org/10.1016/S1473-3099(16)30325-5 
De, P., Jolly, A., Cox, J., & Boivin, J. (2006). Characterizing the drug-injecting networks of 
102 
 
cocaine and heroin injectors in Montreal. Canadian Journal of Public Health, 97 (3), 
207-209. 
Doerrbecker, J., Friesland, M., Ciesek, S., Erichsen, T., Mateu-Gelabert, P., Steinmann, J., 
. . . Steinmann, E. (2011). Inactivation and survival of hepatitis C virus on inanimate 
surfaces. Journal of Infectious Diseases, 204, 1830-1838. doi:10.1093/infdis/jir535 
Doerrbecker, J., Behrendt, P., Mateu-Gelabert, P., Ciesek, S., Riebesehl, N., Wilhelm, C., 
…Steinmann, E. (2013). Transmission of hepatitis C virus among people who inject 
drugs: viral stability and association with drug preparation equipment. Journal of 
Infectious Diseases, 207, 281-287. doi:10.1093/infdis/jis677 
Erickson, P., Butters, J. Walko, K., Butterill, D., Caverson, R., …Tupker, E. (2002). Centre 
for Addiction and Mental Health (CAMH) and harm reduction: A background paper 
on its meaning and application for substance use issues. Retrieved from 
http://www.camh.ca/en/hospital/about_camh/influencing_public_policy/public_polic
y_submissions/harm_reduction/Pages/harmreductionbackground.aspx 
Evans, J., Morris, M., Yu, M., Page, K., & Hahn, J. (2014). Concordance of risk behaviour 
reporting within HCV serodiscordant injecting partnerships of young injection drug 
users in San Francisco, CA. Drug and Alcohol Dependence, 142, 239-244. 
doi:10.1016/j.drugalcdep.2014.06.028 
Field, A. (2013). Discovering Statistics Using IBM SPSS Statistics (4th ed.). Thousand Oaks, 
California: Sage Publications Inc. 
Friis, R., & Sellers, T. (2009). Epidemiology for Public Health Practice (4th ed.).  
Mississauga, Ontario: Jones and Bartlett Publishers. 
Garfein, R., Rondinelli, A., Barnes, R., Cuevas, J., Metzner, M., Velasquez, M., …Teshale, 
103 
 
E. (2012). HCV infection prevalence lower than expected among 18-40-year-old 
injection drug users in San Diego, CA. Journal of Urban Health, 90 (3), 516-528. 
doi:10.1007/s11524-012-9728-0 
Gillies, M., Palmanteer, N., Hutchinson, S., Ahmed, S., Taylor, A., & Goldberg, D. (2010). 
The provision of non-needle/syringe drug injecting paraphernalia in the primary 
prevention of HCV among injection drug users: a systematic review. BMC Public 
Health, 10 (721). Retrieved from http://www.biomedcentral.com/1471-2458/10/721 
Grebely, J., Lima, V., Marshall, B., Milloy, M., DeBeck, K., Montaner, J., …Wood, E. 
(2014). Declining incidence of hepatitis C virus infection among people who inject 
drugs in a Canadian setting, 1996-2012. Public Library of Science, 9 (6), e97726. 
doi:10.1371/journal.pone.0097726 
Hagan, H., Pouget, E., Williams, I., Garfein, R., Strathdee, S., Hudson, S., …Ouellet, L. 
(2010). Attribution of hepatitis C virus seroconversion risk in young injection drug 
users in 5 US cities. Journal of Infectious Diseases, 201, 378-385. 
doi:10.1086/649783 
Hahn, J., Evans, J., Davidson, P., Lum, P., & Page, K. (2010). Hepatitis C virus risk  
behaviours within the partnerships of young injecting drug users. Addiction, 105, 
1254-1264. doi:10.1111/j.1360-0443.2010.02949.x 
Harm Reduction Coalition (2011). Getting Off Right Safety Manual. Retrieved on April 5,  
2017 from http://harmreduction.org/drugs-and-drug-users/drug-tools/getting-off-right/ 
Havens, J., Lofwall, M., Frost, S., Oser, C., Leukefeld, C., & Crosby, R. (2013).  
Individual and network factors associated with prevalent hepatitis C infection among 
 rural Appalachian injection drug users. American Journal of Public Health, 103 (1), 
104 
 
e44-e52. doi:10.2105/AJPH.2012.300874 
Hilbe, J. (2009). Logistic Regression Models. Boca Raton, Florida: Chapman & Hall/CRC. 
Hosmer, D., & Lemeshow, S. (2000). Applied Logistic Regression (2nd ed.). New York, NY: 
 John Wiley & Sons, Inc. 
Iversen, J., Wand, H., Gonnermann, A., & Maher, L. (2010). Gender differences in hepatitis 
C antibody prevalence and risk behaviours amongst people who inject drugs in 
Australia 1998-2008. International Journal of Drug Policy, 21, 471-476. 
doi:10.1016/j.drugpo.2010.04.004 
Iversen, J., Dolan, K., Ezard, N., & Maher, L. (2015). HIV and hepatitis C virus infection and 
risk behaviours among heterosexual, bisexual, and lesbian women who inject drugs in 
Australia. LGBT Health, 2 (2), 127-134. doi:10.1089/lgbt.2014.0116 
Jongbloed, K., Thomas, V., Pearce, M., Christian, K., Zhang, H., Oviedo-Joekes, E., 
…Spittal, P. (2015). The Cedar Project: Residential transience and HIV vulnerability 
among young Aboriginal people who inject drugs. Health & Place, 33, 125-131. 
doi:10.1016/j.healthplace.2015.02.008 
Kim, N., Jin, H., McFarland, W., & Raymond, H. (2015). Trends in sources and sharing of 
needles among people who inject drugs, San Francisco, 2005-2012. International 
Journal of Drug Policy, 26, 1238-1243. doi:10.1016/j.drugpo.2015.08.013 
Lavrakas, P. (Ed.). (2008). Encyclopedia of Survey Research Methods (Vols. 1-2). Thousand  
Oaks, California: Sage Publications Inc. 
Lloyd-Smith, E., Kerr, T., Zhang, R., Montaner, J., & Wood, E. (2008). High prevalence of 
syringe sharing among street involved youth. Addiction Research and Theory, 16(4), 
353-358. doi:10.1080/16066350701823094 
Mehrabadi, A., Craib, K., Paterson, K., Adam, W., Moniruzzaman, A., Ward-Burkitt, B., 
105 
 
…Spittal, P. (2008). The Cedar Project: A comparison of HIV-related vulnerabilities 
amongst young Aboriginal women surviving drug use and sex work in two Canadian 
cities. International Journal of Drug Policy, 19(2), 159-168. 
doi:10.1016/j.drugpo.2007.07.005 
Mehrabadi, A., Paterson, K., Pearce, M., Patel, S., Craib, K., Moniruzzaman, A., …Spittal., 
P. (2008). Gender differences in HIV and hepatitis C related vulnerabilities among 
Aboriginal young people who use street drugs in two Canadian cities. Women & 
Health, 48 (3), 235-260. doi:10.1080/03630240802463186 
Miller, C., Johnston, C., Spittal, P. Li, K., Laliberte, N., Montaner, J. & Schechter, M.  
(2002). Opportunities for prevention: Hepatitis C prevalence and incidence in a 
cohort of young injection drug users. Hepatology, 36(3), 737-742. 
doi:10.1053/jhep.2002.35065 
Miller, C., Strathdee, S., Kerr, T., Li, K., & Wood, E. (2006). Factors associated with early 
adolescent initiation into injection drug use: implications for intervention programs. 
Journal of Adolescent Health, 38, 462-464. doi:10.1016/j.jadohealth.2005.03.004 
Miller, C., Kerr, T., Fischer, B., Zhang, R., & Wood, E. (2009). Methamphetamine injection 
independently predicts hepatitis C infection among street involved youth in a 
Canadian setting. Journal of Adolescent Health, 44 (3), 302-304. 
doi:10.1016/j.jadohealth.2008.08.007 
Miller, C., Pearce, M., Moniruzzaman, A., Thomas, V., Christian, W., …Spittal, P. (2011). 
The Cedar Project: Risk factors for transition to injection drug use among young, 
Aboriginal people. Canadian Medical Association Journal, 183(10), 1147-1154. 
doi:10.1503/cmaj.101257  
106 
 
Montgomery, M., Fatch, R., Evans, J., Yu, M., Davidson, P., Page, K., & Hahn, J. (2012). 
Injecting risk behaviour among traveling young injection drug users: travel partner 
and city charcacteristics. Journal of Urban Health, 90 (3), 500-515. 
doi:10.1007/s11524-012-9718-2 
Morris, M., Evans, J., Montgomery, M., Yu, M., Briceno, A., Page, K., & Hahn, J. (2014). 
Intimate injection partnerships are at elevated risk of high-risk injecting: A multi-
level longitudinal study of HCV-serodiscordant injection partnerships in San 
Franscico, CA. Public Library of Science, 9 (10), e109282. 
doi:10.1371/journal.pone.0109282 
Myers, R., Shah, H., Burak, K., Cooper, C. & Feld, J. (2015). An update on the management 
of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for 
the Study of the Liver. Canadian Journal of Gastroenterology and Hepatology, 29 
(1), 19-34. 
Myers, R., Krajden, M., Bilodeau, M., Kaita, K., Marotta, P., Peltekian, K., …Sherman, M. 
(2014). Burden of disease and cost of chronic hepatitis C virus infection in Canada. 
Canadian Journal of Gastroenterology and Hepatology, 28 (5), 243-248. 
Northern Health. (2016). About Northern Health. Retrieved on April 2, 2017 from  
https://northernhealth.ca/AboutUs.aspx 
Ontario Human Rights Commission. (2013). Policy on Preventing Discrimination because of  
Gender Identity and Gender Expression. Retrieved on August 18, 2016 from 
http://www.ohrc.on.ca/sites/default/files/Policy%20on%20preventing%20discriminati
on%20because%20of%20gender%20identity%20and%20gender%20expression.pdf 
107 
 
Paintsil, E., He, H., Peters, C., Lindenbach, B., & Heimer, R. (2010). Survival of hepatitis 
C virus in syringes: Implication for transmission among injection drug users. Journal 
of Infectious Diseases, 202 (7), 984-990. doi:10.1086/656212 
Paintsil, E., Binka, M., Patel, A., Lindenbach, B., & Heimer, R. (2014). Hepatitis C virus 
maintains infectivity for weeks after drying on inanimate surfaces at room 
temperature: Implications for risks of transmission. The Journal of Infectious 
Diseases, 209, 1205-1211. doi:10.1093/infdis/jit648 
Palmanteer, N., Kimber, J., Hickman, M., Hutchinson, S., Rhodes, T., & Goldberg, D. 
(2010). Evidence for the effectiveness of sterile injecting equipment provision in 
preventing hepatitis C and human immunodeficiency virus transmission among 
injecting drug users: a review of reviews. Addiction, 105, 844-859. 
doi:10.1111/j.1360-0443.2009.02888.x 
Palmanteer, N., Hutchinson, S., Innes, H., Schnier, C., Wu, O., Goldberg, D., & Hickman, M. 
(2013). Review and meta-analyses of the association between self-reported sharing of 
needles/syringes and hepatitis C virus prevalence and incidence among people who 
inject drugs in Europe. International Journal of Drug Policy, 24, 85-100. 
doi:10.1016/j.drugpo.2012.08.006 
Pawlotsky, J., Feld, J., Zeuzem, S. & Hoofnagle, J. (2015). From non-A, non-B hepatitis to  
hepatitis C cure. Journal of Hepatology, 62, S87-S99.  
doi: 10.1016/j.jhep.2015.02.006 
Plitt, S., Gratrix, J., Hewitt, S., Conroy, P., Parnell, T., Lucki, B., …Singh, A. (2010). 
Seroprevalence and correlates of HIV and HCV among injecting drug users in 
Edmonton, Alberta. Canadian Journal of Public Health, 101(1), 50-55. 
108 
 
Pouget, E., Hagan, H., & Des Jarlais, D. (2011). Meta-analyses of hepatitis C seroconversion  
in relation to shared syringes and drug preparation equipment. Addiction, 107, 1057-
1065. doi:10.1111/j.1360-0443.2011.03765.x 
Public Health Agency of Canada [PHAC]. (2010a). Epi-update: Hepatitis C virus (HCV)  
among Aboriginal people surveyed by three national enhanced surveillance systems 
in Canada. Ottawa, Canada: Centre for Communicable Disease and Infection Control, 
Infectious Disease Prevention and Control Branch, Public Health Agency of Canada. 
Public Health Agency of Canada [PHAC]. (2010b). Epi-update: Hepatitis C virus (HCV) 
In youth aged 15 to 24 years. Ottawa, Canada: Centre for Communicable Disease and 
Infection Control, Infectious Disease Prevention and Control Branch, Public Health 
Agency of Canada. 
Public Health Agency of Canada [PHAC]. (2013). I-Track: Enhanced surveillance of HIV, 
hepatitis C and associated risk behaviours among people who inject drugs in Canada. 
Phase 2 Report. Ottawa, Canada: Centre for Communicable Disease and Infection 
Control, Infectious Disease Prevention and Control Branch, Public Health Agency of 
Canada. 
Public Health Agency of Canada [PHAC]. (2014a). Summary of key findings from I-Track 
Phase 3 (2010-2012). Ottawa, Canada: Centre for Communicable Diseases and 
Infection Control, Infectious Disease Prevention and Control Branch, Public Health 
Agency of Canada. 
Public Health Agency of Canada [PHAC]. (2014b). A pilot behavioural and biological 
surveillance survey for HIV and other bloodborne infections among Aboriginal 
people in Reginal, Saskatchewan. Ottawa, Canada: Centre for Communicable 
109 
 
Diseases and Infection Control, Infectious Disease Prevention and Control Branch, 
Public Health Agency of Canada. 
Rachlis, B., Hogg, R., Wood, E., Li, K., & Kerr, T. (2008). Factors associated with 
geographic migration among a cohort of injection drug users. Health & Place, 14, 
536-543. doi:10.1016/j.healthplace.2007.10.006 
Rachlis, B., Wood, E., Zhang, R., Montaner, J., & Kerr, T. (2009). High rates of  
homelessness among a cohort of street-involved youth. Health & Place, 15, 10-17. 
doi:10.1016/j.healthplace.2008.01.008 
Rapid Response Service. (2014). Hepatitis C virus (HCV) reinfection rates among people  
who use drugs. Toronto, Ontario: Ontario HIV Treatment Network. 
Rempel, J., & Uhanova, J. (2012). Hepatitis C virus in American Indian/ Alaskan Native and 
Aboriginal peoples of North America. Viruses, 4, 3912-3931. doi:10.3390/v4123912 
Rhodes, T., & Treloar, C. (2008). The social production of hepatitis C risk among injecting  
drug users: a qualitative synthesis. Addiction, 103, 1593-1603. doi:10.1111/j.1360-
0443.2008.02306.x  
Riley, D. & O’Hare, P. (2000). Harm Reduction: Policy and Practice. Retrieved from 
http://canadianharmreduction.com/node/889 
Roux, P., Fugon, L., Jones, J., & Comer, S. (2013). Hepatitis C infection in non-treatment  
seeking heroin users: The burden of cocaine injection. The American Journal on 
Addiction, 22, 613-618. doi:10.1111/j.1521-0391.2013.12058.x 
Roy, E., Boudreau, J., & Boivin, J. (2009). Hepatitis C virus incidence among young street- 
involved injection drug users in relation to injection experience. Drug and Alcohol 
Dependence, 102, 158-161. doi:10.1016/j.drugalcdep.2009.01.006 
Roy, E., Boivin, J., & Leclerc, P. (2011). Initiation to drug injection among street youth: A 
110 
 
gender-based analyses. Drug and Alcohol Dependence, 114, 49-54. 
doi:10.1016/j.drugalcdep.2010.09.003 
Roy, E., Arruda, N., Leclerc, P., Haley, N., Bruneau, J., & Boivin, J. (2012). Injection of 
drug residue as a potential risk factor for HCV acquisition among Montreal young 
injection drug users. Drug and Alcohol Dependence, 126, 246-250. 
Scheidell, J., Khan, M., Clifford, L., Dunne, E., Keen, L., & Latimer, W. (2015). Gender 
differences in planning ability and hepatitis C virus among people who inject drugs. 
Addictive Behaviours, 47, 33-37. doi:10.1016/j.addbeh.2015.03.019 
Shannon, K., Kerr, T., Marshall, B., Li, K., Zhang, R., Strathdee, S., …Wood, E. (2010). 
Survival sex work involvement as a primary risk factor for hepatitis C virus 
acquisition in drug-using youths in a Canadian setting. Archives of Pediatric and 
Adolescent Medicine, 164 (1), 61-65. doi:10.1001/archpediatrics.2009.241  
Spittal, P., Pearce, M., Chavoshi, N., Christian, W., Moniruzzaman, A., Teegee, M., &  
Schechter, M. (2012). The Cedar Project: High incidence of HCV infections in a 
longitudinal study of young Aboriginal people who use drugs in two Canadian cities. 
BMC Public Health, 12 (632). Retrieved from http://www.biomedcentral.com/1471-
2458/12/632  
Spittal, P., Hogg, R., Li, K., Craib, K., Recsky, M., Johnston, C., …Wood, E. (2006). Drastic 
elevations in mortality among female injection drug user in a Canadian setting. AIDS 
Care, 18 (2), 101-108. doi:10.1080/09540120500159292 
Strike, C., Buchman, D., Callaghan, R., Wender, C., Anstice, S., Lester, B., …Millson, M. 
(2010). Giving away used injection equipment: missed prevention message? Harm 
Reduction Journal, 7 (2), 1-7. 
Tabachnick, B., & Fidell, L. (2013). Using Multivariate Statistics (6th ed.). Boston, MA: 
111 
 
Pearson Education, Inc. 
Thibault, V., Bara, J., Nefau, T., & Duplessy-Garson, C. (2011). Hepatitis C transmission in  
Injection drug users: Could swabs be the main culprit? Journal of Infectious Diseases, 
204, 1839-1842. doi:10.1093/infdis/jir650 
Wood, E., Stolz, J., Montaner, J., & Kerr, T. (2006). Evaluating methamphetamine use and  
risks on injection initiation among street youth: the ARYS study. Harm Reduction 
Journal, 3 (18), 1-6. doi:10.1186/1477-7517-3-18 
World Health Organization [WHO]. (2015). Guidelines for the Screening, Care and  
Treatment of Persons with Hepatitis C Infection. Retrieved on April 2, 2017 from 
http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 
Wozniak, L., Prakash, M., Taylor, M., & Wild, C. (2007). Everybody’s got it, but…: 
Situational and strategic participation in normalized HCV discourse among injection 
drug users in Edmonton, Canada. International Journal of Drug Policy, 18, 388-396. 
doi:10.1016/j.drugpo.2007.02.006 
Zibbell, J. (2015). Strategies for preventing hepatitis C among young persons who inject  
 drugs. Washington, DC: Health and Human Services Office of HIV/AIDS and 
 Infectious Disease Policy. 
Zibbell, J., Hart-Malloy, R., Barry, J., Fan, L., & Flannigan, C. (2014). Risk factors for HCV 
infection among young adults in rural New York who inject prescription opioid 
analgesics. American Journal of Public Health, 104 (11), 2226-2232. 
doi:10.2105/AJPH.2014.302142 
 
 
 
112 
 
Appendix A: UNBC Research Ethics Approval 
 
  
113 
 
Appendix B: Consents for Prince George I-Track Data 
 
114 
 
 
115 
 
 
 
 
116 
 
Appendix C: Predicted Probability Calculations 
1) Predicted probability of HCV positive status of PWIDs who have been injecting for less 
than two years (1.0) and have been injecting with others (1.0): 
P (Y) = e (-4.170 + 2.062 * 1.0 + .912 * 1.0) =  e (-1.196)   = 0.302     = 0.23                    
  1 + e (-4.170 + 2.062 * 1.0 + .912 * 1.0)       1 + e (-1.196)    1.302 
2) Predicted probability of HCV positive status of PWIDs who have been injecting for less 
than two years (1.0) and have been injecting alone (2.0): 
P (Y) = e (-4.170 + 2.062 * 1.0 + .912 * 2.0)     = e (-0.284)            = 0.752      = 0.43                 
1 + e (-4.170 + 2.062 * 1.0 + .912 * 2.0)     1 + e (-0.284)          1.752 
3) Predicted probability of HCV positive status of PWIDs who have been injecting for more 
than two years (2.0) and have been injecting with others (1.0): 
P (Y) = e (-4.170 + 2.062 * 2.0 + .912 * 1.0) =  e (0.866)  = 2.377  = 0.70                 
  1 + e (-4.170 + 2.062 * 2.0 + .912 * 1.0)  1 + e (0.866)       3.377 
4) Predicted probability of HCV positive status of PWIDs who have been injecting for more 
than two years (2.0) and have been injecting alone (2.0): 
P (Y) = e (-4.170 + 2.062 * 2.0 + .912 * 2.0) =  e (1.778)  = 5.918     = 0.86                   
  1 + e (-4.170 + 2.062 * 2.0 +. 912 * 2.0)  1 + e (1.778)      6.918 
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Supplement 1: I-Track Research Survey 
 The I-Track research project monitors the prevalence of HIV, HCV and associated 
risk behaviours among persons who inject drugs (PWID) in Canada (Public Health Agency 
of Canada, 2013). The surveillance system was developed as part of the Federal Initiative to 
Address HIV/AIDS to further the understanding of the HIV epidemic (PHAC, 2013). One of 
the key components of the Federal Initiative is the development of knowledge from sentinel 
surveillance programs of vulnerable populations across Canada (PHAC, 2013).  
 The PHAC Centre for Communicable Diseases and Infection Control developed and 
implemented the I-Track surveillance system in collaboration with provincial health 
authorities and community organizations (PHAC, 2013). The primary objectives of the I-
Track research are to describe: 
o the prevalence of HIV and HCV; 
o drug use, injection and sexual behaviours; 
o HIV and HCV testing behaviours; 
o care and treatment history of HIV and HCV 
o core knowledge of HIV-related risk behaviours, modes of 
transmission, and risk reduction strategies; and  
o trends in prevalence and core behavioural measures (PHAC, 2013). 
Ongoing behavioural and biological surveillance can serve as an early warning system for the 
spread of blood-borne infections. Moreover, knowledge gained from the I-Track system 
helps to inform and evaluate the development of public health policies, programs and 
interventions such as new prevention technologies and therapies (PHAC, 2013). 
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Pilot Study 
The I-Track pilot phase was conducted in 2002 and 2003 in four sentinel sites: 
Regina, Sudbury, Toronto and Victoria (Health Canada, 2004). Prior to the pilot project, 
several centres in Ottawa and Quebec (SurvUDI) had already been conducting studies of 
PWIDs since 1995. These SurvUDI sites were included in the pilot phase of the I-Track 
questionnaire and collection of dried blood spot (DBS) specimens (Health Canada, 2004). 
 The purpose of the pilot study was to assess the feasibility of the proposed methods 
for conducting behavioural and biological surveillance of PWID populations across Canada 
(Health Canada, 2004). Research methods included a survey instrument consisting of 35 core 
questions, additional site-specific questions, and a standardized collection of dried blood spot 
(DBS) samples. A total of 794 participants were recruited in the sentinel sites, and an extra 
297 participated at the selected SurvUDI centres (Health Canada, 2004). 
 The results of the pilot study revealed high levels of reported needle sharing, high 
levels of risky sexual activity, and unacceptably high prevalence of HIV (8.1%) and HCV 
(63.8%) infections within PWID populations (Health Canada, 2004). The pilot study also 
successfully demonstrated the overall feasibility of national level risk behaviour surveillance 
and laid the foundation for future phases of the system (Health Canada, 2004).  
Phase 1  
 I-Track Phase 1 was underway by spring of 2003 and was expanded to include seven 
sentinel sites: Edmonton, Regina, Sudbury, Victoria, Toronto, Winnipeg, and the SurvUDI 
centres in Ottawa and Quebec (PHAC, 2006). By May 2005, a total of 3,031 participants had 
completed the survey and provided biological samples for testing of HIV and HCV (PHAC, 
2006). Results revealed an increase in both HIV prevalence (13.2%) and HCV prevalence 
(65.7%). The prevalence of HCV infections between sentinel sites ranged from 61.5% in 
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Winnipeg to 68.5% in Victoria. As a result of the high prevalence estimates, it was 
recommended that the surveillance be expanded to include more urban and semi-urban sites 
to capture local differences between PWID populations (PHAC, 2006). 
Phase 2 
 I-Track Phase 2 occurred between 2005 and 2008, and was expanded once again to 
include ten sentinel sites across Canada: Victoria, Central and North Vancouver Island, 
Prince George, Edmonton, Regina, Thunder Bay, Sudbury, Toronto, Kingston and the 
SurvUDI sites (PHAC, 2013). Results of HIV prevalence (13.2%) remained stable, while 
HCV prevalence (69.1%) continued to increase (PHAC, 2013). Moreover, the addition of 
new sentinel sites revealed substantial geographical variations in HCV infections existed 
between sentinel sites. For instance, the prevalence of HCV among Thunder Bay I-Track 
participants was 50%, while the prevalence of HCV among Prince George I-Track 
participants was 76.7% (PHAC, 2013).   
Phase 3 
 I-Track Phase 3 occurred between 2010-2012 in 11 sites: all of those sites previously 
enlisted, as well as Whitehorse. Overall results revealed a slight decrease in both HIV 
prevalence (11.2%) and HCV prevalence (68%) from the previous Phase 2 results (PHAC, 
2014). In Prince George, the Phase 3 results also showed a 12% decrease from in HCV 
prevalence from 76.7% in 2008 to 65% (PHAC, 2014). Despite the decrease, both Phase 2 
and Phase 3 results identified Prince George I-Track participants as having among the highest 
prevalence of HCV of all sentinel sites (PHAC, 2014).  
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I-Track Research Methods 
 Cross-sectional surveys were conducted at selected sentinel sites during each phase of 
the I-Track research (PHAC, 2006; 2013; 2014). As noted in the I-Track overview section, 
each consecutive phase from the Pilot Study to Phase 3 increased in the number of sentinel 
sites. The target population of the surveillance system included PWIDs over the age of 14, 16 
or 17 (varied by province) who voluntarily participated in the survey (PHAC, 2006). The 
intended research outcomes were point estimates of HIV and HCV serostatus, and reported 
behavioural risk data (PHAC, 2006). 
Sample Size 
 Venue-based, convenience sampling at needle exchange programs (NEPs) offered a 
suitable site for recruitment because of high reported rates of NEP use by PWIDs in Canada 
(Health Canada, 2004; PHAC, 2006). The optimal sample size target was between 150-250 
participants per sentinel site. Smaller communities, such as Prince George, were able to 
obtain the minimum number of participants during each phase of the survey. Length of time 
to achieve the required sample size varied from 2 weeks to 8 weeks, depending on the venue 
and the availability of resources (Health Canada, 2004). The recruitment and sampling of I-
Track participants in Prince George commenced in mid-May and ended in late June in both 
survey phases.  
Recruitment of Participants 
 Recruitment strategies were constrained by time, budget and access to populations 
(Health Canada, 2004). The most popular method for promoting the survey was by word of 
mouth (PHAC, 2013: PHAC, 2014). This occurred within the PWID population, as well as 
by staff working at the sentinel site. Staff involved in the needle exchange program promoted 
the survey to their clients, and directly solicited PWIDs to participate (Health Canada, 2004).  
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 Two weeks prior to the commencement of the Prince George survey, posters and 
pamphlets were distributed by interviewers to 36 community services frequented by PWIDs. 
During Phase 3 recruitment, staff members at the needle exchange and the Wellness Van 
were also given promotional posters and small flyers to hand out to eligible clients. Whether 
by word of mouth or displayed on posters and pamphlets, the purpose of the survey, the 
eligibility requirements, and the $20 reimbursement were clearly explained to potential 
participants (PHAC, 2006). 
Eligibility Criteria 
 All participants were voluntary and fulfilled five eligibility criteria:    
• minimum age of consent (14, 16 or 17 years of age depending on province) 
• IDU within the past 6 months prior to the interview 
• capable of providing informed consent (as determined by site coordinator) 
• able to complete the interview in English or French 
• had not previously participated in the current phase of the survey (PHAC, 2013) 
The site coordinator and/or interviewer determined if the eligibility criteria were adequately 
met for each participant prior to obtaining verbal consent.   
Training of Staff 
 In Prince George, a site coordinator and 3 interviewers were hired by the Northern 
BC Aboriginal HIV/AIDS Coalition and Northern Health. The site coordinator and 
interviewers were trained by the National I-Track co-ordinator and data specialist according 
to the standardized I-Track procedural guidelines. A three-day training workshop reviewed 
all aspects of the survey protocol; namely, research ethics, questionnaire administration, 
routine infection control, dried blood specimen collection technique, awareness of PWID 
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culture/language, and debriefing (PHAC, 2006). The survey team met for two extra training 
days to practice survey interviewing, organize details of participant recruitment and 
screening, and review site-specific safety concerns. 
Survey Implementation in Prince George 
  The Prince George I-Track survey took place at the AIDS Prevention/ Needle 
Exchange Program in the downtown core. Open interview times were scheduled daily and 
conveyed to NEP staff. Potential participants were actively solicited by NEP staff and/or the 
site coordinator when interviews were being conducted. In Phase 2, the site coordinator 
conducted the initial screening of participants because she was an employee of the NEP and 
was familiar with the clients. In Phase 3, both the site coordinator and interviewers conducted 
initial screenings, as they were all employees of the NEP and were familiar with the clients.  
 Interviews were conducted in private offices in the same building as the NEP. For 
safety reasons, at least two members of the I-Track team were always on site together. 
During Phase 2, participants were compensated $20 in cash, whereas in Phase 3 they were 
reimbursed $20 in gift certificates ($10 increments for McDonalds, Tim Hortons or Mohawk 
Bucks). All interviews were conducted on a first come, first served basis during the times 
posted. The site coordinator kept a confidential list of participants’ first names and last initial 
to minimize any duplicates in participation within one survey cycle. 
Data Collection 
Informed consent. Once eligibility was confirmed and the participant was willing to 
proceed, the site coordinator or the interviewer reviewed a description of the survey. 
Participants were asked if they preferred to read the description themselves, or have the 
survey staff read it to them. The consent informed the candidates of their rights as a research 
study participant with respect to 1) choosing not to answer any question, 2) ending the 
123 
 
interview at any time, and 3) the fact that their right to service and/or treatment would not be 
affected by their decision to participate or not (Health Canada, 2004). Verbal consent was 
obtained after the survey description, ethical approval and consent agreement were reviewed 
(Health Canada, 2004). 
 All participants were assessed by the site coordinator or interviewer to be competent 
to give consent prior to starting the survey. Many clients who were willing to participate 
were under the influence of drugs and/or alcohol. Anyone who was too intoxicated to 
participate was kindly encouraged to return at a later time to complete the survey. 
Questionnaire. The interviewer-administered I-Track questionnaire collected 
information on socio-demographic items, characteristics of drug use, injecting and sexual risk 
behaviours, HIV and Hep C testing and treatment history, use of local health services, and 
HIV-related knowledge. The Pilot Study and Phase 1 questionnaires were comprised of 45-
65 core questions which had been adopted from the SurvUDI and other research involving 
PWID risk behaviours. The Phase 2 and Phase 3 questionnaires had 49 and 81 core questions 
respectively. The majority of the questions were step-wise, branching questions with skip 
patterns to ensure that respondents were only asked questions that applied to their responses. 
Both Phase 2 and Phase 3 questionnaires were conducted using a laptop computer program 
designed by the PHAC for interview data collection. Average time for each interview was 
20-30 minutes. 
Site-specific questions. Each sentinel site was encouraged to add site-specific 
questions to the core survey questionnaire. The purpose of the site-specific questions was to 
obtain feedback from PWIDs on local programs and resources (Health Canada, 2004). The 
Prince George I-Track Phase 2 questionnaire had 14 additional questions, and the Phase 3 
questionnaire had 28 (PHAC, 2008; PHAC, 2012). The Prince George site-specific questions 
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were used to improve relations between PWIDs and the RCMP, to support the expansion of 
the NEP to include a mobile outreach van, and to determine the need for crack pipes as a 
harm reduction intervention.   
Post-interview debriefing. At the end of the interview, participants were provided 
with time to ask any questions about the survey. Interviewers also provided harm reduction 
counselling for safer sex and safer injection practices. It was noted during both surveys that 
many I-Track participants were interested in formal HIV and HCV testing immediately after 
the interview. However, a public health nurse was most often not available during the 
interview times. The Prince George I-Track Phase 3 final report recommended that public 
health nursing services be provided concurrently with future phases of the survey for 
participants who were interested in formal HIV and HCV testing after they had completed 
the interview. 
Biological specimen collection. Upon completion of the questionnaire, a biological 
sample (dried blood sample or oral fluid exudates) was collected and tested for HIV and 
HCV antibodies. A suitable finger on the non-dominant hand was cleaned with an alcohol 
swab (PHAC, 2006). A finger prick blood sample was obtained using a Sure-Step micro-
lancet. It had been determined in the pilot study that most participants preferred to have the 
interviewers administer the lancet and to assist with blood extraction (Health Canada, 2004). 
It was noted that when interviewers assisted with DBS collection by performing the lancing 
procedure client stress was reduced, the interview time was shortened and the quality of the 
sample collected was improved (Health Canada, 2004).  
 A large drop of free-flowing blood was collected onto a cotton-fiber based product 
designed for the collection of body fluids (Health Canada, 2004). Five 1/2" diameter 
perforated circles on each specimen collection paper needed to be filled with blood. The 
125 
 
minimum number of circles for adequate testing was three, but most participants were able to 
provide all five (PHAC, 2007). It was emphasized that the blood needed to drop from the 
finger, not be dabbed onto the paper to avoid contamination. A bandage was applied after 
blood collection and routine infection precautions were practiced by all staff (PHAC, 2007).  
 Filter papers were carefully labelled with a computer-generated encrypted code that 
corresponded with the code that was on the participant's completed questionnaire (PHAC, 
2007). There were no personal identifiers on any questionnaire or DBS collection paper. 
Each specimen paper was then allowed to dry in a suspended position for at least 3 hours, 
carefully packaged as per I-Track protocol, and sent to the HIV reference laboratory in 
Ottawa for testing (Health Canada, 2004). 
HCV laboratory testing. The I-Track survey research used DBS specimens to assess 
HCV serostatus. The decision to use DBS came from a combination of information from the 
literature and the results of feasibility exercises (e.g., feasibility for M-Track Ontario Lambda 
survey) (PHAC, 2009). HCV antibody detection, acceptability to participants, cost-
effectiveness, and stability for transportation and storage were all important considerations 
when choosing DBS specimen collection (PHAC, 2009). 
 All I-Track DBS specimens were tested for HCV antibodies at the National HIV and 
Retro-virology Laboratories in Ottawa (PHAC, 2009). HCV testing for DBS specimens was 
conducted using the Ortho Version 3 EIA. Validation testing has concluded that the 
sensitivity and specificity of the Ortho EIA when used with DBS was measured at 96.6% and 
100% respectively (PHAC, 2009). As a result, HCV point estimates obtained through DBS 
specimens and EIA testing are considered valid and reliable. 
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Supplement 2: Hepatitis C Virus 
The hepatitis C virus (HCV) is very unique and complex in its pathogenicity, mode of 
transmission, environmental viability, and natural history. Persons who inject drugs (PWIDs) 
are particularly susceptible to the inherent complexities of HCV, and has manifested into 
very high prevalence of acute and chronic infections within PWID populations. The purpose 
of Supplement Two is to describe the unique qualities of HCV, outline the transmission and 
long-term outcome of HCV infection among PWIDs, and review the challenges of providing 
HCV treatment to the particularly vulnerable PWID population. 
HCV Pathogenicity 
 The HCV genome is classified as genus Hepacivirus within the Flaviviridae family 
(Irshad, Mankotia, & Irshad, 2013; Ray, Bailey, & Thomas, 2013). Initially known as “non-A 
non-B hepatitis”, HCV was identified as a unique infectious virus in 1989 (Irshad et al., 
2013, p. 7896). As with all RNA viruses, HCV has very poor proofreading abilities and 
makes frequent replication errors (Ray et al., 2013). Continuous mutations cause HCV to be 
very heterogeneous with six identified genotypes and 120 identified sub-types or quasi-
species (Irshad et al., 2013). Genotype 1a is the most common HCV genotype found among 
PWIDs in North America and northern Europe (Ray et al., 2013).  
 HCV has been described as an "infectious enigma" because it is extremely mutable 
and is able to evade host immunological detection and elimination (Previsani & Lavanchy, 
2004). Efforts to develop a vaccine to control the spread of HCV have been impeded by the 
multiple infectious genotypes and sub-types dispersed worldwide (Irshad et al., 2013; 
Previsani & Lavanchy, 2004; Ray et al., 2013). Moreover, all HCV genotypes have been 
extremely evasive in their responsiveness to anti-viral treatments (Previsani & Lavanchy, 
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2004). The lack of effective vaccine and unsuccessful anti-viral medications have contributed 
to the rapid spread of HCV among vulnerable populations such as PWIDs.    
HCV Transmission 
 HCV is a blood-borne pathogen transmitted by blood-to-blood contact (BCCDC, 
2013; WHO, 2014). Transmission is most often caused by unsafe medical practices, blood 
transfusions, and injection drug use (BCCDC, 2013; WHO, 2014). High-risk groups include 
health care workers by accidental needle stick injuries; blood transfusion recipients prior to 
1990; and PWIDs by sharing injection equipment (BCCDC, 2013; WHO, 2014). It is 
estimated that 80% of incident HCV infections occur among PWIDs (PHAC, 2011).  
Low risk HCV exposures include: sharing toothbrushes, nail clippers and razors that 
may have tiny amounts of blood on them; skin piercings caused by tattoos, acupuncture or 
electrolysis; sexual intercourse; and vertical transmission during childbirth (BCCDC, 2013; 
WHO, 2014). HCV is not spread by coughing or sneezing; hugging or kissing; sharing 
cutlery or dishes; swimming in treated pools with open cuts or scrapes; being bitten by 
insects such as mosquitoes; skin contact with body fluids such as saliva, feces, urine or 
vomit; or breast-feeding (BCCDC, 2013; WHO, 2014). 
The WHO (2014) estimates 80% of acute and chronic infections remain 
asymptomatic, leaving the host and recipient unaware of the potential for HCV transmission. 
Those who become symptomatic may experience multiple symptoms, including; fever, 
nausea, vomiting, abdominal pain, dark urine, loss of appetite, fatigue, grey stool, arthralgia, 
and jaundice (WHO, 2014). However, with an incubation period ranging from two weeks to 
six months, transmission can occur well before those infected develop symptoms or undergo 
HCV serostatus testing (WHO, 2014).  
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 The ability of HCV infections to remain asymptomatic contributes to the high-risk of 
transmission between unaware PWIDs. Mild flu-like symptoms have been reported during 
the acute phase, but they resemble other viral infections and often remain ignored (BCCDC, 
2013; WHO, 2014). The WHO (2014) strongly recommends that PWIDs presenting with any 
symptoms be screened for HCV due to the high-risk of infection within this population. 
Currently, the most accurate method to identify acute infection is by HCV antibody screening 
followed by viral RNA serology (Chan, 2014). 
Prolonged Environmental Viability 
Since 2010, the ability to create HCV in cell cultures has allowed for increased 
understanding of HCV viability on inanimate vectors and surfaces. In laboratory settings, 
multiple studies have repeatedly demonstrated the ability of HCV to remain infectious 
despite extended environmental exposure (Doerrbecker et al., 2011; Doerrbecker et al., 2013; 
Paintsil et al., 2010; Paintsil et al., 2014; Strike et al., 2010; Thibault et al., 2010). Research 
findings conclude that HCV can be transmitted by sharing contaminated drug injection 
equipment even after it is exposed to heat, cold, or disuse for prolonged periods of time 
(Doerrbecker et al., 2013; Paintsil et al., 2010; Paintsil et al., 2014). The prolonged 
environmental viability of HCV combined with the ubiquitous sharing of injection equipment 
has greatly contributed to the transmission of HCV among PWIDs.          
Natural History of HCV 
Acute HCV Infection 
 The initial six months of HCV infection is considered the acute phase (WHO, 2014). 
HCV enters the human host through blood-to-blood contact and travels to the liver via the 
circulatory system (Ray et al., 2013). Once the virus passes into liver cells (hepatocytes), the 
RNA unwinds and replicates by utilizing the liver's lipoprotein pathways (Ray et al., 2013). 
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HCV RNA continues to replicate and serum RNA levels become detectable within 2-3 weeks 
of exposure, whereas serum HCV antibodies are not detectable until 4-10 weeks after 
exposure (Chan, 2014).  
 Blood-to-blood exposure to HCV triggers both an innate and adaptive immune 
response in the susceptible host. The innate immune response involves natural killer (NK) 
cells that work to rapidly eliminate infected hepatocytes from the liver by cytolysis (Irshad et 
al., 2013). If the host’s NK response is ineffective or compromised, HCV RNA will continue 
to replicate and invade hepatocytes (Irshad et al., 2013). The adaptive immune response is 
delayed, but involves cytolytic T-lymphocytes (CTLs) that are antigen-specific and can 
identify and eliminate HCV-infected hepatocytes (Irshad et al., 2013). The clearance of HCV 
infection depends on the production and persistence of the host’s CTLs (Irshad et al., 2013).  
Spontaneous Clearance of HCV 
 It is broadly estimated that 15% to 45% of incident HCV infections are eliminated by 
effective host immune responses known as spontaneous clearance (BCCDC, 2013; WHO, 
2014). When a host achieves spontaneous clearance, serum HCV antibodies remain 
detectable, but there is no live HCV RNA in the body (BCCDC, 2013). Several factors have 
been associated with spontaneous clearance, including; HCV genotype, host genetic factors, 
female sex, mode of acquisition, clinical symptoms of HCV infection, concurrent 
immunosuppressive therapy, and HIV co-infection (Maasoumy & Wedemeyer, 2012; 
Westbrook & Dusheiko, 2014). Therefore, the host immune response, host characteristics, 
host co-morbidities, and the HCV genotype all influence the spontaneous clearance of acute 
HCV infection. 
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HCV Reinfection 
 Reinfection is defined as “the detection of infection with a strain distinct from the 
primary strain after spontaneous [clearance] or treatment-induced suppression” (Westbrook, 
2014, p. S60). Multiple cohort studies have indicated spontaneous HCV clearance or 
effective anti-viral treatment do not protect against reinfection (Rapid Response, 2014). 
Multiple studies have also indicated the incidence of HCV reinfection is similar to the 
incidence of naïve HCV infection (Rapid Response, 2014). Moreover, broad conclusions 
suggest that in PWID populations with high HCV prevalence, those under the age of 30 who 
have received treatment for HCV appear to be at highest risk for re-infection (Rapid 
Response, 2014). However, more research on HCV reinfection is strongly recommended.  
HCV reinfection among PWIDs highlights the controversy surrounding the provision 
of anti-viral treatment to PWIDs. HCV anti-viral treatments are extremely expensive, and 
providing PWIDs with the treatment remains ethically challenging due to issues of 
medication adherence, severe side effects, and the ongoing risk for HCV reinfection with 
continued injection drug use. Undoubtedly, increased rates of successful anti-viral treatment 
would decrease viral loads and reduce the incidence and prevalence of HCV infections 
among PWIDs. However, reinfection rates may offset the benefits of anti-viral treatment if 
not accompanied by changes in high-risk behaviours such as sharing injection equipment 
(Westbrook & Dusheiko, 2014). Providing expensive anti-viral treatments to infected PWIDs 
and the potential for reinfection is ethically challenging and more research is required.   
HCV Disease Outcomes 
Chronic HCV (CHC) Infection 
If detectable levels of HCV RNA remain persistent in the blood beyond six months it 
is considered to be a chronic infection (WHO, 2014). CHC is confirmed by fluctuating liver 
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enzymes and detectable HCV RNA serum levels (Chan, 2014). Further blood testing 
confirms the viral genotype, while other diagnostics assess the degree of liver damage 
(WHO, 2014). HCV genotype and the extent of liver damage (fibrosis or cirrhosis) are 
important factors to be considered when developing treatment and management plans (WHO, 
2014). CHC infections are not susceptible to spontaneous clearance, and can remain 
undiagnosed until symptoms of liver disease emerge (Westbrook, 2014). 
Over time, the accumulation of necrotic hepatocytes results in fibrotic liver tissue, 
while the loss of healthy hepatocytes results in de-compensated liver function (Irshad et al., 
2013). The gold standard for assessing liver fibrosis is the liver biopsy, but it is costly, 
invasive, requires expert interpretation, and may cause excessive bleeding or liver damage 
(Chan, 2014). Less invasive techniques to determine progression of fibrosis include blood 
tests of albumin levels, platelet count, prothrombin time, and non-invasive sonographic 
elastography to measure liver stiffness (Ray et al., 2013). These tests do not always confirm 
cirrhosis, and a liver biopsy may still be required. 
During CHC infection, hepatic steatosis, oxidative stress and/or insulin resistance 
begin to progress concurrently with hepatocyte necrosis (Irshad et al., 2013). HCV-induced 
steatosis is the accumulation of fat deposits in the liver which also contributes to liver de-
compensation over time (Irshad et al., 2013). HCV interferes with the liver's ability to secrete 
lipids and fatty acids from hepatocytes, and results in lipid accumulations often referred to as 
"fatty liver” disease (Irshad et al., 2013). Moreover, oxidative stress caused by CHC infection 
results in significant liver cell damage due to inflammation from the host immune response. 
As noted by Ray et al. (2013), HCV is not only a very heterogeneous virus, but CHC is also 
very heterogeneous with variable individual manifestations, variable rates of progression, and 
variable disease outcomes. 
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Cirrhosis of the Liver  
One of the long-term outcomes of CHC and liver fibrosis is cirrhosis of the liver. Of 
those who develop CHC, 15-30% will develop liver cirrhosis within 20 years (WHO, 2014), 
while 41% will develop cirrhosis within 30 years of initial infection (Westbrook, 2014). 
Liver cirrhosis is "a condition that results from permanent damage or scarring of the 
liver…[and] leads to a blockage of blood flow that prevents normal metabolic and regulatory 
processes" (Canadian Liver Foundation, 2015). As cirrhosis progresses, the liver is unable to 
filter out toxins leading to toxin accumulation and progressive de-compensated liver function 
(Canadian Liver Foundation, 2015).  
Progressive fibrosis and inflammation of the liver also lead to portal hypertension, 
where blood flow in the liver is restricted and portal venous pressure is greatly increased 
(Westbrook, 2014). Portal hypertension leads to gastric and esophageal varices in 50% of 
patients with cirrhosis (Westbrook, 2014). Excessive bleeding from ruptured varices is the 
second most common cause of death (after hepato-cellular carcinoma) for cirrhotic patients 
with CHC (Westbrook, 2014).   
Hepato-cellular Carcinoma (HCC)  
For patients with CHC infection who develop cirrhosis, the risk of progression to 
HCC is 1-4% per annum (Chan, 2014; Westbrook, 2014). HCC is a cancer that attacks liver 
cells and grows into multiple malignant tumours throughout the liver (Canadian Liver 
Foundation, 2015). However, HCC does not develop in CHC infected patients prior to 
advanced cirrhosis. Multiple studies have shown that providing anti-vial treatment for HCV 
in patients with cirrhosis results in significant risk reduction for the development of HCC 
(Westbrook, 2014). Although the risk for HCC is not completely eliminated, the use of HCV 
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anti-viral treatment shows promising results for reducing the overall burden of disease caused 
by CHC infection (Westbrook, 2014).  
Further Complications 
 Several other factors have been associated with an increased risk for cirrhosis in those 
with CHC infection. These include: age at infection, male gender, alcohol consumption, 
obesity, insulin resistance, Type II diabetes, co-infection with hepatitis B virus or HIV, and 
immunosuppressive and genetic factors (Chan, 2014; Ray et al., 2013; Westbrook, 2014). Of 
particular concern to the PWID population are high rates of HIV/HCV co-infection and 
subsequent disease complications.  
Although effective anti-viral treatments exist for HIV and HCV independently, 
multiple complications arise with concurrent HIV and HCV treatments including hepato-
toxicity and cytopenia (Ray et al., 2013). Accelerated progression of HIV disease has been 
observed in persons co-infected with HIV/HCV, as well as impaired recovery of CD4 cells 
after anti-retro viral therapy treatments (WHO, 2014). PWIDs co-infected with HIV/HCV 
have also shown increased progression of cirrhosis, de-compensated liver, and HCC than in 
those mono-infected with HCV (WHO, 2014).  
It is estimated that HIV/HCV co-infection accounts for 93% of cases of HCC 
(Westbrook, 2014) and co-infection of HIV/HCV has been associated with the development 
of HCC at a much younger age, and a much more rapid onset (WHO, 2014). In addition to 
increased HCC incidence among co-infected patients, there is a much poorer prognosis with 
studies reporting a 10-fold increase in mortality (Westbrook, 2014). Increased prevention and 
screening efforts, combined with the early treatment of HIV and HCV infections may greatly 
decrease the long-term outcome of HIV/HCV co-infections within PWID populations.   
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Recent Advancements in HCV Treatment 
 Advancements in successful HCV treatment has occurred very rapidly over the past 
four years. All-oral, single tablet, direct-acting anti-viral agents (DAAs) are now government 
approved and widely available. With estimated 90% cure rates, DAAs are proving highly 
effective because they target multiple stages of the HCV lifecycle (Pawlotsky, Feld, Zeuzem, 
& Hoofnagle, 2015). According to the Canadian Association for the Study of the Liver 
(CASL) consensus guidelines, HCV genotype 1a (the most common genotype found within 
North American PWID populations) is successfully treated with sofosbuvir 400mg/ 
ledipasvir 90mg (SOF/LDV) for eight to twelve weeks depending on HCV RNA levels 
and/or cirrhosis (Myers, Shah, Burak, Cooper, & Feld, 2015). If contraindicated or 
ineffective, multiple recommendations of other DAA treatment combinations are provided in 
the CASL guidelines (Myers et al., 2015).   
According to the CASL guidelines, injection drug use is considered to be a “relative 
contraindication” and the guidelines recommend that “All patients with chronic HCV 
infection should be considered for antiviral therapy” (Myers et al., 2015, p. 3). However, 
concerns raised about non-adherence are well justified due to the constant threat of HCV 
developing resistance to the DAAs. The enigmatic HCV has a large population of related 
variant viruses known as quasi-species and a high replication rate that results in constant 
mutations (Myers et al., 2015). However, multiple strategies to overcome HCV resistance to 
DAAs are advised, including: avoiding DAA monotherapy, avoiding dose reductions due to 
treatment related side-effects, and maximizing adherence (Myers et al., 2015). Despite 
skepticism about drug adherence among PWIDs, it is strongly recommended that high-risk 
populations receive DAA treatment as soon as possible to reduce viral loads and decrease 
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HCV transmission between hosts, as well as reduce the progression of CHC infections to 
advanced liver disease (Pawlotsky et al., 2015). 
Summary of HCV 
 As outlined in Supplement Two, the HCV pathogen, mode of transmission, natural 
history, and disease outcomes display many unique characteristics. First of all, HCV is highly 
prevalent among PWIDs, and is easily transmitted due to asymptomatic infections and 
ubiquitous sharing of drug injection equipment. Secondly, spontaneous clearance occurs in 
15% to 45% of incident cases, but high rates of reinfection have been evidenced by research. 
Thirdly, those who are asymptomatic remain unaware of CHC infection until advanced liver 
fibrosis or cirrhosis has developed. Fourthly, the progression of cirrhosis to decompensated 
liver disease or HCC is influenced by variations in the host, virus genotype, and the 
environment. Finally, despite concerns of medication adherence and potential risks of 
reinfection, DAA treatment among eligible PWIDs must be promptly implemented to 
decrease the financial, social and personal burden of CHC infections.  
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Supplement 3: Drug of Choice (Three Category) Analyses 
The multivariate LR analyses that was conducted with the three-category drug of 
choice variable (IV_DRUG_OF_CHOICE3) will be presented in this supplement. During 
bivariate analyses, the amphetamine category in the drug of choice variable was found to be 
significantly associated with HCV infection, χ2 = 14.70, df (2), p = .001. Similarly, studies in 
the related research had also indicated amphetamine injection as significantly associated with 
HCV infections among young PWIDS (Grebely et al., 2014; Miller et al., 2009). As a result, 
the three-category drug of choice variable (IV_DRUG_OF_CHOICE3) was thoroughly 
examined in the multivariate analyses before it was deemed problematic and replaced with a 
two-category drug of choice variable (IV_DRUG_OF_CHOICE2).  
As shown in Table 11, the bivariate analyses of HCV status (DV_HCV_VALID) and 
the three-category drug of choice variable (IV_DRUG_OF_CHOICE3) rendered one cell 
with less than five cases (n = 2) in the amphetamine category of HCV positive cases. 
Multiple statisticians have cautioned that small cell sizes in bivariate analyses may become 
problematic in multivariate analyses, resulting in large SEs and large β coefficients (Field, 
2013; Hilbe, 2009; Hosmer & Lemeshow, 2000; Tabachnick & Fidell, 2013). However, due 
to the clinical relevance of the amphetamine category within the multivariate analyses, it was 
decided to proceed with multivariate LR modeling and carefully assess the results. 
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Table 11  
Bivariate analyses of IV_DRUG_OF_CHOICE3 and HCV status 
 
 
Variable Label 
(Variable Name) 
 
HCV Status 
(DV_HCV_VALID) 
Positive % (n)   Negative % (n) 
 
 
Pearson’s 
χ2 
 
 
p 
 
Drug of choice 
(IV_DRUG_OF_CHOICE3) 
Cocaine/ crack 
Opiates 
Amphetamine 
 
 
 
41.9 (112) 
27.3 (73) 
0.7 (2) 
 
 
 
16.1 (43) 
10.5 (28) 
3.4 (9) 
 
 
 
14.70 
 
 
 
.001 
 
Multivariate Logistic Regression 
 The full multivariate LR model including the three-category drug of choice variable 
(IV_DRUG_OF_CHOICE3) is presented in Table 12. Three IVs with significant Wald 
statistics (p < .05) are identified: number of years injecting (IV_INJECTION_YEARS), drug 
of choice: amphetamine (IV_DRUG_OF_CHOICE3), and injection partners 
(IV_INJECTION_PARTNERS).  
Table 12  
Full model including ten IVs (IV_DRUG_OF_CHOICE3) and one interaction variable 
 
Variable 
 
Β 
 
SE 
 
Wald 
 
p 
 
Exp (β) 
95% CI 
lower, upper 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
 
2.16 
 
.45 
 
23.27 
 
.000 
 
8.70 
 
3.61, 20.96 
 
Drug of choice: Cocaine (ref) 
(IV_DRUG_OF_CHOICE3) 
 
 
 
 
 
 
 
10.07 
 
 
.007 
 
 
 
 
 
 
Drug of choice: Opiates 
(IV_DRUG_OF_CHOICE3) 
 
-.18 
 
.35 
 
.27 
 
.602 
 
.83 
 
.42, 1.65 
 
Drug of choice: Amphetamine 
(IV_DRUG_OF_CHOICE3) 
 
-2.84 
 
.89 
 
10.06 
 
.002 
 
.06 
 
.01, .34 
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Table 12 (Continued) 
 
Injection partners 
(IV_INJECTION_PARTNERS) 
 
.94 
 
.37 
 
6.67 
 
.010 
 
2.56 
 
1.25, 5.24 
 
Residential mobility 
(IV_residence6months) 
 
-.67 
 
.38 
 
3.19 
 
.074 
 
.51 
 
.25, 1.07 
 
Receptive sharing 
(IV_RECEPTIVE_SHARING) 
 
-.40 
 
.45 
 
.81 
 
.370 
 
.67 
 
.28, 1.60 
 
Unstable housing 
(IV_HOUSING) 
 
-.32 
 
.37 
 
.75 
 
.387 
 
.725 
 
.35, 1.50 
 
Travel to DTES 
(IV_TRAVEL_EASTVAN) 
 
.47 
 
.55 
 
.72 
 
.396 
 
1.60 
 
.54, 4.69 
 
 
Gender 
(IV_SEX_GENDER) 
 
.66 
 
1.11 
 
.35 
 
.555 
 
1.93 
 
.22, 17.05 
 
Involved in sex trade 
(IV_SEX_TRADE) 
 
-.16 
 
.46 
 
.12 
 
.729 
 
.85 
 
.34, 2.11 
 
Aboriginal status 
(IV_aboriginal) 
 
.24 
 
1.11 
 
.05 
 
.832 
 
1.27 
 
.14, 11.20 
 
Aboriginal status x Gender 
(IV_aboriginal x 
IV_SEX_GENDER) 
 
-.11 
 
.81 
 
.02 
 
.890 
 
.89 
 
.18, 4.39 
 
Constant 
 
-4.41 
 
1.93 
 
5.20 
 
.023 
 
.01 
 
 
As presented in Table 13, the three significant IVs identified in the initial model were 
then included in a new multivariate LR model. The three categories in the drug of choice 
variable (IV_DRUG_OF_CHOICE3) did not exhibit overly large β coefficients or SEs. 
Therefore, it was retained in the new model. 
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Table 13 
New model including three significant IVs 
 
Variable 
 
β 
 
SE 
 
Wald 
 
p 
 
Exp (β) 
95% CI 
lower, upper 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
 
2.18 
 
.43 
 
26.43 
 
.000 
 
8.87 
 
3.86, 20.39 
 
Drug of choice: Cocaine (ref) 
(IV_DRUG_OF_CHOICE3) 
 
 
  
9.12 
 
.010 
  
 
Drug of choice: Opiates 
(IV_DRUG_OF_CHOICE3) 
 
-.06 
 
.33 
 
.03 
 
.859 
 
.94 
 
.50, 1.79 
 
Drug of choice: Amphetamine 
(IV_DRUG_OF_CHOICE3) 
 
-2.53 
 
.84 
 
9.02 
 
.003 
 
.08 
 
.02, .42 
 
Injection partners 
(IV_INJECTION_PARTNER) 
 
.83 
 
.33 
 
6.24 
 
.012 
 
2.30 
 
1.20, 4.43 
 
Constant 
 
-4.09 
 
.93 
 
19.47 
 
.000 
 
.02 
 
 
After running the new model with only the significant IVs, a second model was 
sequentially created by adding in the other seven IVs and one interaction term from the 
original model. As shown in Table 14, the second model showed no significant improvement 
in fit when compared with the new model (p = .386). Thus, the new model was accepted as 
the best fit model.  
Table 14 
Comparing the new model and the full model (Three IVs) 
 
Test statistic 
 
New model 
 
Initial full model 
 
Omnibus Test of Model 
Coefficients (Block) 
 
χ2 = 52.23, df (4), p < .001 
 
χ2 = 8.70, df (8), p = .368 
 
-2 Log Likelihood 
 
249.30 
 
240.60 
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Assessing the Fit of the Best Model 
 The multivariate LR model identified three IVs that significantly contribute to the 
best fit model. The Hosmer and Lemeshow (2000) GOF test result was χ2 = 0.98, df (4), p = 
.912. The lack of significance of this statistical test indicates a well-fitted model (Hilbe, 
2009). Using the Hosmer and Lemeshow GOF test, the dispersion parameter was calculated 
as GOF χ2 = 0.98 / df (4) = 0.25. As stated by Field (2013), over-dispersion is not present 
until the dispersion parameter is greater than one, and not problematic until it approaches two 
(p. 772). Over-dispersion violates the assumption of independence, but is not a concern in the 
current model. 
 Residual outliers. A listing of residual outliers identified six cases (4.6%) with 
residual z-scores greater than +/- 1.96 and six cases with residual z-scores greater than +/- 
2.58. Upon closer inspection, each case reported injecting for more than two years, injecting 
cocaine or opiates, and injecting alone. However, they all tested HCV negative in the lab test 
results. As a result, the predicted outcome of HCV positive status based on the behaviours 
reported by these participants was not observed in reality. However, assessing the residual 
outliers confirmed that these cases were not problematic, and there was no clear reason for 
any to be removed from the model. 
 Further examination confirmed a Cooks Distance of < 1.0 for all residuals (maximum 
value was 0.49519), and all DF Beta values for the constant and the IVs were also < 1.0. The 
Leverage statistic was calculated using the equation [(k + 1) / N] where k is the number of 
IVs and N is the sample size. The expected leverage value was [(3+1 / 261)] = 0.015 and a 
leverage of [3(3+1) / 261] = 0.046 was used as a cut-off point for assessing influential 
outliers (Field, 2013). Nineteen cases had leverage values greater than 0.046 ranging from 
0.048 to 0.165. 
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 Upon closer inspection, the largest leverage values belonged to nine cases all of 
whom reported amphetamine as their primary drug of choice. This is concerning because 
such large leverage values indicate these cases have an excessively large influence on the fit 
of the model. As recommended by Field (2013), nine cases were removed from the analyses 
and when the model was run once again, the SEs, Wald statistics, and 95% CIs became 
extremely large. The three-category drug of choice variable (IV_DRUG_OF_CHOICE3) was 
clearly problematic.          
Bootstrapping. A final test to assess the fit of the model was conducted using the 
bootstrap function in SPSS. As presented in Table 15, the bootstrapped CIs are excessively 
large and unacceptable. Clearly, the removal of the three-category drug of choice variable 
(IV_DRUG_OF_CHOICE3) from the multivariate LR model was warranted, and needed to 
be replaced by the two-category variable (IV_DRUG_OF_CHOICE2) and re-constructed. 
Table 15 
Bootstrap of best model (1,000 samples) (Three IVs) 
 
Variable 
 
β 
 
SE 
 
P 
 
Exp (β) 
95% CI 
lower, upper 
 
Number of years injecting 
(IV_INJECTION_YEARS) 
 
2.11 
 
.45 
 
.001 
 
8.22 
 
3.68, 22.85 
 
Drug of choice*: Opiates 
(IV_DRUG_OF_CHOICE3) 
 
-.10 
 
.34 
 
.750 
 
0.91 
 
0.47, 1.82 
 
Drug of choice*: Amphetamine 
(IV_DRUG_OF_CHOICE3) 
 
-2.50 
 
6.62 
 
.002 
 
0.08 
 
1.97-10, 0.32 
 
Injection partners 
(IV_INJECTION_PARTNERS) 
 
.90 
 
.35 
 
.004 
 
2.45 
 
1.36, 5.27 
 
Constant 
 
-1.05 
 
.45 
 
.007 
 
0.35 
 
0.13, 0.76 
*The referent category cocaine/ crack is not listed because bootstrapping does not include referent categories 
the sampling process. 
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Summary of Drug of Choice (Three Category) Analyses 
 Much effort was spent analyzing the three-category drug of choice variable 
(IV_DRUG_OF_CHOICE3) within the multivariate LR model. Bivariate analyses found the 
variable strongly associated with HCV (χ2 = 14.70, p = .001). However, when it was included 
in multivariate LR analyses, the amphetamine category was statistically problematic due to 
small cell size, and was reluctantly collapsed into a larger stimulants category with cocaine/ 
crack. Studies in the literature review identified amphetamine (specifically crystal meth) 
injection as significantly associated with HCV seroconversion; particularly among young 
PWIDs aged 14 to 26 years who have been injecting for less than two years (Grebely et al., 
2014; Miller et al., 2009). Although the current thesis research was unable to conclusively 
identify injecting amphetamine as a significantly associated risk behaviour due to small 
sample size, it is suspected that PWIDs injecting these drugs are at very high-risk for HCV 
infection. 
 
